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ABSTRACT
Food allergies are most common during infancy Food allergy is a growing health problem with 
very limited treatment options For infants, cow’s milk protein allergy (CMPA) is the 
predominant food allergy, occurring in 2 - 7 5 % o f population Infant formula which is often 
cow’s milk based, is the only approved alternative for breastfeeding However the proteins 
(casein and whey) in cow’s milk result in allergic symptoms in the infants These allergic 
symptoms can be avoided by providing the infants with hydrolysates o f cow’s milk protein 
instead o f the intact protein Whey protein hydrolysates, small bioactive peptide components 
o f milk have been tested in mouse models for their anti-inflammatory/immunomodulatory 
properties however to date no studies have repeated efficacy of hydrolysates in a humanised 
mouse model setting In this study a large number of hydrolysates were screened in vitro to 
identify hydrolysates with anti-inflammatory properties In vitro we demonstrated that 147 
hydrolysate significantly reduced DC maturation in a P-PARy dependent manner To 
mvestigate the anti-inflammatory potential of hydrolysate 147 in a human relevant model of 
food allergy we developed a novel humanised mouse model o f OVA driven food allergy We 
directly compared two different strains o f nonobese diabetic severe combined immunodeficient 
mice lacking the cytokine receptor common gamma chain (yc7') (NSG-SCF versus NSG- 
SGM3) expressing human cytokine genes for their suitability as a humanised mouse model
Using NSG-SCF mice a human immune system was developed through engraftment of CD34+ 
hematopoietic stem cells Using an OVA sensitisation and challenge protocol the model of food 
allergy was developed in these humanised mice The capacity o f hydro lysate 147 to mediate 
anti-inflammatory effects was examined through repeated administration o f 147 hydrolysate 
after sensitisation and before challenge with OVA Both 147 hydrolysate and the wpc80 parent 
control equally reduced anaphylaxis. In comparison to wpc80 parent control, 147 reduced
specific antibody responses, including OVA-specific IgG l, reduced the production of the pro- 
inflammatory cytokines IL-6, IL-17 and induced higher levels o f the anti-inflammatory 
cytokine IL-10 in spleens and small intestines of OVA treated mice 147 in comparison to 
wpc80 was more potent at promoting a Thl/Th2 balance in the spleen and most significantly 
suppressed the accumulation o f granulocyte populations in bone marrow and liver while 
simultaneously reducing the T , B and myeloid cell populations m the bone marrow of OVA 
mice
For the first time, we have shown that a novel milk protein hydrolysate provided efficacy in 
comparison to its whey parent control in terms of reducing OVA driven allergy in a humanised 
mouse model This study demonstrated that 147 may prevent the development o f other food 
allergies (egg-ova) in addition to CMPA (but not examined here) In addition this study, 
presents a framework, from which suitable conditions for testing functional foods, can be 
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"The conception that antibodies that should protect against disease are also 
responsible for disease, sounds at first absurd"
Clemen von Pirquet (1906)
The term “allergy” was coined by Clemen von Pirquet in 1906 to call attention 
to the unusual propensity of some individuals to develop signs and symptoms of 
reactivity or hypersensitivity reactions when exposed to certain substances Although 
the statement quoted above pertained to the cause o f serum sickness (Silverstein 
1906) allergic disorders are also associated with the production of allergen- specific 
IgE and the expansion o f allergen specific T cell populations Both IgE and T cells 
are reactive with what typically or otherwise are harmless environmental substances 
These disorders are increasingly prevalent in the developed world and include 
allergic rhinitis (also known as hay fever), atopic dermatitis (also known as eczema) 
allergic (or atopic) asthma and some food allergies (Holgate et al 1999, Kay et al 
2001) Some people develop a potentially fatal systemic allergic reaction termed 
anaphylaxis within seconds or minutes o f exposure to allergens (Sampson et al 
2005)
In recent years it has become clear that much o f the pathology and therefore 
the burden of disease associated with allergic disorders reflects the long term 
consequences of chronic allergic inflammation at sites of persistent or repetitive 
exposure to allergens (Kay et al 2001) This realisation has led to renewed efforts to 
define additional therapeutic targets in allergic disease (Kraft et al 2007, Holgate et 
al 2008), to devise improved strategies to induce immunological tolerance to the 
offending allergens (Larchee et al 2006, Akdis et al 2007) and even to manipulate
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the immune response to prevent the initial development o f allergic disorders 
(Kukkonen et al 2007)
1.2 FOOD ALLERGY
The last decade has witnessed a significant rise in the prevalence of food 
allergies worldwide, as well as in the number of food proteins that can trigger an 
immune response (allergens) A substantial 18% increase in reported food allergies 
in children, under the age o f 18 years, has been observed between 1997 and 2001 
(Branum et al 2008) Food allergy is defined as “an adverse health effect arising 
from a specific immune response that occurs reproducibly on exposure to a given 
food” (Boyce et al 2010) Within this definition are (1) IgE-mediated food allergies 
which occur within minutes of the ingested allergen and (2) non-IgE-mediated food 
allergies which are the delayed-type and occur 2-3 hours after ingestion In the 
majority of food allergy patients, ingestion o f food allergens causes gastrointestinal 
(diarrhea, vomiting), cutaneous (uticana), bronchopulmonary (dyspnea), 
cardiovascular (hypotension) symptoms and in severe cases, lethal anaphylactic 
shock (Ben-Shoshan et al 2011, Benhamou et al 2010) Recent studies indicate that 
up to 10% of the population in the western world now suffer from at least one type 
of food allergy (Prescott et al 2013) Food allergies are most common during 
infancy For infants, cow’s milk protein allergy (CMPA) is the predommant food 
allergy, occurring in 2-3% worldwide (Host et al 2014) Although cow’s milk 
avoidance is the dietary management for infants who suffer with CMPA, accidental 
exposure is common, which can trigger an allergic response or, in more severe cases, 
anaphylactic shock While it is reassuring that up to 90% of infants outgrow CMPA 
and develop tolerance by the age o f five (Host et al 2014) the small percentage of
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children who do not develop tolerance have an increased risk of developing 
conditions associated with atopy, such as asthma, dermatitis, and allergic rhinitis, or 
additional food allergies in later life a phenomena known as the “atopic march” 
(Vandenplas et al 2007) This prevalence of food allergy that has increased globally 
places a large burden on affected patients and their families The reason for this 
increasing prevalence remains to be elucidated, but many theories including 
increased hygiene, increased dietary fat, antioxidants, vitamin D insufficiency and 
skin sensitisation have been proposed (Lack et al 2008) Food allergy not only 
affects the patient but the whole family as well Childhood food allergy has a 
significant impact on general heath perception, emotional impact on the parent and 
limitations on family activities (Sicherer et al 2001) It also has been shown that the 
diagnosis of food allergy causes significant alterations in meal preparations, social 
activities, and school attendance and contributed to mcreased stress levels in the 
family (Bollinger at al 2006) Although quick treatment o f the mild symptoms with 
anti-histamine or injection o f epinephrine for chronic symptoms saves many lives, 
day to day treatment and prophylactic treatment should be established to suppress the 
symptoms and to improve the life o f the allergic patient To understand where and 
how food allergy against dietary proteins can occur, we first need to briefly discuss 
the role of the comprehensive mucosal system
1.3. INTESTINAL IMMUNE SYSTEM
In the healthy gut, the immune system is able to create a balance between the 
level o f protective mucosal immunity and systemic tolerance Immune homeostasis 
in the gut develops as a relationship that is established between the intestinal
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microbiota, luminal antigens, and the epithelial barrier (Iweala et al 2006) 
Microbial colonization o f the intestine begins after birth, where the sterile gut o f the 
newborn is gradually colonized by environmental bacteria and by contact with the 
maternal intestinal flora and surroundings and possibly by genetic factors 
(Houghteling et al 2016) Exposure to microbial flora early in life allows for a 
change m the T helper 1 (T h 1)/Th2 cytokine balance, favouring a T hI cell response 
(Qian et al 2017) At birth, the immune system o f an infant is not fully developed 
and tends to be directed toward a T h2 phenotype to prevent rejection in utero The 
T h2 phenotype, however, leads to the stimulated production of IgE by B cells and 
thus increases the risk for allergic reactions through the activation of mast cells 
Microbial stimulation early in life will reverse the T h2 bias and stimulate the 
development o f Th I phenotype and stimulate the activity o f T helper 3 cells Th3 
(T von der Weid et al 2001) T h3 cells are CD4 T lymphocytes with a similar 
phenotype to conventional Tregs that secrete TGF-p and IL-10 and are distinctive for 
also expressing IL-4 (Peterson, 2012, Inobe et a l , 1998) In this manner, their 
combined action will lead to the production o f IgA by B cells IgA contributes to 
allergen exclusion and will thereby reduce exposure o f the immune system to 
antigens Cytokines produced by the Th I phenotype will also reduce inflammation 
and stimulate tolerance toward common antigens (Kirjavainen et al 1999)
1.4 BASIC PATHOGENESIS OF FOOD ALLERGY
Allergic inflammation is a fundamental pathological change associated with food 
allergy, and type 1 hypersensitivity o f the immune system is the basic mechanism of 
allergic inflammation (Barnes 2009) There are two phases in the basic process of
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allergic inflammation the induction (sensitisation) phase and effector phase (Figure 
1 1) The induction phase involves antigen presenting cells (APCs) that phagocytose 
food proteins and process and present them to CD4+ T helper 2 cells (T h2) The T h2 
cells in turn release pro-inflammatory cytokines such as interleukin IL-4, IL-5 and 
IL-13 This results in activation and class switching of B cells which produce IgE 
and binding o f the high afficity IgE receptor on the membrane of mast cells and 
basophils, forming sensitised mast cells and basophils The differentiation o f B- 
lymphocytes into IgE-expressing cells depends on three signals The first signal is 
delivered through the B-cell antigen receptor and is pivotal m determining the 
antigenic specificity o f the response The second signal is primarily provided through 
cytokines derived from T h2 cells, such as IL-4 and IL-13 Under tight regulation, 
theses cytokines stimulate transcription through Ig constant region genes The third 
signal is provided via the interaction between the constitutively expressed CD40 
molecule on B-lymphocytes and CD 154 (CD40 ligand) a molecule expressed on T- 
lymphocytes Thus the elevated levels of IgE observed in atopic individuals might 
reflect the preferential activation of T h2 cells (Jelinek 2000) The effector phase 
begins when the same allergen cross-links two adjacent IgEs on sensitised mast cells 
or basophils activated mast cells or basophils subsequently release pro- 
inflammatory mediators or cytokines, thereby causing the clinical manifestations of 
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FIGURE 1.1 Schematic representation illustrating the key events during 
sensitisation and an allergic reaction. When antigen passes through the epithelial 
barrier, it is taken up and processed by APCs. These cells present the antigen in the 
contect of MHC class II molecule. Together with co-stimulatory molecules (CD40, 
CD86, CD80) and ligand binding to the CD28 receptor on antigen-specific naive T 
cells, leads to T cell activation and development o f T h2 phenotype. Activated T cells 
stimulate B cells differentiation into plasma cells, which start to produce antigen- 
specific antibodies (IgE). These antibodies bind to the high-affinity receptor FceRl 
on mast cells and basophils. Upon re-exposure or challenge o f the same antigen the 
antibodies cross-link and degranulation of the mast cell is induced. The release of a 
range o f compounds results in allergic symptoms.
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1.5. TRANSMITTERS OF ALLERGY
As shown in figure 1 1 all key cells and molecules involved in transmitting the 
biological message to primary effector cells are messengers of allergy, represents 
the most complicated process whose underlying mechanism remain unknown 
However, allergic inflammation reflects a complex interplay between several 
inflammatory cells including mast cells, basophils, T lymphocytes, dendritic cells 
(DC), innate lymphoid cells, eosinophils and neutrophils These cells produce 
multiple inflammatory mediators, including lipids, cytokines, chemokines and 
reactive oxygen species (Barnes 2011) In this chapter, the roles of some key cells 
involved in innate and adaptive immunity in the transmission from biological 
messages o f allergen to primary effector cells will be discussed
1.6. FOOD ALLERGY AND THE INNATE IMMUNE SYSTEM
1.6.1. DENDRITIC CELLS
As a part of professional antigen-presenting cells (APCs), DCs are crucial in
order to sample, process, and display antigens to naive T cells, either to initiate
immune responses or to induce immune tolerance (Steinman et al 2003) Pertaining
to food-derived antigens, roles of DCs in the intestine and associated lymphoid
tissues are of particular interest, partly due to the fact that these cells can pick up
antigens directly from the intestinal lumen or antigens that have been transported
across the intestinal epithelial cell (IEC) (Coombes et al 2008) (Figure 1 2) IECs are
the first line o f defence against harmful pathogens and antigens These epithelial
cells are highly organised and connected by tight junctions In adults the connections
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are solid so the barrier is impermeable to damage by molecules but for infants the 
exact permeability is not known (Hill et al 2017) In the healthy gastrointestinal 
tract, however, commensal bacteria and their products modulate intestinal DCs to be 
tolerant via interaction with the pattern recognition receptors (PPRs) of DCs (de 
Kivit et al 2014) In addition, non-inflamed healthy IECs are also able to suppress 
inflammatory DCs inducing tolerogenic DCs It is the existence of tolerogenic 
CD103+ DCs however in murine intestines and mesenteric lymph nodes that points 
to the important role o f DCs Murine DCs were able to convert naive CD4+ T into 
Foxp3+ T Regulatory (TReg) cells via TGF-/I and retinoic acid (Coombes et al 2007) 
A recent study shows a functional homology between murine CD103+ DCs and 
human CD141hlghDCs in cross-presenting antigens to CD8+T cells (Hamffa et al
2012) hence eliciting a query of whether human intestinal CD141hlgh DCs can also 
serve as tolerogenic DCs Notably m a mouse model o f peanut allergy, oral 
sensitization with peanut extract was accompanied by a shift in intestinal DC 
subsets, that is, less tolerogenic CD103+ DCs but more inflammatory C D llb +DCs 
(Smit et al 2011) DC-recognition o f allergens can be mediated by their C-type lectin 
receptors, such as DC-SIGN and mannose receptor (Salazar et al 2013) 
Subsequently m the presence o f IL-4 (potentially released by allergen-activated 
innate immune cells), allergen-presenting DCs polarize naive CD4+ T cells into T h2 
cells, which in turn direct B cells to produce IgE (Galli et al 2008) The important 
role of DCs for mediating allergic reaction against food proteins is indeed supported 
by a finding from the adoptive transfer study of DCs from cow's milk-allergic mice 
into naive recipients Importantly, this DC transfer induced spontaneous production 
o f cow's milk-specific IgE in the naive mice in the absence o f antigen challenge 
(Chambers et al 2004) Omahzumab (anti-IgE antibody) reduced serum IgE and
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altered the presentation by DCs to T cells (Schroeder et al 2010) Taken together, an 
interaction between IECs, and intestinal DCs under homeostatic conditions 
contributes to immune tolerance in the healthy gastrointestinal tract In the presence 
of harmful antigens however, DCs can also initiate the allergic reaction by sampling 
and processing allergens and then presenting allergen-derived peptides to CD4+ T 
cells, which will be followed by the activation o f pro-allergic effectors including 
tissue mast cells, basophils, and eosinophils These results highlight the dual role of 




Figure 1.2 Layers of the intestinal immune barrier. The barrier consists o f a 
protective layer o f epithelial cells covered with mucus and a range of immune 
cells. The main cell type in the epithelial layer is the gate-keeping epithelial cells, 
but other specialized cells are also present. The crypts o f the villi contain mucus- 
producing goblet cells. The lamina propria under this epithelial layer contains 
many immune cells including dendritic cells, macrophages, and lymphocytes. 
After antigen passes through the epithelial barrier, it is taken up by dendritic cells. 
The antigen-presenting dendritic cells migrate to the mesenteric lymph nodes and 
present their MHC-antigen complex to T cells inducing T-cell activation. In the 
Peyer’s patch (organized lymphoid nodules) antigen-presenting dendritic cells 
also interact with T cells. T cells then drive the immune response activating other 
immune cells, for example, B cells.
1.6.2. MAST CELLS AND BAOPHILS: THE PRIMARY EFFECTOR CELLS
OF ALLERGY
Mast cells (MCs) and basophils are the key effector cells responsible for 
allergic inflammation They directly respond to allergen challenge through 
immunoglobulin dependent or independent mechanisms (Vliagoftis et al 2005) In 
the GI tract, MCs comprise 1-5% of mononuclear cells in the lamina propria and the 
submucosa, and are also found intraepithehal and deep m the muscle and serosal 
layers Basophils are granulocytes, which mature in the bone marrow, circulate m the 
blood and are recruited to allergic inflammatory sites In contrast, progenitors o f 
MCs migrate from the bone marrow to the peripheral tissues and undergo their 
terminal differentiation ui situ. MCs that complete their differentiation in the skin or 
intestine develop into connective tissue MCs and mucosal MCs, respectively MCs 
and basophils express the high-affinity receptor for IgE and, upon crosslmking of 
FceRI-bound IgE with antigen, rapidly produce diverse preformed mediators, 
cytokines (e g  IL-4 and IL-13) and lipid mediators, leading to the induction o f 
immediate-type hypersensitivity
Based on the anatomical location, human MCs are classified into mucosal 
MCs and connective tissue MCs, depending on protease content MCs are divided in 
two large subsets MCT, containing tryptase but little or no chymase, and MCTC, 
containing tryptase, chymase and carboxypeptidase MCC, which express chymase 
but little or no tryptase, also have been described, but they appear to be infrequent 
MCT prevail in the intestinal and pulmonary mucosa, near T cells, whereas 
MCTC are found in the skin and lymph nodes, in addition to the lung and the gut 
submucosa In the human small intestine, MCT represent -98%  of all MCs in the
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mucosa and ~13% of MCs in the submucosa are MCT (Amin et al 2012) Briefly, 
mast-cell activity in humans can be indirectly measured by the diameter size o f the 
induced wheal after skin prick test (SPT) with milk extract (Ford et al 2014) while m 
mice mast-cell activity can be measured by the elevation o f serum levels o f mouse 
mast-cell /?-chymase/mast cell protease 1 (MCP1) a specific marker for mucosal MC 
degranulation (Caughey 2007) Basophils are the rarest type o f granulocyte that 
mature in the bone marrow from CD34+ myeloid stem cells and are then released 
into the circulation Like mast cells, basophils express the high affinity IgE receptor 
and synthesize histamine due to the actions o f histadine decarboxylase This 
archetypal pro-allergic mediator is stored within intracellular granules bound to 
proteoglycans but is released from the cells following stimulation (Noun-Ana et al 
2001) The release o f this biogenic amine is one o f the most important pro-allergic 
mediators that governs the classical hallmarks o f acute inflammation Although in 
humans MCs are more numerous than basophils, the latter are at least one order of 
magnitude more sensitive to IgE-mediated provocation than mast cells This along 
with their usual location in the blood, places basophils as potentially important 
contributors to systemic anaphylaxis In general, basophils are involved with late- 
phase reactions and are uniquely capable of rapidly releasing T h2 cytokines IL-4 and 
IL-13 and both cytokines contribute to increased adhesion molecule that potentiate 
further inflammatory cell influx into the region (Gibbs et al 1996) Basophils also 
express CD40 ligand, which in conjunction with IL-4 and IL-13 causes class 
switching in B cells (Yanagihara et al 1998)
Human MCs in contrast produce little or no IL-4 and it seems unlikely that 
they can fulfil the above immunomodulatory roles as effective as basophils Upon 
activation MCs and basophils release three major groups o f proinflammatory
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mediators causing pathological damages (Kalesmkoff et al 2010) and clinical 
symptoms of allergy (Henmno et al 2006, Pettiper et al 2007) MCs release three 
groups of mediators, including preformed granule products, such as histamine, 
tryptase, chymase and heparm, newly synthesized arachidomc acid products, such as 
leukotnene C4 (LTC4) and prostaglandin D2 (PGD2) and cytokines, such as IL-4, 
IL-13, and eotaxin (Iwahiet et al 2005) These products greatly contribute to 
pathological damage in different tissues Symptoms of allergies occur after the 
activation of mast cells or basophils Theoretically, the degranulation of mast cells 
and basophils is the definitive event in allergy, whereas IgE alone serves as only one 
o f the key messengers Although MCs and basophils play a decisive role in food 
allergy, the cell types involved m the sensitisation o f primary effector cells are also 
essential for the occurrence o f allergy For example, an individual allergic reaction to 
grass pollen or certain foods requires long process to obtain sensitisation to that 
specific allergen and not other allergens. This natural phenomenon suggests that 
MCs or basophils should be pnmed before activation Degranulation is a cellular 
process that releases antimicrobial cytotoxic or other molecules from secretory 
vesicles called granules found inside MCs and basophils
In humans, basophils are short-lived cells that account for less than 1% of 
circulating granulocytes in the blood In contrast, MCs are located in the tissue and 
mast cell progenitors have the potential to proliferate locally m the tissue in response 
to IL-3, IL-4 and IL-9 These products greatly contribute to pathological damage in 
different tissues (Yu et al 2006) These MC secretory products are activation 
markers for mast cells whereas histamine, LTC4 and PGD2 are activation markers 
for basophils A range o f specific surface membrane activation markers are used to 
distinguish mast cells from basophils CD203c (ectonucleotide pyrophosphatase/
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phosphodiesterase 3) and the high affinity IgE receptor FceRl are specific surface 
markers for MCs and basophils which are employed in flow cytometric analysis 
(Boumiza et al 2003). CD117 or c-kit is a receptor o f stem cell factor which is 
expressed on the surface o f all MCs, independent o f maturation and activation status 
but not expressed on basophils. Thus, MCs can be distinguished by routine flow 
cytometry as CD203+ FceR 1+ c-kit+ and basophils as CD203+ FceRl+ c-kit'. Roles of 
other innate immune subsets including neutrophils, monocytes, natural killer 
(NK), y8 T cells, innate lymphoid cells (ILCs) and natural killer T (NKT) cells 
during allergic reaction to food proteins remain to be elucidated. Elevated numbers 
o f neutrophils, y8 T cells and NKT cells have been shown to accumulate in 
chronically inflamed digestive tissues o f food allergy patients (Semeniuk et al 2009, 
Turunen et al 2004, Jyonouchi et al 2014) but the actual roles o f these innate cells 
are unknown. It is possible that these cells are accumulated in the inflamed sites 
mainly because o f the elevated levels o f inflammatory chemokines during chronic 
allergic reaction and indirectly activated by the circulating inflammatory cytokines, 
hence contributing to the chronic inflammatory reactions (Galli et al 2008). 
Nevertheless, several murine studies suggest that these cells could play key roles 
during allergy. Neutrophils have been indicated to be important in both sensitization 
and induction o f allergic skin inflammatory reactions as well as mediating alternative 
mechanisms o f anaphylactic reaction (Mocsai 2013). On the other hand, murine 
tissue y8 and invariant NK T cells were suggested to exert regulatory roles to 
suppress food allergy (Bol-Schoenmakers et al 2011). Human studies are required to 
clarify these murine findings.
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1.7 FOOD ALLERGY AND THE ADAPTIVE IMMUNE SYSTEM
1.7.1. CD4+ T CELLS
CD4+ T cells serve an important role as the master regulator o f adaptive immune 
responses Through their plasticity to differentiate into at least proinflammatory 
T h1/Th2 /T h17 or anti-inflammatory TReg cells, CD4+ T cells crucially influence the 
outcome of inflammatory reactions either resulting as a resolved or persistent 
inflammation (Zhu et al 2010) T hI and T h2 cells are not 2 distinct CD4+ T-cell 
subsets, but they simply represent polarized forms o f the highly heterogenous 
CD4+ Th cell-mediated immune response T h I cells are characterized by the 
prevalent production o f IL-2, IFN-y, and TNF-a, without IL-4, IL-5, and IL-13 
production In contrast, Th2 cells are characterized by the prevalent production of 
IL-4, IL-5, and IL-13 in the absence o f IFN-y and TNF-a production (Romagnam 
1994) The Th 1/Th2 polarization is clear-cut in murine models on the basis of 
artificial immunization, whereas it is usually less restricted among human T h cell- 
mediated responses Signals through contact molecules, as well as through cytokine 
receptors, elicit a complex series o f molecular interactions that culminate in the 
binding o f cell type-specific transcription factors and subsequent activation of 
cytokine genes The main transcription factor for T h2 differentiation is GATA-3, 
which inhibits the production of IFN-y, and also directly regulates IL-5 and IL-13 
expression
The main transcription factor involved in T h I lineage commitment is the 
protein T-box expressed in T cells (T-bet) Transduction of T-bet into fully 
polanzed T h2 cells converts them into IFN-y-producing T h I cells and 
simultaneously represses the T h2 cytokines IL-4 and IL-5 A model for T h1/Th2 
polarization that involves a balance between specific GATA-3 transcription factors
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has been proposed (Rengarajan et al 2000) Th 17 cells produce a range o f cytokines 
including IL-17A, IL-17F, IL-21 and IL-22 express the transcription factor Roryt and 
are physiologically important to eliminate intracellular and extracellular pathogens 
and play a pivotal role m the pathogenesis o f autoimmune disease Th2 cells are 
known to be important for eradicating helminths However, through secretion o f IL- 
4, IL-5, and IL-13, T h2  cells also contribute to the pathogenesis of allergy (Galli et 
al 2008) In line with this, PBMC from patients exhibited protein-specific T h2- 
polansed immune responses producing, high levels o f IL-4, IL-5, and IL-13 with low 
production o f T h I-cytokine IFN-y (Andre et al 1996, Campbell et al 1996, Schade et 
a l 2000)
The current findings indicate that most food allergies are characterized by TH2- 
polanzed immune responses accompanied by the impairment of TReg cells Although 
it was originally proposed that each subset of CD4+ T cells permanently retained a 
specific differentiated identity (T hI or Th2 or T hI 7) resulting in non-overlappmg 
distinct subsets (O’Shea et al 2010) It is clear now that there is a level o f plasticity 
in the T cell phenotype particularly during chronic inflammation in vivo (Hirahara et 
al 2013). This allows CD4+T cells to secrete signature cytokines that have been 
associated with other subsets or even to further convert into other subsets For 
example, it has been shown that T cells derived from chronic allergic asthma patients 
co-expressed and coproduced both TH2 and TH17 transcription factors and cytokines 
(Wang et al 2010) Thus whether TH2-polanzed immune responses in food allergic 
patients could also exhibit or even convert to TH1- or TH17-immune responses 
remains to be seen
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1.7.2. ADAPTIVE IMMUNITY AND T-REGULATORY CELLS
Regulatory T cells (T Reg) are a subset of CD4+ T cells which possess potent 
immunomodulatory ability and are defined as CD4+ CD127lowCD25hlgh FoxP3+. The 
expression o f CD127 has been used to separate immune suppressive TReg (CD127 low) 
from activated effector T cell populations (CD127hlgh) (Hartigan-O’Connor et al
2007). One possible mechanism that exists to modulate allergic inflammation can be 
attributed to the suppressive role o f TReg cells. These cells can be further classified as 
thymus-derived (natural TReg ) or peripherally derived and whose activation is 
dependent on T cell receptor engagement with cytokines (induced TReg) (Abbas et al 
2013). Their suppressive functions can occur through either secretion o f anti­
inflammatory cytokines (e.g., IL-10 and TGF-/J and IL-35), metabolic disruption, or 
attenuation o f DC maturation and/or functionality (Vignali et al 2008). It has been 
shown that a fine balance between Treg and pro-allergic TH2 cells, including cell 
frequency and functionality, determines the development o f allergy (Akdis et al
2004). Co-culture o f Treg cells in the presence o f DC reduced the antigen 
presentation ability and co-stimulatory function o f DC through cyclic adenosine 
monophosphate (cAMP) production by the Treg cell and subsequently reduced the 
expression o f the co-stimulatory molecules CD80 and CD86 on DC (Safinia et al
2013). Supporting evidence o f a Treg suppressive role in allergy came from a 
clinical study of patients with IPEX (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked) syndrome caused by a deletion in a noncoding region of 
the FOXP3 gene, the central gene for Treg differentiation. These patients had a 
defect in Treg frequency as well as functionality and more importantly exhibited 
severe food allergic phenotype particularly against cow's milk proteins (Torgerson et 
al 2007). IPEX patients also suffer from autoimmune diabetes and/or thyroiditis
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reiterating that the impairment o f Treg allows many types o f inflammation to occur 
(Cheng et al 2012) In addition, lower frequencies o f TGF-/?-producmg T cells were 
observed in the duodenal mucosa o f children with food allergy as compared to non- 
allergic subjects (Westerholm- Ormio et al 2010) To summarize, defects in 
Treg frequency and functionality partly contribute to food allergy pathogenesis
1.8. ALLERGY TYPICALLY BEGINS DURING INFANCY
Newborns have specific dietary needs Breast milk significantly enhances 
growth and development in the first months o f life When breastfeeding is not 
possible, infant formula is the only approved infant nutrition However this is not 
without consequences Neonates are exposed to a large number of microorganisms, 
foreign proteins, and chemicals and resistance to infection relies both on the 
protective factors in breast milk and on the infant developing his/her own innate and 
adaptive (antigen-dnven) immumty The neonatal immune system functions 
differently from that of an adult (Kelly et al 2000) Whether one can define the 
infant’s immune system as classically “immunosuppressed” is somewhat debatable 
as little antigen exposure occurs in utero From an immunological standpoint the 
infant’s cells require considerable “education” in the early postnatal period 
Deficiencies in antigen presentation (Kellt et al 2000) contribute to T cell 
immaturity The germ-free status o f the intrauterine environment favors T-helper 2 
(Th2) type cytokine response over a T-helper 1 (T hI) response (Cummins et al 
1997) Together, the naive and altered cytokine response by the infant’s immune 
system will contribute to lower immune competence in the infant Infants are often 
unable to produce all o f the enzymes required for complete digestion of dietary
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protein such as gastric pepsin and this, coupled with their high stomach pH (up to 
four times higher than that o f an adult), can often result in the incomplete digestion 
of proteins in newborns (Figure 1.3) (Henderson et al 2001). The allergic potential of 
peptides is dependent on the level of exposure and their size, with larger peptides 
being more allergenic and increasing risk o f sensitisation to specific food proteins 
(Figure 1.3). As the immature gastrointestinal barrier o f vulnerable infants is more 
permeable, it enables these larger proteins to be absorbed. Once crossed over the 
gastrointestinal barrier, these larger peptides can activate and overexpress Type 2 
helper T-cells (T h2), which act as key drivers of allergy. If the development o f the 
gastrointestinal immune system and oral tolerance can be stimulated in the early 
stages o f life, the likelihood o f activating this allergic cell type and, thus, inducing 
sensitisation is greatly reduced (Vickery et al 2011).
Adult
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V s Larger undigestedproteins
Figure 1.3.The conditions within the infants gastrointestinal tract that can potentially 
impact their ability to digest larger proteins and therefore increase susceptibility to 
allergenicity.
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1.9. MECHANISM OF SENSITISATION TO FOOD-IMMUNE TOLERANCE
The gastrointestinal tract, the largest immunologic organ in the body, is 
exposed to a constant barrage of exogenous antigens on a daily basis (Chehade et al
2005) The mucosal immune system has evolved to inhibit responses to harmless 
antigens (e g , commensal bacteria, food protein) while maintaining the ability to 
mount a vigorous protective response when faced with pathogens As already 
discussed in section 1 3 homeostasis between tolerance and immunity is therefore an 
active immune process This fine balance can be modified by several factors in the 
intestine and when disrupted can lead to a breach in oral tolerance and inappropriate 
allergic sensitization to food proteins Remarkably, only a single epithelial layer 
separates this antigenic load from the lymphocytes, APCs, stromal cells and other 
immune cells in the lamina propria, which together comprise the gut associated 
lymphoid tissue (GALT) In the small intestine these are called the Peyer’s patches 
(Figure 1 2) Within the Peyer’s patches, unique populations o f DCs interact with 
dietary antigens and determine the fate of the resulting adaptive response, i e , 
immunity versus tolerance (Chehade et al 2005) In this context, immune tolerance 
is defined as the antigen-specific suppression of cellular or humoral immune 
responses Normally, when the initial antigen exposure occurs through the GI tract, 
a robust T cell-mediated suppression develops called oral tolerance (Coombes et al
2008) However, in 4—6% o f children, this mechanism appears to fail, leading to 
sensitization and elicitation (Fana et al 2005) Depending on the amount o f antigen, 
three distinct immunological mechanisms can contribute to tolerance to food 
antigens, that is induction o f regulatory T cells (Tregs), clonal anergy o f T cells and 
deletion o f T cells (Weiner et al 2011) In the mesenteric lymph nodes, Tregs are
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mainly generated by CD103+CX3CR1+ DC Here, the tolerogenic CD103+CX3CR1 + 
DC present the food antigens to CD4+ T cells Tolerogenic CD103+CX3CR1+ DC, 
but also macrophages, mostly express IL-10, and TG F-p, which induce Treg 
formation (Mamcassamy et al 2010) Upon interaction o f DC with the Treg subtype 
Th3, a cascade o f Treg subtype induction and maintenance is initiated, while the 
secreted TG F-p at the same time inhibits ThI and Th2 subtype T cells (Weiner et al 
2011) This type o f tolerance induction is only initiated when the food antigen is 
present in lower doses This mechanism is considered to be a central mechanism of 
tolerance induction for food antigens
At higher antigen doses, tolerance is mamly caused by clonal deletion and 
clonal anergy PRR-mediated activation, and especially toll like receptor (TLR) 
signaling, has also been found to be essential in these processes TLRs influence the 
T-cell response, as peptide-MHC-II-complex presentation together with a lack o f co- 
stimulatory molecules on dendritic cells dunng high antigen exposure is thought to 
cause T-cell clonal anergy (Strobel 2003). Anergy is caused by a strong signal 1 
which can be initiated through TCR activation o f APC and then APC presents 
antigen to T cell In the absence o f signal 2 (co-stimulation) anergy can also occur 
Clonal deletion o f T cells is the other process that occurs at high antigen exposure 
This usually occurs in the Peyer’s patches It is thought to be caused by natural killer 
T cells, possibly via Fas-FasL interaction with T cells that leads to apoptosis o f food 
antigen recognizing T cells (Kim et al 2006 ) (Figure 1 3)
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Figure 1.3. Oral tolerance induction. Normal immunity is induced by the interaction 
between an antigen-presenting dendritic cell and a naive T cell. Due to the binding of 
the T cell receptor with the MHC-peptide complex and the co-stimulatory molecules, 
the T cell becomess activated. However, the default state in the gut is tolerance 
against dietary antigens. Different mechanisms are involved in inducing tolerance. 
When a high dose o f antigen is present, the main mechanisms involved are anergy 
and deletion o f T cells. Anergy occurs when co-stimulatory molecules are lacking 
during the interaction between dendritic cells and T cells. This leads to an 
unresponsive T cell. Deletion also occurs at high-antigen levels. Fas-Fas ligand- 
induced apoptosis is induced in antigen specific T cells after interacting with, for 
example, a natural killer T cell. The main mechanism inducing tolerance at a low 
dose of antigen is the induction o f regulatory T cells. Tolerogenic factors (IL-10, 
TGF-P) produced by epithelial cells result in a more tolerogenic dendritic cell. When
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this cell interacts with a T-helper 3 cell, the T cell produces TGF-(3, which leads to 
differentiation towards a regulatory T cell and the inhibition o f ThI and Th2 cells
1.10. THERAPEUTIC INTERVENTION FOR FOOD ALLERGY
1.10.1. DIETARY PROPHYLAXIS FOR FOOD ALLERGY
The exponential increase in allergic diseases continues to remind us o f the urgent
need to devise strategies to curb this trend A number o f approaches have been 
tested, including allergen avoidance, immune modulation, and dietary manipulation 
Supplementing the diet, rather than food allergen avoidance, is attractive because it 
is relatively simple and inexpensive to administer and the risk o f any adverse 
nutritional consequences is low This strategy includes the use o f probiotics and 
prebiotics, bioactive peptides and vitamms The innate immune system has the 
ability to modulate adaptive immune responses to food proteins Therefore, the type 
o f gastrointestinal microbiota o f the newborn and the preservation o f intestinal 
permeability is crucial for preventing the development o f food allergies The dietary 
modulation o f nutritional factors through prebiotics, probiotics and bioactive 
preparations represent a novel approach and a challenge for dietitians and paediatric 
allergists The modulation o f the immune system using functional foods is a 
promising research hypothesis in the attempt to induce a tolerogenic immune 
environment (Fiocchi et al 2010)
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1.10.2. PREBIOTICS
Prebiotics have been defined as “non-digestible food components that 
beneficially affect the host by selectively stimulating the growth and/or activity of 
one or a limited number o f bacteria in the colon and thereby improving host health”, 
and recently redefined as “a selectively fermented ingredient that allows specific 
changes, both in the composition and/or activity in the gastrointestinal microbiota 
that confers benefits” (Cuello-Garcia et al 2016). In December 2016, a panel of 
experts convened by the International Scientific Association for Probiotics and 
Prebiotics (ISAPP) suggested a new definition, i.e., “a substrate that is selectively 
utilized by host microorganisms conferring a health benefit” (Cuello-Garcia et al 
2016). Based on the body o f available evidence, the Guidelines for Atopic Disease 
Prevention (GLAD-p) panel concluded that it is likely that prebiotic supplementation 
in infants reduces the risk o f developing recurrent wheezing and possibly also the 
development o f food allergy. However, there is very low certainty that there is an 
effect of prebiotics on other outcomes, other than an indirect effect due to its effect 
on the microbiome. In fact, their activity can be affected by many individual factors 
(e.g., host’s microbiota or the genetic predisposition to diseases).
Environmental factors such as diet or antibiotics can also influence the use of 
prebiotics (Cuello-Garcia et al 2016). The gut microbiota has been shown to respond 
rapidly to dietary change (David et al 2014), with increased dietary fiber being 
associated with changes in the production o f microbial metabolites including short 
chain fatty acids (SCFA); acetate, butyrate, and propionate. These SCFA metabolites 
have anti-inflammatory effects (Maslowski et al 2009), both locally in the gut 
mucosa and beyond (Thombum et al 2014), inducing Treg and tolerogenic DC
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(Arpaia et al 2013, Furusawa et al 2013). Lower levels o f butyrate and propionate 
have been measured in infants with allergic disease at 1 year o f age (Bottcher et al 
2000). Prebiotic dietary sources are primarily derived from plants and commonly 
found in foods like chicory, asparagus, garlic, leeks, onion, and artichoke. To 
consider a substance a prebiotic, it must be able to resist digestion and absorption in 
the GI and be fermented by intestinal microbiota (Gibson et al 2004). Human milk 
contains oligosaccharides (HMOS) that also serve as prebiotics, as these non- 
digestible HMOS show a clear effect on the gut microbiota. HMOS are the third 
most abundant solid component in breast milk after fat and lactose. They play a key 
role in the development and well being o f the baby playing a decisive role in the 
immature infant’s immune system and promoting a healthy intestinal flora.
Clinical interventions trials o f prebiotic supplementation o f humans 
examining allergic disease outcomes have shown reduced development o f atopic 
dermatitis /eczema in infancy; however these trails have been limited to infants fed 
infant formula (Arslanoglu et al 2008). Given the various benefits o f HMOs, there 
has been a lot o f interest in figuring out how to introduce HMOs into formula. There 
are several infant formulas available supplemented with functional alternatives to 
HMO such as galacto oligosaccarides (GOS) and/or fructo oligosaccharides (FOS) 
which are nondigestible carbohydrates that mimic the effect o f HMOs to some extent 
(Roberfroid et al 2010). However, earlier this year, Nestle were the first company to 
replicate and produce two HMOs (2 -fucosyllactose (2-FL) and lacto-N-neotetraose 
(LNnT)) and add these to infant formula (Nan Optipro Supreme, Nestle, Spain) to 
make the composition o f the infants gut more similar to breast fed babies. These 
ingredients were approved by the European Food Safety Authority (EFSA) and have 
been approved by the European Commission and the US FDA. This formula may
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reduce the risk o f infectious diseases in children aged up to 18 months o f life, 
compared with babies fed with the standard formula without oligosaccharides
1.10.2 PROBIOTICS
Probiotics are living microorganisms that have been proposed as lmmune- 
modulators o f the allergic response by affecting phagocytosis and production o f pro- 
inflammatory cytokines, and thus have been advocated as therapeutic and preventive 
interventions for allergic diseases (Fiocchi et al 2015) They are present in everyday 
food (not only in yoghurt or fermented milk, but also in cheese, either hard or soft 
and also in less expected sources such as kefir, miso soup or tempe) and many 
people consume them daily The probiotic effects of complex oligosaccharides in 
human milk promote the establishment o f a bifidogemc microbiota which, in turn, 
induces a milieu of tolerogenic immune responses to foods Earlier studies suggested 
a positive effect of probiotic interventions on atopic dermatitis, but meta-analyses 
have failed to confirm it (Rather et al 2016) The new World Allergy Organization 
(WAO) guidelines determined that it is likely that probiotic supplementation in 
infants reduces the risk of developing eczema and suggested that probiotics should 
be recommended in mothers o f high-risk infants and in infants at high risk of allergic 
disease, where “high nsk for allergy in a child” is defined as having a biological 
parent or sibling with an existing or history o f allergic rhinitis, asthma, eczema, or 
food allergy The recommendations are conditional, and based on very low-quahty 
evidence, with no specific recommendation regarding strains, dose, treatment 
duration etc
In terms of tolerance development in those with established food allergy, one 
study from Australia performed oral immunotherapy (OIT) to peanut in combination 
with Lactabillus rhamnosus GG, showing that 89 7% of the study participants in this
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arm were desensitized to peanut. The authors speculate that this protective effect 
may be seen because of the possible effect of the probiotic on T regulatory cells 
(Tang et al 2015). Further scientific confirmation is required to include probiotics 
and prebiotics in the therapeutic plans. Practical implications and how this should be 
incorporated in advising food allergy sufferers are also unclear in terms o f advising 
regular intake o f foods high in short-chain fructo-oligo saccharides, fermented foods 
and yoghurts.
1.10.3. MILK PEPTIDES (BIOACTIVES) AS FUNCTIONAL FOODS
The last 40 years has seen a dramatic rise in allergic diseases such as asthma, 
eczema and hay fever, particularly in the western world. Along with these allergies 
has come an increase in food-related allergies. Today almost one child in every 
classroom worldwide has a need to avoid, milk, eggs or nuts. In Ireland, milk 
allergies are twice as common as egg allergies and three times as common as peanut 
allergies. The main treatment strategy for most allergies is based on allergen 
avoidance which is particularly challenging for cow’s milk as it forms the basis for 
many milk based essential products for infant nutrition. Cow’s milk is an ideal 
protein source as it has all nine essential amino acids (leucine, isoleucine, valine, 
phenylalanine, tryptophan, histidine, threonine, methionine, lysine) and so it is very 
important to enable more children to consume it without developing an allergy to it 
(Mcgregor et al 2014). The fact that many children are not bom with milk allergy is 
very encouraging and suggests that there may be ways to prevent it. Children do not 
inherit a specific allergy but rather a genetic tendency to develop allergic disease.
Breast milk is the gold standard for the growing infant, however 0.5-1% of 
breast-fed infants develop cow’s milk allergy after weaning to solids (Saarinen et al
27
2000) As such there has been a push for industry to produce new food products or 
functional foods that are capable o f improving infant health within the context of 
food allergy These ingredients are referred to as “bioactives” as they are known to 
be active within the body Given Irelands position as a leading dairy producer our 
research funded by Food for Health Ireland (FHI) and backed by 5 industry partners 
(Kerry Foods, Carbery Foods, Glanbia, Dairy Gold Ingredients and Irish Dairy 
Board) is focused on studying bioactives in dairy products that are capable of 
preventing or reducing the incidence o f inflammatory allergic disease in infants 
Milk derived bioactives have been reported to possess a variety o f biological 
activities, including antioxidant, anti-inflammatory, anti-hypertensive and anti­
cancer activities (Raikos et al 2014) The goal o f this current research is to find 
bioactives with anti-inflammatory activity that can be incorporated as ingredients in 
functional foods There has recently been a rapid increase in consumer interest in the 
health-enhancing roles o f specific foods or physiologically active food components, 
so-called functional foods (Hasler, 1998) Generally speaking all foods are functional 
as they have nutritional value and are fundamental for survival A functional food 
can be described as ‘a food that can beneficially affect one or more target functions 
m the body beyond adequate nutritional effects m a way that is relevant to either an 
improved state o f health and well-being and/or a reduction of risk o f disease’ (ISIL 
Europe, 2012)
There is a lack o f treatment options available for food allergy While the most 
common treatment o f food allergy is the complete avoidance, there are some 
pharmacological treatments available Anti-IgE (omalizamab) and anti-histamine 
drugs have been widely used to treat these allergic responses However, as these 
treatments are often costly, associated with multiple side-effects and are not
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universally efficacious (Korhonen et al 2003) food derived milk peptides with anti­
inflammatory activity could be used as a new alternative for the prevention/reduction 
o f the incidence of inflammatory diseases such as food allergy.
1.11. MILK DERIVED HYDROLYSATES
1.11.1 POSSIBILITY TO PREVENT/TREAT ALLERGY WITH MILK 
PROTEIN HYDROLYSATES
While genetics play a central role in food allergy (Sicherer et al 2000) the 
environment to which we are exposed is also largely responsible, with diet being a 
leading component. As already discussed dietary proteins supply a pool of amino 
acids that form various protein molecules, which play intricate roles across the 
body’s metabolic pathways. While dietary protein is renowned for its fundamental 
role in growth and tissue repair (Van Loon 2007) it also boasts a plethora of health 
benefits, with specific peptides playing a major role in the functioning and regulation 
o f the immune system from birth, as well as in protecting against infection by 
inhibiting microbial growth (Raikoset et al 2014). Over the past decade, growing 
evidence has demonstrated the potential o f dietary components in mitigating and 
even blockading the progression of inflammation (Giugliano et al., 2006; Pan et al.,
2009). Peptides are an important group of bioactive substances in functional foods, 
which can be generated by enzymatic hydrolysis, microbial fermentation, or 
gastrointestinal digestion of food protein. Bioactive peptides are usually composed 
of 3 to 20 amino acid (AA) residues and may contain different AA composition and
29
sequences (Shahidi and Zhong, 2008). Recently, interest has been growing in 
developing anti-inflammatory peptides from food proteins for their health- 
promoting, desirable safety and anti-allergy effects (Dyer et al., 2008; Chakrabarti et 
al., 2014; Kumar et al., 2015).
Whey protein constitutes approximately 20% of milk protein and is a natural 
by-product from cheese production. Whey protein is basically a mixture o f globular 
protein, such as (3-lactoglobulin ((3-LG,) a-lactoferrin and BSA. As a high-quality 
protein source (Sousa et al., 2012), whey protein can release a wide variety of 
bioactive peptides. However, the allergic potential o f peptides is dependent on the 
level of exposure and their size, with larger peptides being more allergenic and 
increasing risk of sensitisation to specific food proteins (Figure 1.4). As the 
immature gastrointestinal barrier o f vulnerable infants is more permeable, it enables 
these larger proteins to be absorbed. Following passage across the gastrointestinal 
barrier, these larger peptides can activate and enhance expansion o f Type 2 helper T- 
cells (T h2), which act as key drivers o f allergy. If the development o f the 
gastrointestinal immune system and oral tolerance can be stimulated in the early 
stages o f life, the likelihood o f activating this allergic cell type and, thus, inducing 
sensitisation is greatly reduced.
Proteins can be pre-digested or hydrolysed into smaller protein chains outside 
o f the body, and are known as protein peptides or hydrolysates. The process of 
breaking down proteins to shorter peptide sequences is termed ‘hydrolysis’. This 
process happens naturally in the gastrointestinal tract and can be simulated in the 
laboratory or on an industrial scale. During the normal transit through the 
gastrointestinal tract, milk proteins are exposed to proteinases such as pepsin, trypsin 
and chymotrypsin which break them down into smaller peptides. These peptides are
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further digested by brush border peptidases present at the surface of intestinal 
epithelial cells where they produce amino acids, however, some oligopeptides still 
remain intact (Segura-Campos et al 2011) In laboratory or at an industrial scale, 
milk hydrolysates are released either by treatment of milk proteins with food grade 
enzymes or through fermentation with bacteria. The shorter peptide sequences often 
possess bioactive properties beyond their nutritional contribution along with 
eradicating any protein-specific allergemcity (Hartmann et al 2007, Kit et al 2003) 
Once the hydrolysates are released, they can potentially have bioactive properties 
and exert their effects in receptive cells, including those present in the 
gastrointestinal tract (Rico-Cabello et al 2012) The bioactivities of the resulting 
hydrolysates are variable dependmg on a range o f factors, including the enzyme 
used, the processing conditions and the final size o f the peptide sequence following 
hydrolysis (Clemente 2000) The degree o f hydrolysis (DH) is defined as the 
percentage o f cleaved peptide bonds, i e the number o f hydrolysed bonds per total 
number of peptide bonds m the protein (Nielson et al 2001) This affects the size and 
ammo acid composition of the peptides, which subsequently determines the 
biological activity o f the peptide Hence, DH is an important consideration from the 
perspective o f functional food research (Jamdar et al 2010)
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Figure 1.4 The allergenicity of proteins is dependent on their size. A)
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infants. B) Composition o f FHI proposed allergy-prevention infant 
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infant formula: smaller peptides for infants with mild allergy. D) 
Composition o f specialised infant formula: amino acids for infants with 
severe allergy.
Much o f the experimental data on milk hydrolysates come from model 
organisms such as mice and rats; however, a number o f studies have been carried out 
in humans (Nongonierma et al 2016). Horiguchi et al (2005) examined the effects of 
the administration of wheat gluten hydrolysate on the immune function o f healthy 
human volunteers and reported that NK cell activity increased significantly after 
intervention (6 days) without severe side effects. Soybean peptides produced by 
theroase or biophrase significantly increased the numbers o f C D llb + (cell surface
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antigen o f macrophages and DC) and CD56+ (cell surface antigen on NK cells) cells 
in serum of peripheral blood from healthy human volunteers after a single oral 
administration o f 8g of soya bean peptides (Yimit et al 2012)
Several milk protein hydrolysates enhance immune cell function by 
increasing secretion of immunoglobulins. Immunoglobulins are glycoprotein 
molecules that specifically recognise antigens from bacteria or viruses and aid in 
their destruction through a highly complex and specific immune response (Calder et 
al 2002). Hydrolysates o f as 1-casein, as2-casein and p-casein stimulated the 
immune system through the enhancement o f immunoglobulin G (IgG) and IgA 
concentrations (Hata et al 1999) Several recent studies have demonstrated that food 
derived peptides exert various immunomodulatory effects on both innate and 
adaptive immune responses including induction o f or modulation o f cytokine and 
antibody production, stimulation o f lymphocytes to proliferate, augmentation of 
phagocytic ability o f macrophages, enhancement of natural killer (NK) cell activity, 
improvement o f the defensive ability o f the body against invading pathogens and 
inhibition o f pro-inflammatory responses to bacterial components such as 
lipopolysaccharide (LPS) (Zang et al 2012, Wenjia et al 2016, Yang et al 2009, 
Duarte et al 2010) These effects can be mediated by direct binding of food derived 
peptides to the receptors on the surface o f immune cells The immunomodulatory 
capacity of peptides isolated from food protem hydrolysates is dependent on the 
amino acid composition, sequence length, charge, hydrophobicity and structure of 
the peptide molecule (Berthou et al 1987, Drouin & Boutin 2010) Milk hydrolysates 
can modulate the gastrointestinal immune system by inhibiting proliferation and 
maturation of localised immune cells Particular milk hydrolysates modulate the 
MAP kinase and NF-xp pathways that consequently control the secretion o f several
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cytokmes that can induce inflammatory responses and strengthen the host defence 
mechanisms (de Medina et al 2010) Immune cells, such as monocytes and 
macrophages, play an important role in inflammatory responses and tissue repair and 
remodelling by either interacting directly with microorganisms during infections 
and/or secretion of cytokines that mediate biological effects (Mahida 2000)
On the other hand, hydrolysates have also been shown to promote the 
immune response Casein peptides induced innate host immune responses in 
humans, by stimulating the proliferation o f lymphocytes and macrophages (Meisel 
1997) Similar suppression o f a pro-inflammatory response by down-regulation of 
IL-8 m inflamed Caco-2 cells was recorded by casein hydrolysate and its size 
fractions Further validation o f  the anti-inflammatory activity was performed m 
porcine colonic explants and the casein hydrolysate, and its size fractions down- 
regulated IL -la , IL-lp and IL-8 expression (Mukhopadhya et al 2015) Bovine k- 
casein hydrolysate inhibited circulatory IFNy secretion and suppressed IL- 
10 and FoxP3 expression in concanavahn A (ConA)-stimulated rat splenocytes 
(Requena et al 2008) This bovine K-casein, m a human macrophage cell line U937, 
was associated with the suppression o f circulatory pro-inflammatory cytokmes IL- 
ip, TNFa and IL-8 production (Requena et al 2009) Saint-Sauveuret et al (2008) 
suggested that acidic or neutral peptide fractions from whey protein isolate better 
stimulated splenocyte proliferation and the cytokine secretion Javier et al (2014) 
reported that tryptic whey p-lactoglobuhn digest fraction enriched in acidic and large 
peptides increased the secretion o f IFN-y (a ThI cytokine), while fractions 
containing short peptides enhanced TNF-a production o f monocytes Vogel et al 
(2002) demonstrated that the immunomodulatmg and anti-inflammatory properties 
o f lactofemcin peptide are more related to the positively charged region o f the
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peptide. Thus, the amino acid constituents, sequence and the length o f the peptides 
are very important for their immunomodulatory activity.
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Figure 1.4 Mechanisms of action of immunomodulatory protein hydrolysates or 
peptides derived from food proteins
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1.4 SUPPLEMENTATION OF INFANT FORMULA WITH FUNCTIONAL 
FOODS
Breast feeding provides the best source o f nutrition for infants, however, when 
breast feeding is not an option or if breast milk is not available in adequate amounts, 
infant formula is the only alternative to meet the nutritional needs o f the growing 
infant These include cow’s milk or soy-based infant formulas, hypoallergenic infant 
formulas, and other formulas designed to meet the specific nutritional and dietary 
needs of infants Such needs include helping to lower the risk of food allergies and 
improve immune health These infant formulas are also developed to mimic the 
composition o f breast milk Human breast milk is typically the sole source of 
nutrition required for the first six months o f an infant’s life It’s nutrient content has 
not only been used to establish dietary recommendations for infants, but is also used 
as the model system for developing infant formulas Breast milk is unique in its 
physical structure and composition, with very specific types and concentrations of 
protein, fat, carbohydrate, vitamins and minerals, enzymes, hormones, growth 
factors, host resistance factors, inducers and modulators o f the immune system and 
anti-inflammatory agents (Ballard et al 2014). This composition is important not 
only to promote infant growth and development, but also to support optimal health 
by protecting infants from food allergies, illnesses and to promote gut health Diet 
has a major impact on the child development, hence, infant and follow-on formulas 
are formulated to be as similar as possible to the composition o f breast milk from 
healthy, well-nourished women
Current infant milk formulae on the market, suitable for infants with cow’s 
milk allergy are comprised o f extensively hydrolysed cow’s milk proteins (Figure 
1 3) These milk formulae provide the infant with the high nutritional quality o f the
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proteins, while also reducing their allergenic properties, due to their small size 
(Terheggen-Lagro 2002). However, while these extensively hydrolysed formulae 
are more tolerable and prevent allergic symptoms, they cannot induce tolerance to 
the allergen because extensive protein hydrolysis results in the loss o f 
immunogenicity. This reduces stimulation to the immune system, inhibiting its 
ability to develop tolerance to these otherwise harmless milk proteins. Although 
strict avoidance o f cow’s milk is advised for the management of cow’s milk allergy 
recent studies suggest that exposure to cow’s milk allergens can, in fact, be 
beneficial for infants that are at risk o f developing milk allergy through targeting and 
influencing the immune system from birth (Staden et al 2007).
Partially hydrolysed formulae, however, have been shown to reduce the 
prevalence o f atopic dermatitis in infants compared to whole-protein formula 
(Spieldenner et al 2011, Vandenplas et al 2014). Partial hydrolysis o f proteins 
retains the protein’s immunogenicity, which provides the infant with an opportunity 
to develop oral tolerance to the whole protein (Hensen et al 2012). Among these 
hydrolysates, both in vitro and in vivo studies have identified cow’s milk-derived 
whey and casein hydrolysates that have positive modulatory effects on the immune 
system. They have been shown to display similar beneficial effects to breastmilk on 
gut colonisation, through increasing Bifidobacterium levels, which are decreased in 
formula fed infants and are required to bring about immune balance, thereby 
promoting oral tolerance (Hemandez-Ledesma et al 2014, Chirico et al 1997). The 
increasing number o f and health promoting effects attributed to milk-derived 
bioactive peptides make them potential ingredients of functional food. The main goal 
o f the current research is to identify milk protein hydrolysates that have a capacity to
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both suppress allergenic T helper cell responses and to stimulate Treg cells so they 
can be added to infant formula to potentially prevent allergy
1.11 ANIMAL MODELS OF ALLERGY
Unfortunately all therapeutic approaches for food allergy currently are still in 
clinical phase I-III and patients can only protect themselves through strict avoidance 
o f all allergen-containing food products (Benede et al 2 0 1 6 ) However many 
important questions about food allergy cannot be answered by in vitro molecular 
experiments alone and an appropriate in vivo experimental platform becomes an 
urgent need Mechanistic research or modifications of experimental conditions using 
human studies cannot be easily performed m patients Moreover the amount and 
types o f tissue samples that can be collected from patients with food allergy are very 
restricted Therefore animal models become very valuable research tools o f choice 
Animal models help us get greater insights into three major aspects o f food allergy 
1) the evaluation o f food allergens 2) studies on immunological responses and 
mechanisms and 3) the development of preventative and therapeutic treatments 
(Oyoshi et al 2014) In the field o f food allergy, there is insufficient information 
regarding the nature of food allergens and the mechanisms responsible for loss or 
lack o f tolerance in patients It is difficult to develop a true homologous model at 
this time because feeding o f food allergens to mice elicits oral tolerance as it does in 
most human subjects Instead mucosal adjuvants such as aluminium hydroxide and 
cholera toxin have been widely used to overcome oral tolerance to co-admimstered 
antigens to generate Th2 responses (Ganeshan et al 2 0 0 9 ) The use o f these models
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has already provided significant advances in our understanding o f the potential 
mechanisms o f pathogenesis o f food allergy and in the development of new 
therapies
In recent years, the anti-inflammatory effects o f several bioactive peptides and 
hydrolysates have been evaluated m mouse models (Chakrabarti et a l , 2014) Two 
tnpeptides, Valyl prolyl proline (VPP) and Isoleucyl prolyl prolme (IPP) 
demonstrated beneficial effects in a model of intestinal enterocolitis through their 
mediation o f anti-inflammatory activities (Chatterton et al 2013). They recently 
reported that the hydrolysate of milk casern containing both VPP and IPP improved 
the vascular endothelial function o f subjects with stage I hypertension Feeding with 
peptide concentrates obtained from hydrolysis o f whey proteins showed significant 
edema decrease in paw edema test (Mochizuki et al 2010) Oral intake o f a com 
gluten hydrolysate reduced inflammatory injury m a rat model o f experimental 
colitis (Tavares et a l , 2013) Furthermore Wu et al (2006) found that the IFN-y/IL-4 
ratio increased in spleen T cells from mice fed with chitosan hydrolysate, suggesting 
a change toward a more Tiil-like phenotype Since IL-10 producing Treg cells can 
inhibit T h2 cells, another way to dampen down the T h2 response is to promote the 
differentiation of Treg cells by administration of specific peptides (Palomares et al
2010) This upregulation o f IL-10 production was observed in splenocytes obtained 
from mice treated with P-lactoglobulin trypsin hydrolysates, while intact p- 
lactoglobulm on the contrary downregulated IL-10 (Duan et al 2012) Ndiaye et al 
(2012), also found an increased amount o f IL-10 producing cells m the small 
intestine lamina propria of mice after oral administration of yellow pea protein 
hydrolysate Increasing evidence suggest that protein hydrolysates could be a 
promising alternative anti-inflammation agent because of their high safety
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Recently humanised allergy models have been developed to utilise the 
engraftment of human haematopoietic cells using severely immunodeficient mice. 
These models hold advantage over murine models o f food allergy as they generate a 
system whereby human T and B cell compartments o f the adaptive immune response 
capable o f generating T h2 and food-specific antibody responses against allergens can 
be studied in vivo (Shultz et al 2016). Such humanised mice allow for the testing of 
food mechanisms and specifically the role of IgE antibodies and mast cells in a 
humanised setting. Humanised mice are generated by the transplantation o f human 
hematopoietic cells into recipient mice (Rongvaux et al 2013) and the multi-potency 
of these cells are discussed in the next section.
1.12. HEMATOPOIETIC STEM CELLS
The developing mammalian blood system, contains more than ten distinct 
mature cell types, that arise from one specific cell type, the hematopoietic stem cell 
(HSC). Within the system, only HSCs possess the ability o f both multi-potency and 
self-renewal. Multi-potency is the ability to differentiate into all functional blood 
cells. Self-renewal is the ability to give rise to an identical daughter HSC without 
differentiation. Since mature blood cells are predominantly short lived, HSC 
continuously provide more differentiated progenitors while properly maintaining the 
HSC pool throughout life by precisely balancing self-renewal and differentiation 
(Ogawa et al 1993). The frequency o f HSC is highest in the CD34+ cell population 
although a lower number o f HSC might be found in the CD34' fraction as well 
(Kondo et al 2003). CD34, a ligand for L-selectin is expressed by only 0.5-5% of 
blood cells in human fetal liver, cord blood and adult BM (Digiusto et al 1994, 
Krause et al 1996). These rare cells can be isolated from different sources: fetal 
liver, granulocyte-colony stimulating factor (G-CSF) mobilised peripheral blood
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cells, adult bone marrow and umbilical cord blood (UCB) and have multi-potential, 
are self-renewing and/or undergo commitment to common myeloid or lymphoid 
progenitors (Metcalf et al 2007) One o f the first models o f HSC engraftment was 
described by Lapidot et al in which human HSCs were injected into irradiated SCID 
mice (Lapidot et al 1992) Recently, human CD34+ (Burton et al 2017) 
CD34+ CD38“ (Ishikawa et al 2005) and Lm“ CD34+ CD38“ (Takagi et al 2012) 
HSCs have been the main cells used to repopulate immunodeficient mice, most of 
them isolated from UCB and enriched by magnetic separation, cell sorting or both 
It is well established that UCB is a better source than bone marrow o f HSCs with 
high engraftment level (Kim et al 1999) CD34+ cells are transplanted into adult 
mice by either intravenous or intrafemoral injection From these studies it is now 
well established that neonatal mice have more potential than adult HSCs (Ueda et al 
2001) as they tend to have greater multilmeage human hematopoietic differentiation 
including T and B cell development when compared to mice engrafted as adults The 
number o f cells that needs to be injected and the engraftment that can be expected 
are therefore highly variable depending on the source o f CD34+ cells used It has 
been demonstrated that female NSG mice are more supportive o f human engraftment 
than male NSG when HSC are transplanted at a limiting dose (McDermott et al
2010) It is therfore crucial that the appropriate transplantation protocol is chosen in 
order to enable the expenmantal question to be answered
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1.12. HUMANISED MOUSE MODELS OF ALLERGY
Recently mice engrafted with human immune cells have been used to study 
human allergic responses in mice. These models hold advantage over murine models 
o f allergic inflammation as they generate an adaptive immune system capable of 
generating food-specific antibody responses following allergen ingestion as well as 
fostering the development o f the human innate effector cells such as mast cells and 
basophils. During this period such models have been improved and they have been 
used for an increasing array o f studies (Table 1.1).
The ability to study human allergies in an in vivo setting in mice has opened 
up a wide range o f possible avenues for research. Major limitations in the past have 
hindered the application o f the approach and o f these one o f the most important 
deficiencies has been the inability o f mouse factors to support human cells. Many 
essential factors required for human immune cell development and function are 
species specific and cannot be provided by the mouse. Therefore some of the studies 
listed in table 1.1 have adopted the strategy of replacing mouse genes with their 
human counterparts enabling the development and function o f granulocytes (mast 
cells and basophils) and potentially disabling the same of the corresponding mouse 
cells. Human cytokines can be overexpressed as transgenes in humanised mice 
(Willinger et al 2010). This approach has been used to generate human IL-3, 
granulocyte macrophage colony stimulating factor (GM-CSF) and stem cell factor 
mice (NSG-SGM3). In these mice, human cytokine expression is driven by the 
cytomegalovirus promoter which leads to ubiquitous expression.
Humanised mice can also use knock in technology to replace genes in mice 
for e.g IL-3 and GM-CSF two cytokines crucial for myeloid cell development and
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function were replaced in the mouse with the human loci for both genes to generate 
IL-3/GM-CSF KI mice for studying inflammatory responses in the lung In these 
mice there was no significant improvement in HSC engraftment and the high 
expression of GM-CSF in these mice ensures that any effects were evident in the 
lung Hense the tissue specific expression o f IL-3 or GM-CSF in KI mice was 
sufficient for tissue-specific development and migration o f human cells but not for 
systemically reconstituting entire human myeloid cells However the KI strategy 
does allow correct expression in appropriate organs (lung) where IL-3 and GM-CSF 
are normally expressed and at physiological concentrations (Willmger at al 2010) in 
contrast to delivery by hydrodynamic injection or overexpression as in IL-3/GM- 
CSF/SCF transgenic mice
To create a hematopoietic microenvironment more suitable for human 
myeloid development mouse strains that express the human 220-ammo acid isoform 
of the human membrane-bound stem cell factor (mSCF) have been used These 
transgenic mice expressed human membrane-bound SCF from a cassette including 
the human SCF cDNA expressed from the human phosphoglycerate kinase (PRK) 
promoter and are designated NODCg-Prkdc SC1D IL2rg tmlwjl Tg (PGK1- 
KITLG*220) 441 Daw/J or NSG-SCF mice SCF, also known as steel factor or kit 
ligand critically regulates the migration and survival o f mast cell precursors, 
promotes the proliferation o f both immature and mature mast cells, enhances mast 
cell maturation and also plays a role in HSC maintenance (Billerbeck et al 2011) 
Takagi et al (2012) reported higher engraftment o f CD45+ (97%) m the bone marrow 
m comparison to the NSG control (63%) and mast cells had engrafted sufficiently in 
all organs Engraftment o f human HSC requires preconditioning o f immunodeficient 
recipients usually with irradiation but HSC engraftment can also occur without
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irradiation in NSG-mSCF mice (Brehm et al 2012) In the absence of irradiation 
using transgenic expression of human membrane-bound SCF in non-irradiated mice, 
exhibited high engraftment levels o f T and B cell compartments o f the adaptive 
immune response and developed peanut-specific human IgE responses and mast cell- 
mediated anaphylactic sensitivity to ingested peanut following sensitisation (Burton 
et al 2017) This is the first humanised mouse model study o f peanut allergy and it 
paves the way forward for the study o f cellular and molecular interactions in the 
human food allergy response
To overcome the limited development o f the myeloid lineage, Ito et al (2013) 
used NOG mice transgemcally expressing human IL-3 and GM-CSF to show the 
superior engraftment o f granulocytes, basophils and mast cells in comparison to mast 
cells that develop in NSG-SGM3 and IL-3/GM-CSF knock m mice The engraftment 
o f human HSC in the bone marrow showed 4 and 3 fold increases and there was also 
an increase m myeloid DC When mice were sensitised with sera from patients that 
were allergic to Japanese cedar pollen and then challenged with antigen they 
developed a passive cutaneous anaphylaxis (PCA) reaction This was the first model 
to demonstrate that human cells generated in mice can mediate human allergic 
reactions in a reliable manner
Gut inflammation was recently assessed in a Hu-PBL-SCID-NSG- model 
This model was created by injection of human peripheral blood leucocytes (PBLs) 
which results in rapid engraftment o f CD3+T cells by the end o f the first week This 
model is excellent for studying human T cell function in vivo but has only a short 
expenmental window due to the development o f lethal xenogemc GVHD, usually 
within 4-8 weeks PBMCs from known donors with known allergies were used for 
engraftment Mice injected with PBMCs form allergic donors and then challenged
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with specific allergens developed intestinal wall thickening and leucocyte infiltration 
that were mediated by human IgE production (Eschbom et al 2015). Blocking IgE 
with the anti-IgE antibody omalizumab reduced gut inflammation. Co transfer of the 
allergic PBMC and the patient’s own Treg blocked IgE production. This study 
showed the utility of this model to investigate the role o f Tregs in allergic disease 
and the ability to assess therapeutics.
The limitation of the above study using PBMC to reconstitute NSG mice is 
the in ability of mast cells, granulocytes and human DC to functionally engraft. To 
solve this problem a triple transgenic mouse model under the control of a strong 
constitutive promoter provided support for hematopoietic cell development. In NSG- 
SGM3 mice, an immunodeficient strain that expresses transgenes for human stem 
cell factor (SCF), granulocyte macrophage-colony stimulating factor (GM-CSF) and 
IL-3 mice displayed increased human CD4+ T cells in spleen, liver and bone marrow 
and within the CD4+ population T reg cells were increased. This strain also had 
increased myeloid cells, CD15+ granulocytes and myeloid DC in the bone marrow.
Thrombopoietin (TPO) has been demonstrated as a crucial cytokine 
supporting maintenance and self-renewal o f HSCs. Rongvaux et al (2011) generated 
RAG2“'”Yc” ~ mice in which they replaced the gene encoding mouse TPO by its 
human homolog. Homozygous humanization o f TPO led to increased levels of 
human engraftment in the bone marrow o f the hosts, and multilineage differentiation 
o f hematopoietic cells was improved, with an increased ratio o f myelomonocytic 
verus lymphoid lineages. Interestingly, the presence o f human TPO improved 
differentiation o f human granulocytes. Thus, the presence of human TPO in recipient 
mice favours a balance between granulocytes and lymphocytes that better reflects the 
human physiological condition, a finding possibly due to better maintenance and/or
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differentiation o f human myeloid progenitor cells Despite the clear improvement in 
HSC-hke cell populations, as well as a better balance between the myeloid and 
lymphoid lineages, they did not observe any significant effect of TPO humanization 
on the overall engraftment levels in peripheral lymphoid tissues or in the percentages 
of B and T cells








































































Examining the advantages (full HSC engraftment, elevated myeloid, DC, CD4+, 
MC) and limitations (low IgG, GVHD, no improvement in engraftment) o f the 
humanised models and as the TPO and the NOG IL-3/GM-CSF mice were not 
commercially available, the NOD/SCID IL2rynu11 stem cell factor (SCF) and 
NOD/SCID IL2rynu11 triple transgenic SGM3 humanised mouse models were chosen 
to compare the best strain of mouse for the engraftment o f mast cells and basophils. 
The chosen strain o f NOD/SCID IL2rynu11 was then used to investigate the anti­
allergic potential o f milk protein hydrolysates for the treatment o f OVA driven 
allergy. Therefore, the aims o f this study were to develop an experimental humanised 
model of ovalbumin induced allergy and inflammation that mimic the main clinical 
characteristics o f human disease as well as to examine the allergenic and 
immunological properties o f hydrolysed whey proteins using this model.
1.13. AIMS AND OBJECTIVES
This chapter has highlighted the current understanding of how food allergy occurs 
how functional foods in the form of a milk protein hydrolysate modulate cells o f the 
immune system and explored the potential o f hydrolysates as a preventative strategy 
for food allergy. This thesis aims to investigate two distinct areas in food allergy 
treatment which remain to be addressed:
(1) The direct interaction o f hydrolysates with immune cells and elucidate 
the mechanism by which these interactions occur in vitro.
(2) Preclinical evaluation of the efficacy o f a novel non-pharmacological 
treatment (in the form of a cow’s milk protein hydrolysate) in an 
attempt to disrupt the pathogenesis of an inappropriate immune
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response (allergic inflammation) in a humanised mouse model of 
OVA allergy
Despite the advances made in our understanding of how hydrolysates 
modulate the immune system the direct action of hydrolysates with cells o f the 
innate (dendritic cells, MCs and basophils) and adaptive (T cells and B cells) system 
remain unclear The elucidation of these actions will be beneficial as it may pave the 
way for the use of hydrolysates as a functional food ingredient in formula to help 
induce tolerance in allergy prone infants, thereby reducing the risk of allergy and 
associated atopic conditions later in life The goal o f chapter 3 is to determine if and 
how hydrolysates modulate the activation of the immune system in vitro and to show 
the mechanism by which such effect is mediated.
Chapter 4 of this thesis will compare the engrafitment kinetics o f two strains 
of NSG mice m order to choose the best strain of mouse for the engrafitment of mast 
cells and basophils, the mam effector cells o f allergy for the establishment of an 
experimental platform to confidently test functional foods in vivo The chosen mouse 
strain was used in Chapter 5 to ascertain whether a novel cow’s milk protein 
hydrolysate can alter Th2 driven allergy sufficient to suppress allergic inflammation 
in a humanised mouse model o f OVA allergy
Overall this study is designed to further the current knowledge o f the 
bioactive properties of milk protein hydrolysates in terms of their anti-inflammatory 
activity It is hoped that this new platform will allow direct assessment o f how these 
potential anti-inflammatory functional foods act on human cells without having to do 
tests on human volunteers These food derived milk peptides could be used as a new 
alternative m the form of a functional food for the treatment and management of 
inflammatory diseases This thesis will advance our understanding o f how a novel
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milk protein hydrolysate may suppress allergic inflammation in vivo and will be of 
real value to nutritional companies, including infant formula manufacturers as this 
new experimental approach (testing functional foods in a human relevant system) 






2.2 REGULATORY ISSUES 
2.2.1 ETHICAL APPROVAL AND HPRA COMPLIANCE
All procedures involving the use o f animals or human materials were carried out 
by licensed personnel Ethical approval for all work was granted by the ethics committee 
o f Maynooth University (BRESC-2015-007) Project Authorisation was received from 
the HPRA (AE19124/P005) whereby the terms of the animal experiments within this 
project were outlined and adhered to
2.2.2 COMPLIANCE WITH GMO AND SAFETY GUIDELINES
All GMO/GMM work was performed according to approved standard operation 
procedures and recording protocols approved by the Environmental Protection Agency 
(Ireland) Safe working practices were employed throughout this study as documented in 
the Biology Department, Maynooth University Safety manual.
2.2.3 ANIMAL STRAINS
The following mouse strain was used Nonobese diabetic (NOD) severe 
combined immunodeficiency (SCID) common gamma deficient Cg-Prkdc scld IL2rg 
tmiWji/ T g  (PGK1 -KITLG*220) 441 Daw/J, mice abbreviated as NSG-mSCF mice 
expressing human stem factor (SCF) and NOD Cg-Prkdcscld IL2rgtmlWjl /Tg 
(CMVIL3,CSF2,KITLG)lEav/ MloySzJ mice abbreviated as NSG SGM3 mice 
expressing human SCF, hGM -CSF and hIL-3 (Jackson Labs, Bar Harbour, Maine,
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USA). All mice were housed according to Heath Products Regulatory Agency (HPRA) 
guidelines and used with ethical approval under the terms o f AE19124/P005 project 
authorisation from HPRA. Sample sizes for animal experiments were determined by 
statistical power calculation using SISA. SISA software is online at 
http://home.clara.net/sisa/power.htm
2.3 CELL CULTURE
2.3.1 HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)
ISOLATION
Whole blood buffy coat packs, which contained red blood cells, white blood cells 
and platelets, were supplied by the Irish Blood Transfusion Service (IBTS) at St. James’s 
Hospital, Dublin. PBMC were isolated from whole blood by density gradient 
centrifugation. The contents o f buffy coat packs were diluted 1 in 2 with phosphate 
buffered saline (PBS) (Oxoid Ltd., Basingstoke, Hampshire, England). 25 ml diluted 
blood was carefully layered on top o f 15 ml lymphoprep (Axis-Shield PoC AS, Oslo, 
Norway) in a 50 ml centrifugation tube (Sarstedt). The samples were centrifuged at 2400 
rpm for 25 min at room temperature with no brake and low acceleration. After 
centrifugation, the white buffy coat layer containing PBMC was removed into a sterile 
50 ml tube, leaving red blood cells and remaining plasma behind. PBMC were 
centrifuged at 1800 rpm for 10 min at 4 °C with the brake at normal settings. Supernatant 
was removed and the PBMC pellet was washed in 20 ml o f PBS and centrifuged at 1500 
rpm for 5 min at 4 °C for a total o f two times. Remaining red blood cells were lysed using 
5ml lx  red blood cell lysis buffer (Biolegend, London, UK) for 5 min. 25 ml of complete 
RPMI (cRPMI) (RPMI 1640 (Sigma-Aldrich) supplemented with 10 % (v/v) heat 
inactivated FBS, 50 U/ml penicillin (Sigma-Aldrich), 50 pg/ml streptomycin (Sigma-
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Aldrich), 2mM L-glutamine (Sigma-Aldich) and 0.1% (v/v) 2-mercaptoethanol (Gibco)) 
(Table 2.1) was added to stop lysis. PBMC were centrifuged at 1000 rpm for 10 min at 
4 °C to remove platelets. The PBMC pellet was resuspended in 25 ml o f cRPMI and 
counted.
2.3.2 DENDRITIC CELL ISOLATION AND CULTURE
Human CD14+ monocytes were isolated for in vitro generation of dendritic cells 
using human CD14 microbeads (Miltenyi 130-050-201) according to manufacturer’s 
instructions (Auburn, CA, USA).MN). Briefly, PBMC were isolated (see section 2.2.1) 
and resuspended in 80 pi o f MACS buffer to a cell density o f 10 * 106 cells. 20 pi of 
CD 14 microbeads were added and cells incubated for 15 min at 4 °C. 2 ml o f MACS 
buffer was then added per 1 x 107 total cells and the cells were centrifuged at 300 x g for 
10 minutes. All the supernatant was aspirated and up to 108 cells were resuspended in 
500pl o f MACS buffer. LS columns were placed into a MidiMACS separator and rinsed 
with 3 ml of buffer. The cell suspension was applied to the column and the flow-through 
containing unlabelled cells was collected. The column was washed with a further 3 x 3  
ml o f buffer and the column was removed from the separator and placed on a 15 ml 
collection tube. 5 ml of MACS buffer was pipetted onto the column and the magnetically 
labelled CD14+ cells were flushed out by firmly pushing the plunger into the column. The 
CD14+ cell suspension was centrifuged at 300 g for 5 min then resuspended in cRPMI 
and counted. On day 3, 1.5 ml o f cell suspension was removed from each dish and 
discarded. 1.5 ml of fresh cRPMI supplemented with 50 ng/ml GM-CSF (R&D Systems, 
Abingdon, UK) and 70ng/ml IL-4 (R&D) was added. After 6 days, cells were harvested 
by gentle aspiration and centrifuged at 300 g for 5 min. Cells were resuspended in cRPMI 
(Table 2.1) and counted. Cells were seeded at appropriate concentrations relevant to 
experimental assays.
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Human CD4+ T cells were isolated using Human Miltenyi Naive CD4+ T cell 
isolation kitll (130-094-131) according to the manufacturer’s instructions (Auburn, CA, 
USA) Briefly, PBMC were resuspended m 40 pi IX MACS buffer to a cell density of 
10 x 106 cells and 10 pi o f Naive CD4+ T cell biotin- antibody cocktail II was added and 
cells incubated for 5 mm at 4 °C 30pl o f MACS buffer was then added per 1 x 107 total 
cells After addition o f buffer, 20 pi o f Naive CD4+ T cell Microbead Cocktail II per 1 x 
107 cells was added and further incubated for 10 min at 4 °C LS columns were placed 
into a MidiMACS separator and nnsed with 3 ml of buffer The cell suspension was 
applied to the column and the flow-through containing unlabelled cells, representing the 
enriched naive CD4+ T cells was collected The column was washed with a further 3 ml 
of buffer and the unlabelled cells were collected and combined with the flow-through 
from the first wash The CD4+T cell suspension was centrifuged at 300 g for 5 min then 
resuspended in cRPMI and counted
2.3.4 HUMAN T CELL POLARISATION
Isolated naive CD4 T cells (see “Human CD4 T cell isolation protocol”) were 
stimulated using agonist antibodies directed to plate bound CD3 1 mg/ml (BD 
Pharmmgen) and plate bound CD28 1 mg/ml (BD Pharmingen) Plates were coated with 
lpg/ml anti-hCD3 in PBS for 2 hours at 37°C Cells were stimulated in the presence or 
absence o f polarising cytokines (human) with or without 1 mg/ml hydrolysates added on 
Day 0 or on Day 3 The cocktails used to drive specific T-cell subsets and their 
concentrations are represented in the table below
2.3.3 CD4+ T CELL ISOLATION
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Phenotype Cocktail Conc Supplier Cat no
Thl rIL-2 1 Ong/ml R&D 202-1L-010
anti-hIL-4 5jtg/ml R&D MAB304
rIL-12 10ng/ml R&D 219-1L
Th2 rIL-2 1 Ong/ml R&D 202-1L-010
rIL-4 12 5ng/ml R&D 204-1L-010
anti-IFNy 5(ig/ml R&D MAB2852
TReg rIL-2 5gg/ml R&D 202-1L-010
rTGF-p 2ng/ml R&D 204-B-002
Th-17 rIL -ip lOug/ml R&D 240-1B-002
r-6 20ng/ml R&D 206-1L-010
rIL-23 1 Ong/ml R&D 1290-IL-010
rTGF-p 2ng/ml R&D 204-B-002
anti-hlFNy lOftg/ml R&D MAB2852
anti-hIL-4 lOpg/ml R&D MAB304
Cells were transferred to coated anti-CD3 96 round bottom well plates (Fisher, 
Ballycoolin, Ireland) at 1 0 x 106 cells/ml 2pg/ml anti-CD28 was added to cells Cells 
were incubated for three days at 37°C On day 3 cells were refed with lOng/ml IL-2 and 
hydrolysates (1 mg/ml) were added and incubated for a further 3 days at 37°C On day 6 
cells were harvested
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2.3.5 MEASUREMENT OF CELL VIABILITY
Cells were resuspended in their specific growth media and diluted 1/2 in 2 % (w/v) 
ethidium bromide/acndine orange (EB/AO) (Sigma-Aldnch) 10 pi was pipetted on to a 
haemocytometer, live cells (green) and dead cells (orange) were counted using a 
fluorescent light microscope
2.3.5.1 MTT ASSAY
Cell viability was also assessed using the Methylthiazoldiphenyltetrazolium 
bromide (MTT) assay based on the reduction o f MTT reagent into purple formazan 
crystals by viable metabohcally active cells Briefly, CFSE stained PBMC were 
harvested on Day 4, washed with PBS and incubated with 20pl o f MTT solution 
(0.5mg/ml) for 3h at 37°C The media was removed and the formazan crystals were then 
dissolved in 200pl of DMSO and centrifuged for 5 minutes at 300 x g and incubated at 
37°C for 5 minutes The absorbance (optical density (O D)) o f the samples were measured 
at 570nm using a microplate reader (BioTek EL800,Swindon, UK) with Gen5 Data 
Analysis Sotware Cell viability was determined as a % o f control cells
2.3.6 CRYOPRESERVATION AND RECOVERY OF CELLS FROM
LIQUID NITROGEN
For short term storage, CD34+ haematopoietic stem cells were resuspended at 1 - 
2 x 106/ml (CD34+) in 500 pi freezing medium (DMEM containing 10% (v/v) Hyclone 
FBS (LabTech) supplemented with 10 % (v/v) Dimethyl Sulfoxide (DMSO) (Sigma- 
Aldrich)) For PBMC cryopreservation, cells were resuspended at 5 x 107/ml m heat
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inactivated FBS. 50 pi o f DMSO was added to a 1.5 ml cryo-tube (Thermo Fisher 
Scientific, Massachusetts, USA) before the resuspended PBMC were added to the cryo- 
tube. Cells were gradually cooled at 1°C per minute overnight and then transferred to 
liquid nitrogen for storage. To recover cells, vials were quickly thawed at 37 °C. Just as 
the vial contents thawed, cells were transferred to a 15 ml tube (Sarstedt) where 5 ml of 
warmed medium was added (drop by drop) before cells were centriiiiged at 300 g for 5 
min. The pellet was resuspended in 1 ml o f complete cell specific culture media, counted 
and used for experiments as required.
2.4 CELL CHARACTERISATION BY FLOW CYTOMETRY
2.4.1 GENERAL FLOW CYTOMETRY AND CHARACTERISATION OF
CELLS
For analysis by flow cytometry, cells (PBMC, DC or CD4+ ThI, Th2 , T-Reg, 
T h17 cells)) were harvested, washed in sterile PBS and resuspended in FACS Buffer 
(PBS supplemented with 2 % heat inactivated FBS) to yield approximately 1 x 105 
cells/FACS tube (4 ml polypropylene tubes) (Falcon, BD Biosciences, Oxford, UK) or 1 
x 105 cells/well in 96 well V bottom Plate (Lennox, Dublin, Ireland). Fluorochrome 
conjugated antibodies (Table 2.3) or isotype controls were incubated with cells for 15 min 
at 4 °C. After 15 min, cells were washed in 2 ml of FACS Buffer, vortexed and 
centrifuged at 300 g for 5 min. The supernatant was removed and cells resuspended in 
50 pi counting beads (3 x 105/ml) (Calibrite™ Beads, BD Biosciences) or 100 pi o f cell 
fixative (PBS supplemented with 2 % (v/v) formaldehyde solution (Sigma-Aldrich)). 
Cells were then analysed by flow cytometry (Accuri C6 flow cytometer, BD Biosciences) 
using CFlowPlus software (BD Biosciences).
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2.4.2 CFSE LABELLING OF PBMC AND MEASUREMENT OF T CELL 
PROLIFERATION IN  VITRO
Human PBMC were resuspended at 5 x 107/ml in warm PBS PBMC (5 x 1 07) were 
labelled with 10 pM carboxyfluorescein succimmidyl ester (CFSE) Cells were incubated 
for 10 minutes at room temperature in the dark After 10 minutes, 2 ml o f cold PBS was 
added and PBMC were centrifuged at 600 g for 5 minutes then washed twice in PBS 
Labelled PBMC (5 x 104/well) were seeded into a 96 well round bottom tissue culture 
plate (Fisher, Ballycoolm, Ireland) CD3/CD28 Dynabeads® beads (Invitrogen) were 
added (1 x 104/well) to activate PBMC proliferation Hydrolysates (0 5 mg/ml, 1 mg/ml 
or 2 mg/ml) were added one hour later After 4 days, PBMC with or without hydrolysates 
(1 mg/ml) were harvested and the level o f proliferation by CD3+cells was analysed by 
flowcytometry (section 2 3 1) and enumerated using counting beads (3 x 105/ml) 
(Calibnte ™ beads, BD Biosciences)
2.4.3 INTRACELLULAR STAINING FOR TRANSCRIPTION FACTOR 
EXPRESSION IN HUMAN T CELLS
FoxP3, T-bet, Gata-3 and Roryt was analysed mtracellularly using a FoxP3 
staining kit (eBioscience) Briefly, CD4+ T cells were washed in 150pl FACS buffer and 
centrifuged at 950rpm for 5 mins For FoxP3 assays, CD4+ T cells were labelled with 
CD4 FITC and CD25 APC or corresponding isotype control antibodies for 15 min at 4 
°C For ThI assays (T-bet), CD4+ T cells were labelled with CD3 FITC and CD4 APC 
or corresponding isotype control antibodies for 15 min at 4 °C For Th2 assays (Gata-3), 
CD4+ T cells were labelled with CD3 FITC and CD4 PE or corresponding isotype control 
antibodies for 15 min at 4 °C For ThI7 assays (Ror-yt), CD4+ T cells were labelled with 
CD3 FITC and CD4 PERCP or corresponding isotype control antibodies for 15 mm at 4
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°C The cells were washed twice in 150pl o f FACS buffer, centrifuged at 950rpm for 5 
min and fixed with lOOpl fix/permeabilisation buffer (eBioscience) for 1 hour The cells 
were then permeabilised with 200pl permeabihsation buffer, washed with 150pl FACS 
buffer and blocked using 3 pi 2% rat serum for 15 min The cells were labelled with T- 
bet, Gata-3, FoxP3, Ror-yt or isotype control antibodies and left at 4° C overnight 
Samples were washed twice with 150pl FACS buffer, resuspended m counting beads (3 
x 105/ml) and analysed by flow cytometry (Accun C6 flow cytometer, BD Biosciences) 
using CFlowPlus software (BD Biosciences)
2.5 MILK PROTEIN HYDROLYSATES
2.5.1 WHEY AND CASEIN HYDROLYSATES
A number o f Whey and Casein hydrolysates (and their regenerates / upscaled 
samples) were supplied by our collaborators at Food for Health Ireland (FHI), University 
o f Limerick (Alice Nongomenna) Due to Intellectual Property Rights method of 
generation could not be released by FHI Lead functional compounds 56 (LFC56) and its 
regenerate 56R were included as controls These two hydrolysates were included as they 
proved to be functionally bioactive in a bioassay screening platform in FHI phase 1 
Control milk protein substrates were supplied by the industry partners The whey protein 
concentrate (wpc80 81% (w/v) protein) was obtained from Carbery Milk products Group 
(Ballineen, Cork) wpc80 is a food grade powder containing high quality whey protein It 
is manufactured from dairy whey using ultrafiltration and spray drying technology 
Sodium caseinate (NACN-90 4% (w/v) protein was obtained from Kerry Ingredients 
(Listowel, Ireland) NACN is a food grade powder containing high quality casein protein
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2.5.2 PREPARATION OF HYDROLYSATE (FREEZE DRIED MILK 
POWDERS)
Before dissolving the powders, the hydrolysates were allowed to equilibrate 
at room temperature in order to avoid water condensation on the powder Carefully 0 015g 
o f powder was weighed out on a precision scales The powder was dispersed in 1 5ml 
sterile water (stock concentration -  lOmg/ml) using gentle agitation The hydro lysates 
were stirred gently for 15 -30  min at room temperature to ensure complete dispersion 
When the powders were fully dispersed in the water the hydrolysates were centrifuged at 
room temperature at 5000 g for 5 min and the supernatant was retained The supernatant 
was filtered through 0 2 mm cellulose acetate filters (Whatman GD/X) and the 
hydrolysates were added at a working concentration o f 0 5 mg, 1 mg/ml or 2 mg/ml to 
cells Soluble peptides were present in 5% (w/v) aqueous dispersions o f these freeze- 
dried powders
2.5.3 STORAGE OF HYDROLYSATES
On receipt of samples, all hydrolysates were stored at -20°C m the presence o f 
desiccant (e g , silica gel)
2.6 BIOCHEMICAL METHODS
2.6.1 PROTEIN EXTRACTION
Intracellular protein was extracted from human dendritic cells 24 well plates 
were placed on ice and media removed Cells were washed with 1 ml of ice cold PBS 
Cells were scraped m 1 ml ice cold PBS and added to a 1 5 ml tube Samples were 
centrifuged at 15,000 rpm for 5 mm and PBS removed The pellets were then resuspended 
in 90 ¡il cell lysis buffer (Table 2 2) and left on ice for 10 min. Samples were resuspended
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by gently pipetting to aid thee lysis process an left on ice for a further 10 min Protein 
lysates were then subjected to centrifugation at 12,000 g for 10 min at 4 °C 90 pi o f the 
supernatant which constitutes the intracellular protein was added to a new 1 5 ml tube and 
stored at -  20°C Prior to loading protein lysates, samples were mixed with 4X sample 
buffer(Table 2 2) and boiled for 5 mm
2.6.2 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS- 
PAGE)
SDS-PAGE was earned out in accordance with the Laemmli method as modied 
by Studier (Laemmli 1970, Studier 1973). Samples and appropnate prestained (10-180 
kDa) protein markers were loaded into separate 0 75 mm wells Electrophoresis was 
performed at 70 V through a 5% polyacrylamide stacking gel and then through a 10% 
polyacrylamide resolving gel at 90 V for up to 2 hours
2.6.3 IMMUNOBLOTTING
Following separation by electrophoresis, the protems were transferred 
electrophoretically to nitrocellulose membranes (GE Heathcare, Buckinghamshire, 
England) in a BioRad Trans -B lot Turbo Blotting System (BioRad,) at 2 5 A for 30 mins 
1 layer of extra thick blotting paper (BioRad) was placed on the bottom surface of the 
Trans-blot System followed by one layer o f nitrocellulose membrane The resolving gel 
was then placed on top with care to avoid air bubbles Finally 1 more layer o f extra-thick 
blotting paper was added and the unit closed Following transfer , non-specific binding 
was blocked by incubating the nitrocellulose membranes at room temperature for 1 h with 
blocking buffer( tns buffered saline (TBS)), 0 1% Tween-20 with 5% (w/v) non-fat dry 
milk (Table 2 2) under gentle agitation The membranes were then incubated under 
agitation at 4 0 C overnight with the primary antibody diluted in TBS containing 0 1%
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(v/v) Tween-20 (TBST) with 5% BSA as indicated m Table 2 4 The membranes were 
subsequently subjected to 3 x 5 min washes in TBST (Table 2 2) Membranes were then 
incubated in a secondary antibody (Table 2 5) specific for the primary antibody in TBST 
containing 5% (w/v) skimmed milk powder for 1 h in the dark at room temperature The 
membranes were then washed a further 3 times for 5 mm each in TBST in the dark The 
immunoreactive bands were detected using enhanced chemilummescence development 
(WestemBnght ECL HRP Substrate, Advansta, Labtech)
2.6.4 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) OF 
CYTOKINES
All ELISA were earned out according to manufacturer’s instructions (R & D 
Systems, Abingdon, UK or eBioscience, Paisley, Scotland) Specific capture antibodies 
(human IFNy, IL-2, IL-4, IL-5, IL-6, 1L-10 , IL-12/IL-23 p40, IL-13 & IL-17) in PBS 
were added to 96 well Nunc-Immuno™ plates (Thermo Fisher Scientific) and incubated 
overnight at room temperature Plates were then washed 3 times m wash buffer (PBS 
supplemented with 0 05 % v/v Tween 20) and then incubated in blocking solution (PBS 
supplemented with 1 % w/v BSA) for a minimum of 1 h Plates were then washed and 
incubated with 100 pl/well o f sample supernatant or corresponding cytokine standard for 
2 hr at room temperature After washing, plates were incubated with specific detection 
antibodies for a further 2 h at room temperature Plates were washed again and incubated 
with 100 p 1/well of streptavidin horseradish peroxidase (HRP) (R & D Systems) 
conjugate diluted 1/40 in specific reagent diluent (Tns Buffered solution (TBS) (Sigma- 
Aldnch) supplemented with BSA for 20 mm After washing, plates were incubated with 
100 pl/well o f tetramethylbenzidine (TMB) substrate (Sigma-Aldnch) for 20 mm at room 
temperature out o f direct light The reaction was stopped after 20 min by adding 50
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(4.1/well o f 1 M H2SO4. The absorbance (optical density (O.D)) o f the samples and 
standards were measured at 450 nm for all ELISA using a microplate reader (BioTek 
EL800,Swindon,UK) with Gen5 Data analysis software. The cytokine concentration of 
each sample was determined by comparison to the standard curve o f known cytokine 
concentrations using GraphPad Prism5 software.
2.6.5 MEASUREMENT OF TOTAL IgE AND IgGl
Total IgE and IgGl were carried out according to manufacturer’s 
instructions (eBioscience, Paisley, Scotland). Specific capture antibodies (human IgE 
,IgGl ) in PBS were added to 96 well Nunc-Immuno™ plates (Thermo Fisher Scientific) 
and incubated overnight at room temperature. Plates were then washed 3 times in wash 
buffer (PBS supplemented with 0.05 % v/v Tween 20) and then incubated in blocking 
solution (PBS supplemented with 1 % w/v BSA) for a minimum of 2 h. Plates were then 
washed and incubated with 50 pi/well o f sample sera or corresponding standard for 2 hr 
at room temperature. After washing, plates were incubated with specific detection 
antibodies for a further 1 h at room temperature. After washing, plates were incubated 
with 100 pl/well o f tetramethylbenzidine (TMB) substrate (Sigma-Aldrich) for 20 min at 
room temperature out o f direct light. The reaction was stopped after 20 min by adding 
50 pl/well of 1 M H2SO4 . The absorbance (optical density (O.D)) of the samples and 
standards were measured at 450 nm for all ELISA using a microplate reader (BioTek 
EL800,Swindon, UK) with Gen5 Data analysis software. The antibody concentration of 
each sample was determined by comparison to the standard curve o f known 
concentrations of IgE, IgGl using GraphPad Prism5 software.
64
2.6.6 MEASUREMENT OF OVA SPECIFIC IgG l
Ova specific IgGl was assayed by enzyme-linked immunosorbant assay 
(ELISA) 96 well Nunc-Immuno™ plates (Thermo Fisher Scientific) were coated with 
5pg/ml OVA extract diluted in carbonate buffer (pH 9 6) and left overnight at 4°C Plates 
were then washed 3 times with 200 pi washing buffer and blocked with 250pl 1% bovine 
serum albumin (BSA) in PBS with 1% Tween 20 for two hours at room temperature 
After washing, 50 pi diluted serum samples were added to the plates and incubated 
overnight at 4°C Following incubation, plates were washed, and 100 pi of 1 250 diluted 
HRP-conjugated anti-human IgG antibody (eBioscience, Paisley, Scotland) were added 
to each well The plates were further incubated for one hour at 37°C After washing, plates 
were incubated with 100 pl/well o f tetramethylbenzidine (TMB) substrate (Sigma- 
Aldnch) for 20 min at room temperature out o f direct light The reaction was stopped 
after 20 min by adding 50 pl/well of 1 M H2SO4 . The absorbance (optical density (O D)) 
o f the samples were measured at 450 nm for all ELISA using a microplate reader (BioTek 
EL800, Swindon, UK) with Gen5 Data analysis software
2.7 MOLECULAR TECHNIQUES
2.7.1 RNA ISOLATION
Total RNA was extracted using trizol® reagent (Invitrogen) according to the 
manufacturers’s instructions Briefly, 1 x 106 cells were lysed m 1ml trizol at room 
temperature for 5 mm 100 pi o f RNA-grade l-Bromo-3-chloropropane (SigmaAldnch) 
was added to the cells, mixed vigorously and incubated at room temperature for 5 min 
Samples were centrifuged at 12,000 g for 15 mm at 4°C Two distinct layers resulted
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with RNA remaining in the clear, aqueous upper layer. 350-400 pi of RNA was carefully 
removed, ensuring the lower white DNA layer was not disturbed, and precipitated with 
500 pi isopropanol (Sigma-Aldrich). The samples were incubated at room temperature 
for 10 min and followed by centrifugation for 10 min at 4 °C. The resulting RNA pellet 
was washed with I ml 75 % (v/v) ethanol and centrifuged at 7,500 g for 5 min at 4 °C. 
The ethanol was aspirated and the RNA pellet was allowed to briefly air dry prior to 
resuspension in 30 pi RNase-free water (Promega, Southhampton, UK). The purity and 
concentration of RNA was determined using a spectrophotometer (Nanodrop 2000, 
ThermoScientific, Wilmington, DE, USA) which calculated the ratio o f absorbance at 
260 nm to280 nm. A ratio between 1.8 and 2.0 indicated sufficient purity of the RNA. 
Samples outside this range were discarded.
2.7.2 DNASE TREATMENT OF RNA
Genomic DNA was removed from RNA samples by treatment with DNase 1 
(Invitrogen, Paisley, UK). 1 pi o f DNase (Amplification grade) was added to 500 ng of 
RNA and incubated for 15 min at room temperature. 1 pi of 25mM EDTA (Invitrogen), 
to inactivate the DNase, was added to the mixture and incubated at 65°C for 10 min.
2.7.3 cDNA SYNTHESIS
Following DNase treatment o f RNA, total RNA was reverse transcribed using 5X 
All-In-One Mastermix (ABM-NBS Biologicals, Cambridgeshire, UK). This ready to use 
mastermix formulation , containing EasyScript Reverse Transcriptase, RNaseOFF 
ribonuclease inhibitor, dNTP mix ,01igo (dT)s and random primers ,was diluted to a IX
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concentration in nuclease-free water (ABM-NBS Biologicals) The conditions for cDNA 
synthesis were as follows 42 °C for 50 nun, 85°C for 5 min, and 4 °C for 10 min 
Quantification o f cDNA was performed by measuring the absorbance value of the sample 
260nm Samples were stored -20°C until required
2.7.4 REVERSE TRAN SCRIPTION-POLYMERASE CHAIN
REACTION (RT-PCR)
PCR was used to determine the presence o f specific DNA sequences (or mRNA 
following reverse transcription) using primers summarised in Table 2 6 Expression of 
the housekeeping gene, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
as a positive control PCR reactions contained 2 5 mM MgC12 (Promega), 25 mM dNTP 
(Promega), 1 x GoTaq reaction buffer (Promega), 40 U/ml Taq polymerase (Promega) 
and 0 4 pM of the appropnate primer (NCBI BLAST) The reaction mastermix was 
adjustedto a final volume o f 24 pi with nuclease-free water The PCR conditions wereas 
follows denaturation at 95 °C for 45 sec (2 min for first cycle), annealing at 58°C for 45 
sec (optimal annealing temperatures are summarised m Table 2 7 )  and extension for 45 
sec at 72°C DNA products were resolved on a 1 3 % w/v agarose gel and detected by 
binding o f gel red (Biotium, Hayward, CA)
2.7.5 AGAROSE GEL ELECTROPHORESIS
Agarose gels were prepared by adding 1 3% (w/v) agarose in TAE buffer and 
heating until completely dissolved The solution was then cooled before 5 pi GelRed 
nucleic acid stain (Biotium) was added and the solution waspoured into a gel tray 
Following solidification, agarose gels were submerged in TAE buffer and subjected to 
electrophoresis at 110 V Samples were run simultaneously with a 1 Kb molecular weight
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ladder Nucleic acid products were visualised under ultraviolet (UV) light (254nm) and 
images acquired using a Gel Logic 212 Pro gel documentation system (Carestream 
Health,Connecticut,USA)
2.7.6 REAL TIME-POLYMERASE CHAIN REACTION (qPCR)
cDNA was analysed for the quantification o f mRNA expression Briefly, cDNA 
(500 ng) were amplified in the presence o f SYBR® Green Jumpstart Taq ReadtyMix PCR 
mastermix (Qiagen) Accumulation of gene-specific products were measured 
continuously by means o f fluorescence detection over 40cycles Each cycle consisted of 
denaturation at 95 °C for 15 sec, annealing at 95 °C for 30 sec, (Table 2 6) and extension 
at 72 °C for 45 sec followed by a melt curve cycle o f 95 °C for 15 sec, 55 °C for 15 sec 
and 95 °C for a final 15 sec Quantification o f target gene expression was obtained using 
an Eco Real-Time PCR System (Illumina, San Diego, CA USA) Expression was 
quantified m relation to the housekeeping gene GAPDH using the delta CT method The 
ACT method was determined by subtracting the GAPDH value form the target CT value 
for each sample The fold change in relative gene expression was determined by 
calculating the 2-Act values (Schmittgen & Livak 2008)
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2.8 HUMANISED MOUSE MODEL
2.8.1 INTRAVENOUS ADMINISTRATION OF HUMAN CD34+HSCs
A humanised mouse model was developed from a protocol described by 
Brehm et al (Brehm et al 2012) and Billerbeck et al. (Billerbeck et al 2012). NSG-mSCF 
mice (Prkdc scld IL2rg ,mlW)l/Tg PGK1-KITLG*220) 441 Daw/J and NSG-SGM3 mice 
(NOD CgPrkdcscidIL2rgtmlwj1/TgCMVIL3,CSF2,KITLG)lEav/MloySzJ were two strains 
chosen to study engraftment of human CD34+ hematopoietic stem cells (HSCs) in NSG 
mice. NSG-SGM3 mice were irradiated with a conditioning dose of 1.0 Gray (Gy) of 
whole body gamma irradiation. NSG-mSCF mice were non-irradiated. Cord blood- 
derived flow-sorted human CD34+ (HSCs) purchased from Lonza (Basel, Switzerland) 
or freshly isolated human CD34+ HSCs (AnthonyNolan/Holles St) were administered 
into 3-6 week old NSG-SCF and NSG-SGM3 mice by intravenous injection into the tail 
vein using a 27 gauge needle and a 1 ml syringe between 4 h but no longer than 24 h 
following irradiation. Before infusion CD34+ HSCs were washed three times with sterile 
PBS. CD34+ HSCs (5 x 104- 1 x 105) cells/mouse were administered on day 0. Each 
mouse received a total o f 0.3 ml. Following i.v injection, animals were returned to their 
cages where they were monitored closely for the first hour and at regular intervals 
thereafter for any signs o f distress or ill health. Animals were weighed 3 times per week 
and weight loss was documented accordingly. Any animals which displayed greater than 
15 % total bodyweight loss were sacrificed humanely. Engraftment o f CD34+ HSCs was 
examined in peripheral blood, spleen, bone marrow, liver and thymus using flow 
cytometry at 12, 16 and 20 weeks post transplantation.
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2.8.2 CD3+ CELL DEPLETION OF CORD BLOOD
Fresh human cord blood (80 -170ml) was purchased from Anthony Nolan Trust 
UK (Anthony Nolan Cell Therapy Centre, Nottingham, UK) and shipped overnight at 
room temperature (15-25°C) The next morning the CD3+ cells were depleted using the 
RosetteSep system (Stemcell Technologies, Grenoble,France) 1 25ml RosetteSep 
Fluman CD3 Depletion cocktail was added for every 25ml o f cord blood This was mixed 
and incubated for 20 minutes at room temperature The cord blood was then diluted 1 4 
in RoboSep buffer (PBS with 2% foetal calf serum (FCS) and ImM EDTA) This was 
carefully layered over Lymphoprep (Axis Shield PoC AS, Oslo, Norway), with 35ml o f 
blood for 15ml of Lymphoprep and spun at 1200 g for 20 minutes at 20°C and with the 
brake off The enriched cells were transferred to a clean Falcon tube and diluted m an 
equal volume of RobSep buffer (Stemcell Technologies, Grenoble, France) and spun at 
300 g for 10 minutes CD3+ cell depleted cord blood cells were then resuspended in 
RoboSep buffer for further processing using the EasySep separation (described below) 
system
2.8.3 CD34+ CELL PURIFICATION USING EASYSEP
EasySep (Stemcell Technologies, Grenoble, France) human cord blood CD34
positive selection kit II (Cat no 17896) was used for labelling between 80-170ml of
Anthony Nolan cord blood or 60-140 ml o f Holies St cord blood 75(4.1 o f RosetteSep cord
blood CD34 pre-enrichment cocktail II was added for every 15ml o f cord blood. This was
mixed and incubated for 20 minutes at room temperature The cord blood was then diluted
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1:2 in RoboSep buffer (PBS with 2% foetal calf serum (FCS) and ImM EDTA Stemcell 
Technologies). This was carefully layered over Lymphoprep (Asis-Shield PoC AS, Oslo, 
Norway) with 30ml of blood for 15ml o f Lymphoprep and spun at 1200 x g for 20 minutes 
at 20°C with the brake off. The enriched cells were transferred to a clean Falcon tube and 
diluted in an equal volume o f RoboSep buffer (Stemcell Technologies, Grenoble, France) 
and spun at 300 x g for 10 minutes with the brake low. The pre-enriched cells were then 
resuspended in 0.75 ml- 1.0 ml in EasySep buffer and transferred to a 14 ml polystyrene 
round-bottom tube (Coming 17 x 100 mm).100(xl of human CD34 positive selection 
cocktail was added for every ml of sample. This was mixed and incubated for 10 minutes. 
The EasySep magnetic nanoparticles were vortexed for 30 seconds to give a uniform 
suspension and then added to the cell suspension at 50pl/ml o f cells. This was mixed and 
incubated at room temperature for 5 minutes. The cell suspension was brought to a total 
volume of 2.5ml with EasySep buffer. The cells were mixed by gentle pipetting and the 
tube containing the cell suspension was placed, without a lid, into the big easy magnet 
and set aside for 5 minutes. In one continuous movement the magnet containing the tube 
with the cell suspension was inverted thus pouring off the supernatant. Once upright the 
tube was removed from the magnet and the remaining cells were resuspended in EasySep 
buffer. The cells were once again mixed by gentle pipetting and the tube containing the 
cell suspension was placed, without a lid, into the magnet and set aside for 5 minutes. In 
one continuous movement the magnet containing the tube with the cell suspension was 
inverted thus pouring off the supernatant. This was repeated 3 more times and the final 
cell suspension was topped up with EasySep buffer centrifuged at 300 x g for 10 minutes 
with the brake low. All the supernatant was aspirated and finally the yield and purity of 
the labelled fraction was determined using flow cytometry before the cells were either 
injected into mice or cryopreserved in 90% FCS and 10% DMSO.
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2.8.4 ISOLATION OF HUMAN CELLS FROM MOUSE SPLEEN AND
THYMUS
12, 16 and 20 week old male and female NSG-SCF and NSG-SGM3 mice were 
sacnficed by cervical dislocation Spleens and thymus were removed aseptically from 
mice into a 50 ml tube containing cRPMI (Table 2 l).Splenocytes and thymocytes were 
isolated by homogenising spleens and thymus through a 70 pm filter into a fresh 50 ml 
tube using a sterile plunger The homogenates were centrifuged at 300 g for 5 min and 
resuspended in 5 ml o f 1 x red blood cell lysis buffer solution (BioLegend, San Diego, 
CA,) for 5 mm at room temperature 5 ml o f cRPMI was added to the suspension to 
neutralise the lysis solution which was then centrifuged at 300g for 5 min Supernatant 
was removed and the cells were then resuspended for FACS analysis (Section 2 9 1)
2.8.5 ISOLATION OF HUMAN CELLS FROM MOUSE BONE MARROW
12, 16 and 20 week old male and female NSG-SCF and NSG-SGM3 mice were 
sacnficed by cervical dislocation Femurs and tibias were removed aseptically from mice 
into a sterile petn-dish and the surrounding muscle removed The ends o f each bone were 
removed and the bone marrow was flushed into a sterile Petn dish using a 27 gauge needle 
and into cRPMI (Table 2 1) Cell aggregates were disrupted using a 19 gauge needle and 
5 ml synnge Bone marrow aggregates were homogenised through a 70pm filter into a 
fresh 50 ml tube using a stenle plunger and the isolated cells were then suspended in 25 
ml cRPMI This homogenate was layered over 15 ml lymphoprep density gradient (Axis- 
Shield) and centrifuged at 2400 rpm for 25 min with no brake and low acceleration The
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interface was collected by aspiration into a fresh labelled 50ml tube The interface was 
washed twice with 25 ml PBS and centrifuged at 300 g for 5 min Supernatant was 
removed and the cells were resuspended for FACS analysis (Section 2 9 1)
2.8.6 ISOLATION OF HUMAN CELLS FROM MOUSE LIVER
Livers were removed aseptically from mice into a 50 ml tube containing cRPMl 
(Table 2 1) Tissues were homogenised through a 70pm filter into a fresh 50 ml tube using 
a sterile plunger and the isolated cells were then suspended in 25 ml cRPMI This 
homogenate was layered over 15 ml lymphoprep density gradient (Axis-Shield) and 
centrifuged at 2400 rpm for 25 min with no brake and low acceleration The interface was 
collected by aspiration into a fresh labelled50 ml tube The interface was washed twice 
with 25 ml PBS and centrifuged at 300 g for 5 mm Supernatant was removed and the 
cells were resuspended for FACS analysis (Section 2 9 1)
2.8.7 ISOLATION OF HUMAN CELLS FROM MOUSE PERIPHERAL 
BLOOD
At 12, 16 and 20 weeks after HSC transplantation, peripheral blood was collected 
from the facial vein of humanised NSG-SCF and NSG-SGM3 mice Briefly 100-150 pi 
o f blood was collected into an eppendorf tube containing 200pl o f 2mM EDTA and mixed 
thoroughly 1 0 ml of IX RBC Lysis Buffer was added and each tube was gently vortexed 
for 10 sec and incubated at room temperature, protected from light, for 10-15 minutes 
All samples were centrifuged at 350 x g for 5 minutes The supernatant was removed
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without disturbing pellet and the pellet was resuspended for FACS analysis (Section 
2 9  1)
2.9 HUMANISED MOUSE MODEL OF OVA ALLERGY
2.9.1 INTRAVENOUS ADMINISTRATION OF FROZEN HUMAN
CD34+ HSCs
A humanised mouse model was developed from a protocol described 
by Brehm et al (Brehm et al 2011) Female NSG-mSCF mice (Prkdc scld IL2rg ,mlwJVTg 
PGK1 -KITLG*220) 441 Daw/J were chosen to study engraftment o f human CD34+ 
hematopoietic stem cells (HSCs) in NSG mice Cord blood-denved flow-sorted human 
CD34+ (HSCs) purchased from Lonza (Basel, Switzerland) were administered by 
intravenous injection into the tail vein using a 27 gauge needle and a 1 ml syringe Before 
infusion CD34+ HSCs were washed three times with sterile PBS CD34+ HSCs (5 x 104) 
cells/mouse were administered on day 0 Each mouse received a total of 0 3 ml 
Following l v injection, animals were returned to their cages where they were monitored 
closely for the first hour and at regular intervals thereafter for any signs o f distress or ill 
health Animals were weighed 3 times per week and weight loss was documented 
accordingly Any animals which displayed greater than 15 % total bodyweight loss were 
sacrificed humanely In addition an animal welfare score sheet was utilized throughout 
the study Engraftment was monitored in samples o f peripheral blood using flow
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cytometry on Day 46 and in samples of spleen, liver, bone marrow and thymus on Day 
84 preceding allergen sensitization and on Day 130 at the end o f the study
2.9.2 SENSITISATION AND CHALLENGE OF OVA MICE
After 3 months of stem cell engraftment, mice were sensitized by intra-peritoneal 
(i p) injection with Ovalbumin (OVA) (grade V, Sigma-Aldnch, UK) plus alum (Imject 
Alum, ThermoScientific, Rockford,USA) at a 1 2 ratio Each mouse received a total of 
1 OOug o f the solution (OVA+Alum) m 0 3ml once a week for two weeks Ova was 
delivered l p using a 27 gauge needle and a 1 ml syringe Control groups were sham 
sensitized with sterile PBS plus alum Allergen challenge was performed once one week 
after the last gavage (147 or wpc80) by gavage feeding with 50mg o f OVA in 0 3 ml PBS 
Following each procedure the animals were returned to their cages where they were 
monitored for any signs o f distress or ill health. In addition, an animal welfare score sheet 
was utilized throughout the study
2.9.3 PREPARATION AND ADMISTRATION OF HYDROLYSATE 147 
AND WPC80
One day after the last sensitization, Hydrolysate 147 (FHI, UL, Limerick) 
and the parent compound whey protein concentrate 80 (WPC80) (Carbery Milk products 
Group Ballineen, Cork) were prepared as in section 2 5 2 Each mouse received a total of 
50mg o f the solution (147 or WPC80) in 0.3ml once a week for 5 weeks. Administration 
was carried out by oral gavage Briefly the solutions were loaded into a 1 ml syringe
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attached to a feeding needle (Vet Tech,Cheshire, UK) Mice were carefully scruffed and 
the feeding needle was inserted into the mouth o f the mouse The feeding needle was 
carefully guided down the oesaphagus, where the 0 3ml solution o f hydrolysate 147 or 
WPC80 was released from the syringe Following each procedure the animals were 
returned to their cages where they were monitored for any signs of distress or ill health
2.10. ANAPHYLACTIC SCORING SYSTEM
Anaphylactic symptoms were evaluated for 30 to 40 minutes after the first 
challenge dose by using a scoring system as follows 0, no symptoms, 1, scratching and 
rubbing around the nose and head, 2, puffiness around the eyes and mouth, diarrhea, pilar 
erecti, reduced activity, and/or decreased activity with increased respiratory rate, 3, 
wheezing, labored respiration, and cyanosis around the mouth and the tail, 4, no activity 
after prodding or tremor and convulsion, 5, death
2.11. CELLULAR AND CYTOKINE ANALYSIS FROM OVA MICE
2.11.1. ISOLATION OF HUMAN CELLS FROM THE SPLEEN, BONE
MARROW, LIV E R , PERIPERAL BLOOD AND THYMUS
All tissues were prepared as before (Section 2 8 4-2 8 7) The cells were 
resuspended for FACS analysis (Section 2 10 5)
2.11.2 ISOLATION OF HUMAN CELLS FROM THE MESENTERIC
LYMPH NODE
The small intestine together with mesentery was surgically removed The 
intestine was arranged in a fan-shape to visualize the mesenteric lymph nodes Mesentenc
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lymph nodes (MLN) were removed into a 24 well plate containing cRPMI (Table 2 1) 
MLNs were isolated by homogenising through a 70 pm filter into a fresh 50 ml tube using 
a sterile plunger The homogenate was centrifuged at 300 g for 5 min, supernatant was 
removed and the cells were then resuspended in fresh cRPMI and counted for an ex vivo 
culture (Section 2 10 3)
2.11.3 CYTOKINE ANALYSIS FROM MLN CELL CULTURES
Spleens and mesenteric lymph nodes were removed from mice as described 
above and single cell suspensions were prepared Cells were seeded at 2 x 105 per well in 
a 96 well round bottom plate and cultured m cRPMI Cells were unstimulated (media 
alone) or stimulated with lOOug/ml OVA (Sigma-Aldrich) Supernatants were harvested 
after 72 h for detection o f IL-4, IL-5 and IL-13 Cytokines in supernatants were detected 
by ELISA as described in Section 2 6 1
2.11.4 CYTOKINE ANALYSIS FROM THE TISSUES OF OVA MICE
The small intestine, spleen and liver were removed from mice as described 
above and were immediately snap frozen and stored at -  80 0 C Tissues were thawed and 
gut contents removed The tissues were chopped finely and homogenized using an Ultra- 
Turrax homogemzer (IKA, Staufen, Germany) in 1 ml o f chilled homogenization buffer 
(PBS 2 % heat inactivated FBS supplemented with protease inhibitor cocktail (Roche, 
Dublin ,Ireland)) The homogenate was microcentrifuged at 13,000 rpm for 15 min at 4 
°C The supernatant was removed and stored at -20 °C Protein extracts were analysed for 
IL-4, IL-6, IL-10, IL-12, IL-13, IL-17 and IFN-y Cytokines in supernatants were detected 
by ELISA as described in Section 2 6 1
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2.12 ANALYSIS OF HUMAN CELL ENGRAFTMENT IN  VIVO BY FLOW 
CYTOMETRY
2.12.1 DECTECTION OF LEUCOCYTES, MYELOID CELLS, B CELLS, 
T CELLS, MAST CELLS/BASOPHILS AND DENDRITIC CELLS IN 
MOUSE TISSUES
For analysis by flow cytometry, single cell suspensions from spleen, bone 
marrow liver, thymus and peripheral blood were harvested, washed in sterile PBS and 
resuspended in FACS Buffer (PBS supplemented with 2 % heat inactivated FBS) to yield 
approximately 1 x 105 cells/well m 96 well V bottom Plate (Lennox, Dublin, Ireland) 
Fluorochrome conjugated antibodies (Table 2 4) or FMO controls were incubated with 
cells for 15 mm at 4 °C After 15 mm, cells were washed in 2 ml o f FACS Buffer, 
vortexed and centrifuged at 300 g for 5 mm The supernatant was removed and cells 
resuspended in 150 pi facs buffer Cells were then analysed by flow cytometry (Attune 
NXT Acoustic Focusing Cytometer) using attune NXT software (Thermo Fisher 
Scientific)
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2.12.2 DETECTION OF CYTOKINE PRODUCTION BY HUMAN
CELLS
IFN-y and IL4 were analysed intracellularly by flow cytometry. Briefly, 
splenocytes recovered from in vivo studies following stimulation with lOOng/ml Phorbal 
12-myriate 13-acetate (PMA) (Sigma-Aldrich) and lug/ml ionomycin (Sigma-Aldrich) 
and 1X Brefeldin A for 4 h, were washed in 150pl FACS buffer and centrifuged at 950rpm 
for 5 min in 96 well v bottomed plates. Splenocytes were labelled with CD45 Pacific 
Orange, mouse CD45 Pecy7, CD3 Alexa Flour , CD4 FITC, or corresponding FMO 
control antibodies for 15 min at 4 °C.The cells were washed twice in 150 pi FACS buffer, 
centrifuged at 950 rpm for 5 min and fixed with 100 pi fix/permeabilisation buffer 
(eBiocsience) for 1 h. The cells were then permeabilised with 200 pi permeabilisation 
buffer (eBioscience), washed with 150 pi FACS buffer and blocked using 3 pi 2% rat 
serum for 15 min. The cells were labelled with IFNy APC, IL-4 PE dazzle or FoxP3 
brillant violet 421 or fmo control antibodies and left at 4 °C for 1 h. Samples were washed 
twice with 150 pi FACS buffer and analysed by flow cytometry (Attune NXT Acoustic 
Focusing Cytometer) using attune NXT software (Thermo Fisher Scientific).
2.12.3 INTRACELLULAR STAINING OF CELLS TO DETECT FOXP3 
EXPRESSION
FoxP3 expression was analysed intracellularly using a FoxP3 staining kit 
(eBioscience). Briefly , splenocytes recovered form in vivo studies were washed in 150 
pi FACS buffer and centrifuged at 950 rpm for 5 min. Splenocytes were labelled with 
CD45 Pacific Orange, mouse CD45 PECY7, CD3 Alexa Flour 700 , CD4 FITC, CD 127 
PERCP 5.5 and CD25 PECY7 or corresponding FMO control antibodies for 15 min at
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4 °C The cells were washed twice in 150 pi FACS buffer, centrifuged at 950 rpm for 5 
min and fixed with 100 pi fix/permeabilisation buffer (eBiocsience) for 1 h The cells 
were then permeabihsed with 200 pi permeabihsation buffer (eBioscience), washed with 
150 pi FACS buffer and blocked using 3 pi 2% rat serum for 15 min The cells were 
labelled with FoxP3 bnllant violet 421 or fmo control antibodies and left at 4 °C for 1 h 
Samples were washed twice with 150 pi FACS buffer and analysed by flow cytometry ( 




Small Intestine was harvested from experimental mice on day 130 and fixed in 
10% (v/v) neutral buffered formalin (Sigma-Aldrich) for at least 24 h Samples were 
transferred to 70% ethanol for a further 24 h Samples were processed for histology using 
an automated processor (Shandon Pathcentre, Runcorn, UK), which immersed the tissues 
in fixatives and sequential dehydration solutions, including ethanol (70%, 80%, 95% x 2, 
100% x 3) and xylene (x 2) (Sigma-Alrich) After processing, tissues were embedded 
in paraffin wax (Sigma-Aldrich) using the Shandon Histocenter 2 (Shandon) and left set 
overnight at 4 °C 4pm sections were cut using a microtome (Shandon Finesse 325, 
Thermo-Shandon, Waltham, MA, USA) Sections were placed m cold water before being 
transferred to a hot water bath (42 °C) to remove any folding o f the sections Tissue 
sections were placed onto microscope slides (VWR, Ballycoolm, Ireland), and left to air- 
dry overnight at RT Samples were then stained with H &E (Section 2 12 2) or Toluidine 
Blue (Section 2 12 3) and blindly scored using the system outlined in section 2 12 4
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2.13.2 HAEMATOXYLIN/EOSIN STAINING
Before commencement with H&E staining slides were heated to 56 °C for a 
minimum of 1 h to aid wax clearance Slides were then transferred to xylene (Sigma- 
Aldrich) for 10 mm each This was repeated with fresh xylene for a further 10 mm 
Samples were then re-hydrated following immersion in 3 decreasing concentrations of 
ethanol (100% x 2, 95% (v/v) and 80%) for 5 min each Sections were then transferred 
to dFEO for 5 min before being immersed in Haematoxylin (Sigma-Aldrich) for 3 min 
Samples were then washed under dlkO for 2 min before being placed in 1 % acid alcohol 
for 20 seconds Samples were washed again under dlhO before being immersed m Eosin 
Y (Sigma-Aldnch) for 3 min and back to washing again under dFEO Slides were 
dehydrated through immersion in a series o f increasing ethanol concentrations (80%, 95% 
and 100%) for 5 mm each Samples were air dried, mounted with DPX mountmg media 
(BDH) and examined under a light microscope
2.13.3 TOULIDINE BLUE STAINING
Before commencement with Toluidine staining slides were heated to 56 °C for a 
minimum of 1 h to aid wax clearance Slides were then transferred to xylene (Sigma- 
Aldrich) for 10 min each This was repeated with fresh xylene for a further 10 min 
Samples were then re-hydrated following immersion in 3 decreasing concentrations of 
ethanol (100% x 2, 95% (v/v) and 80%) for 5 mm each Sections were then transferred 
to dfhO for 5 min before being immersed in Toluidine blue (Sigma-Aldnch) solution for 
40 sec Slides were dehydrated through immersion in a series o f increasing ethanol 
concentrations (80%, 95% and 100%) for 5 min each Samples were then immersed in
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Xylene for 3 mins Samples were air dried, mounted with DPX mounting media (BDH) 
and exammed under a light microscope
2.13.4 HISTOLOGICAL SCORING
Following H&E staining, slides were coded without reference to prior treatment 
and examined in a blind manner A semi-quantitative scoring chart was used to assess the 
degree o f inflammation and related histological changes o f the Small Intestine 
Pathological scoring was earned out as follows
SCORE Small Intestine /Jejunum
0 Normal
1 Mild hyperplasia with minor mononuclear cell 
infiltration
2 Dispersed but mild villous blunting, necrosis 
and increased cell infiltration
3 Dispersed and moderate villous blunting, 
necrosis with further increased cell infiltration 
and colonic crypt ulceration
4 Dispersed and severe villous bluntmg, necrotic 
cells with pervasive mononuclear cell 
infiltration and colonic crypt ulceration
2.14 STATISTICAL METHODS
The students paired t test was used when statistical analysis was required between 
two experimental groups One way ANOVA was used to test for statistical significance 
o f differences when multiple experimental groups were compared Power analysis was 
earned out to determine the number o f animals that would yield a significant difference
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in the in vivo studies. Statistical methods (Power analysis (SISA)) were used to determine 
the minimum number o f animals per treatment group to obtain a power in the study. SISA 
software is online at http://home.clara.net/sisa/power.htm.
Table 2.1 Media for Cultured Cells
Media Composition Supplier
Complete media for RPMI 1640 Sigma-Aldrich
Human PBMC 10% (v/v) heat inactivated FBS Labtech
Culture 50U/ml penicillin Sigma-Aldrich
50pg/ml streptomycin Sigma-Aldrich
2mM L-glutamine Sigma-Aldrich
0.1% (v/v) 2-mecaptothanol Gibco
Complete media for TexMacs Media Stem Cell
Human T cell polarisation 10% (v/v) Hyclone FBS Labtech
Culture 50U/ml penicillin Sigma-Aldrich
50pg/ml streptomycin Sigma-Aldrich
2mM L-glutamine Sigma-Aldrich
0.1% (v/v) 2-mecaptothanol Gibco
Complete media for IMDM Sigma-Aldrich
For Human 10%(v/v) Hyclone FBS Labtech
Dendritic 50U/ml penicillin Sigma-Aldrich
cell culture 50pg/ml streptomycin Sigma-Aldrich
2mM L-glutamine Sigma-Aldrich
0.1% (v/v) 2-mecaptothanol Gibco
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Table 2.2 Antibodies for Flow Cytometry






CD4 APC/FITC SK3 Mouse
IgG lk
eBioscience
CD8 FITC/PE RPA-T8 Mouse
IgG lk
eBioscience








CD1A FITC HI 149 Mouse
IgG lk
eBioscience
CD19 FITC/APC H1B19 Mouse
IgG lk
eBioscience
CD20 FITC 2H7 Mouse
IgG lk
eBioscience
CD25 APC BC96 Mouse
IgG lk
eBioscience




CD45 FITC/PERCP 2D1 Mouse
IgG lk
eBioscience
CD86 PE IT2.2 Mouse
IgG lk
eBioscience
CD123 APC 6H6 Mouse
IgG lk
eBioscience
CD117 FITC/APC 104D2 Mouse
IgG lk
eBioscience
CD203C PE NP4D6 Mouse
IgG lk
eBioscience
CD33 FITC/APC HIM3-4 Mouse
IgG lk
eBioscience














Gata-3 APC TWAJ Mouse
IgG lk
eBioscience









Table 2.3 Antibodies for Flow Cytometry Attune NxT








CD4 FITC OKT4 Mouse IgG lk eBioscience
CD8 Pacific Blue RPA-T8 Mouse IgG lk Invitrogen
CD19 Bnllant Violet 
510
H1B19 Mouse IgG lk eBioscience
HLA-DR PerCp- Cy5.5 LN3 Mouse IgG lk eBioscience
HLA-DR PE/CY7 L243 Mouse
IgG2ak
Biolegend
CD25ii PE/CY7 BC96 Mouse IgG lk Biolegend
FCeRl
:
PE AER-37 j Mouse IgG lk eBioscience
mCD45 PE/CY7 30-F11 Rat IgG2bk Biolegend
CD45 Pacific Orange 2D1 Mouse IgG lk Invitrogen
CD45 APC-H7 2D1 Mouse IgG lk BD
Pharmingen
CD117 Brilliant Violet 
510
104D2 Mouse IgG lk eBioscience
CD117 PE/CY7 104D2 Mouse IgG lk eBioscience
CD127 PerCp/Cy5.5 A019D5 Mouse IgG lk eBioscience
IFN-y PerCp/Cy5.5 45 .B3 Mouse IgG lk eBioscience
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FoxP3 Bnllant Violet 
421
206D Mouse IgG lk eBioscience
IL-4 PEDazzle 594 MP4-25D2 Rat IgG lk Biolegend
Table 2.4 Buffers
Buffer Composition
Blocking Buffer for 
Immunoblotting
TBS, 0 1% (v/v) Tween-20 (TBST) 
with 5%(w/v) non-fat dry Milk
Laemmli sample buffer 62 5mM Tns-HCL, pH6 8,10 % (w/v) 
glycerol, 2% (w/v) SDS, 0 7 M p- 
mercaptoethanol and 0 001% (w/v) 
bromophenal blue
Phosphate Buffered Saline (PBS) 2 7mM KCI, 1.5mM KH2P04,137mM  
(PBS) NaCL and 8 mM Na2H P04, pH 
7 4
RIPA Lysis Buffer 50mM Tns-HCL pH 7 4, 1% (v/v) 
[gepal, 150mM NaCL, 0 5% (w/v) 
Sodium Deoxycholate, ImM EDTA, 
0 1% (w/v) SDS ImMNasVCL, 1 mM 
PMSF and protease inhibitor cocktail
SDS Running Buffer 25mM Tris, 192 mM glycine, 01% SDS
TAE(Tris-acetate-EDTA) Buffer 40mM Tris Base, 0 l%(v/v) glacial acetic 
Buffer acid, 1 Mm EDTA
TBS (Tris buffered Saline) 25Mm Tris, pH 7 4, containing 0 14M 
NaCL
iTBST(Tris buffered Saline with 25Mm Tris, pH 7 4, containing 0 14M 
jTween) NaCL 0 1% (v/v) Tween -20
Transfer Buffer j25mM Tns,192 mM glycine, 20%
(v/v)methanol
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Table 2.5 Primer Sequences
! Primer Forward 5 - 3 Reverse 3 - 5 Product Anneal
ii1 Size(bp) temp (°C)
GÂPDH ACAGTTGCCATG TTTTTGGTTGA 150 58
TAATGTAGACC GCACAG
PPAR-y AGTGTT GT AC AGÂ GCATCTGTCTT 20Ó 58
Table 2.6 Primary Antibodies for Immunoblotting












Table 2.7 Secondary Antibodies for Immunoblotting
Secondary Dilution Factor Diluent Supplier
ECL Antibodies
Anti-Mouse HRP 1:1000 5% Milk TBST Cell Signalling
Anti-Rabbit HRP 1:1500 5% Milk TBST Cell Signalling
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CHAPTER 3
WHEY HYDROLYSATE 147 EXERTS ANTI­
INFLAMMATORY EFFECTS BY SUPPRESSING NF-kB 
PATHWAY ACTIVATION THROUGH A PPAR-y 
DEPENDANT MECHANISM
3.1 INTRODUCTION
While milk contains components that can modulate the immune system. An increasing 
number of studies suggest that milk proteins, including whey and casein may contain 
biologically active peptides with immunomodulatory properties in their sequences (Wichers 
2009). These bioactive peptide sequences can be released during digestion in the gut and can 
also be produced by in vitro enzyme hydrolysis from parent milk proteins (Phelan and Kerins
2011). Hydrolyzation of cow’s milk proteins, both whey and casein fractions, results in a 
mixture of different peptide-sequences which is called a hydrolysate. Hydrolysates are already 
being produced on a large scale, mainly for the use of managing cow’s milk allergy in infants 
(e.g include Pepti, Aptamil, and Nutricia,). Protein-derived peptides formed during hydrolysis 
have been shown to modulate the gastrointestinal tract at different levels, besides preventing 
IgE induced allergic responses. Immunoregulatory peptides found in cow’s milk hydrolysates 
were shown to induce mucus production (Matinez et al 2013, Trompette et al 2003) and to 
promote anti-inflammatory responses in intestinal epithelial cells (Mukhopadhya et al 2015, 
Piccolomini et al 2012). Once taken up into the lamina propria, hydrolysates may also directly 
influence both innate and adaptive immune cells (Cheng et al 2015, Wong et al 1998). 
Following exposure to casein hydrolysates in vitro macrophages showed both inhibition of 
inflammatory responses (Malinowski et al 2014, Chen et al 2015) and an increased in vitro 
phagocytic activity (Sandre et al 2001,Mao et al 2005, Lebrun et al 2004) in vivo ( Pan et al 
2013,Kazlauskaite et al 2005). Several studies have focused on the in vitro modulation of 
lymphocyte proliferation by individual whey proteins (P-LG, a-LA,) and mixtures of whey
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protein concentrates (WPCs) (Mercier et al 2004, Miyauchi et al 1998, Orsi 2004) However, 
few studies have evaluated the effect of peptides naturally present in whey or those produced 
by enzyme hydrolysis of whey Miyauchi et al (1997) showed that bovine lactofemn (LF) 
inhibited the proliferation of munne splenocytes while a peptic hydrolysate of LF promoted 
cell proliferation especially in a B-cell enriched fraction .The authors concluded that the peptic 
hydrolysate may in fact contain both immunostimulatory and immunoinhibitory peptides 
Furthermore, cow’s milk hydrolysates induced differentiation of specific T cell subsets, 
especially the formation of interleukin-10 (IL-10) producing regulatory T cells, in cultured 
human (Lahart et al 2011), and in munne (Duan et al 2012) lymphocytes Therefore, several 
groups, including ours, propose to help develop a nutritional product enriched with 
immunomodulatory peptides to help prevent food allergies including cow’s milk allergy in 
infants Milk bioaetives generated from either sodium casemate (NaCaS) or whey protein 
concentrate (WPC) may possess anti-inflammatory or anti-allergic properties The 
identification of such bioactives may be useful in promoting tolerance to cow’s milk proteins 
and thus may be beneficial in infant formula to alleviate the symptoms of CMPA or perhaps to 
induce a tolerogenic response to CMP We hypothesize that these hydrolysates may exert 
significant anti-mflammatory/ anti-allergic effects, by modulating the production of pro- 
inflammatory Thl, Th2, or Thl 7 derived cytokines or through the modulation of dendritic cells 
or T cell functions Therefore the objectives o f this chapter are-
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• To screen a range of whey and casein hydrolysates for anti-inflammatory activity
• To identify hydrolysates that have immunosuppressive effects on T cell 
proliferation and cytokine production in vitro
• To determine the effects of hydrolysates on Thl, Th2, Thl7 and T Reg 
differentiation
• To determine the effects of hydrolysates on DC maturation and cytokine 
production
• To identify a mechanism by which hydrolysates can influence key signal 
transduction events involved in inflammatory processes
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3.2. HYDROLYSATES INHIBIT T CELL PROLIFERATION IN  VITRO
In the past, studies have demonstrated differential findings with regard to the capacity 
for hydrolysates (whey or casein derived) to modulate the immune response via suppression of 
T cell proliferation For example, hydrolysates obtained from soy and whey (or more 
specifically the proteins P-lactoglobulin or lactofemn) were shown to enhance proliferation in 
murme spleen lymphocytes (Wong et al 1998) Two synthetic peptides corresponding to the 
sequences f50-51(Tyr-Gly) and f  18-20 (Tyr-Gly-gly) of the whey protein a- lactalbumin 
enhanced both the in vitro proliferation and protein synthesis of PHA-stimulated human 
penpheral blood lymphocytes (Kayser and Meisel, 1996) However, Cross and colleagues 
(1999) showed that a modified WPC rich in glycomacropeptide (GMP), a K-casein-denved 
peptide, present m appreciable amounts m some whey protein concentrate (WPCs) suppressed 
T and B lymphocyte proliferative responses to mitogens in a dose dependent manner (Cross et 
al 1999) Therefore, in collaboration with FHI, this study sought to identify hydrolysates with 
immunosuppressive properties, starting with an investigation of the effects of hydro lysates on 
T cell proliferation These effects were assessed using a human relevant system in the form of 
human penpheral blood mononuclear cells (PBMC) Human biology-based in vitro screening 
systems are valuable as they better reflect the human condition with better predictive outcomes 
than nonhuman biology-based test methods
At the outset of this experiment it was important to include some control compounds that 
are currently used in infant formula Whey protein concentrate 80 (WPC80,) and sodium 
caseinate (NaCn) are food grade intact protein powders used as standard ingredients in infant 
formula Pepti (Aptamil, Nutricia, Dublin) is an extensively hydrolysed powder formula,
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currently used for the treatment of cow’s milk allergy m infants. Lead functional compound 56 
(LFC56) and its upscaled sample LFC56R were included as they have been previously screened 
in an extensive bioassay screening platform in FFII 1 and were shown to have potential health 
benefits on the immune system
In this study, the influence of hydrolysates on T cell proliferation was assessed by 
measuring the proliferation of activated and CFSE labelled PBMC, as detailed in section 2 3 3 
Briefly, PBMC were labelled with a fluorescent proliferation dye, activated with CD3/CD28 
beads and cultured for four days in the presence or absence of hydrolysates (1 mg/ml) Cells 
were harvested on day four and stained with fluorescent antibody CD3 and fluorescent dye-7- 
aminoactinomycin D (7-AAD) to examine viability in CD3+ proliferating T cells PBMC 
proliferation (proliferation dye dilution) was analysed by flow cytometry
In comparison to the PBMC alone group, CD3+ T cells present in the PBMC 
activated with anti- CD3/CD28 beads proliferated significantly In the presence of intact sodium 
caseinate (NaCn), Pepti (extensively hydrolysed formula), lead functional compound 56 
(LFC56) and its regenerate (LFC56R) the proliferation of PBMC was significantly reduced (P< 
0 001) In the presence of whey protein hydrolysates (20, 21) and sodium casemate 
hydrolysates (23, 33) the proliferation of PBMC was significantly reduced (P < 0 05 P < 0 001) 
respectively (Figure 3 1) In contrast casein hydrolysate 48 significantly increased the 
proliferation of PBMC (P < 0 05) PBMC cultured in the presence of the remaining casein 
hydrolysates (24, 34, 35, 37, 38) and whey hydrolysates (40, 41, 42, 43, 46, 47) or the intact 
whey protein control sample (WPC80) did not significantly differ in terms of proliferation 
kinetics in comparison to the positive control sample (PBMC plus CD3/CD28 activation beads) 
This data suggests that specific hydrolysates have either immunosuppressive or
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immunostimulatory capacity in the context of modulating T cell proliferation in vitro However, 
more detailed characterization is required to better understand the effects hydrolysates have on 


















Figure 3.1. Hydrolysates have differential effects on T cell proliferation. PBMC (5 x 
104 per well) were labelled with CFSE in a 96 well round bottom plate and co-cultured 
with anti-CD3/CD28 beads in the presence or absence of hydrolysates (1 mg/ml). On Day 
four, cells were harvested and stained with fluorescent antibody CD3 and fluorescent 
7AAD viability dye to analyse CD3+ proliferation using flow cytometry. Proliferation of 
gated CD3+CFSE diluted live cells was analysed. The assay was performed on three 
PBMC donors (n=3). Statistical analysis was carried out using one way ANOVA Tukey 
Multiple Comparison Test where * <0.05,** <0.01 , **** < 0.000l.UL= University of 
Limerick
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3.3. ANTI-INFLAMMATORY EFFECTS OF SODIUM CASINATE AND WHEY 
PROTEIN HYDROLYSATES IN PBMC ACTIVATED CELLS
One of the main features of food proteins that play a role in their capacity to induce 
an allergic response, is their ability to promote Th2 effector pathways, favoring Th2 rather than 
Thl immunity. IFN-y and IL-2 are key pro-inflammatory cytokines produced by Thl cells to 
mediate inflammatory events during food allergy. Th2 cells secrete IL-4 which is considered to 
drive the allergic response. T regulatory cells secrete IL-10, which plays a pivotal role in the 
maintenance of immune tolerance and suppression of allergic inflammation. IL-6 is a cytokine 
with well-defined pro- and anti-inflammatory properties and is involved in the regulation of 
the T h l7 immune response and inflammation. As outlined before, hydrolysates may help drive 
T-helper cells (Thl, Th2, T-Reg and T h l7) to produce increasing or decreasing amounts of 
various cytokines. Therefore this study explored further the potential anti-allergic potential of 
milk peptide hydrolysates in terms of the secreted cytokine profile. Therefore, hydrolysates 
were assessed in a proliferation assay as described in section 3.2, in order to identify which 
hydrolysates were effective at modulating cytokines in supernatant, determined by ELISA.
In the supernatants, a number o f whey (41, 46, 47) and casein (48) hydrolysates reduced 
the levels of IFN-y (Figure 3.2) while other whey (21) and casein hydrolysates (23, 34, 38) 
significantly increased the levels of IFN-y (P<0.05, PO.Ol, P<0.001, P <0.001). A number of 
whey hydrolysates (21, 40, 41, 42, 43) and casein hydrolysates (23, 24, 35) significantly 
inhibited the Th2 response by decreasing the levels of IL-4 (P< 0.0001) and some hydrolysates 
(34, 37, 42, 46) significantly decreased the pro-inflammatory cytokine IL-6 (P<0.05, 0.01). 
Only two casein hydrolysates (35, 37) were found to significantly increase the level of IL-10 
(P < 0.0001). Table 3.1 shows a detailed summary of all the hydrolysates tested.
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Immunomodulating peptides were selected for further studies on the basis of their either their 
anti- proliferative activity, IFN-y stimulating properties, IL-10 induction and absence of IL-4 
inducing capacity So based on the results of this initial screen a number of whey hydrolysates 
(40,42) and casein hydrolysates (23,34,35) and their optimised regenerate (77,79,80,84,85) 

























Figure 3.2. Hydrolysates alter the production of pro and anti-inflammatory 
cytokines in vitro. T cell proliferation assays were carried out as described before in 
figure 3 1 On day four, supernatant was collected for detection of IL-4, IL-6, IFN-y 
and IL-10 Some hydrolysates significantly reduced the pro-inflammatory cytokines 
IL-6 and IFN-y Some hydrolysates significantly reduced the T h 2 cytokine IL-4 while 
other proteins provided an anti-inflammatory response (35, 37) The assay was 
performed on three PBMC donors (n=3) Statistical analysis was earned out using one­
way ANOVA Tukey Multiple Comparison Test where *<0 05,**< 0 01 and *** <0 001, 
**** < 0  0001 Stars are in comparison to the PBMC+ beads group
Table 3.1. Proliferation and Cytokine Screen of Milk Protein Hydrolysates
LFC PROLIF IFNy IL-6 IL-10 IL-4
NACN
V  ★ ★ ND t 4> ♦ ★ ★ ★ lb
PEPT1
V  ★ ★  ND t V V * * * *
WPC80
V V t V V v v v *
LFC56
V t t V V * * * *
LFC56R
V ND V V V * * * *
20
V  ★ ★ t t V t
21
V * * t ND V V * * * *
23
V * ^  ★ ★ ★ ND V V * * * *
24
ND ND t v V V * * * *
33
V * t ND V t
34
V t  V V V V * V V
35
V t ND ^ k k k k V
37
ND t V  V t  v v v v t
38
ND t ND V t
40
t t t V V * * * *
41
ND V  * t V V * * * *
42
ND t V * V V * * * *
43
ND t ND V V * * * *
46
ND V  V V 4 * V V
47
ND V  ★ ★ t t  kk t
48
t  V V  * V t t V
^  Indicates increased proliferation/production above PBMC * beads
^Ind ica tes decrease proliferation/production compared PBMC +beads 
★  ★  Indicates level o f significance when compared to PBMC +beads 
ND= no difference comDared to PBMC+ beads
3.4 DEGREE OF HYDROLYSIS MAY IMPACT ALLERGENICITY OF
HYDROLYSATES
In order to obtain desirable functional properties of milk protein hydrolysates the 
chemical breakdown of the compound, a process termed hydrolysis must be carried out under 
strictly controlled conditions to a generally low degree of hydrolysis (DH) (Alder-Nissen et al 
1979) DH is defined as the percentage of peptide bonds cleaved (Alder-Nissen 1976) The 
degree of hydrolysis has been shown to influence the biological activities of the hydrolysates, 
as the size and ammo acid composition of the hydrolysate is altered (Chen et al 2012) In all 
experiments whey protein concentrate 80 (WPC80) and sodium caseinate (NaCn) served as 
controls Pepti, (Aptamil, Danone Nutncia,) an extensively hydrolysed formula for the dietary 
management of Cows Milk Allergy was also included as a control Two lead functional 
compounds LFC56 and its optimized sample LFC56R are also included as controls as they 
have previously been screened to contain bioactive compounds Both whey and casern 
hydrolysates with a degree of hydrolysis (DH) ranging from 3 1 % to 45% were tested (Table 
3 1) In terms of allergemcity the smaller the DH% the less nsk for an allergic reaction The 
highest degree o f hydrolysis was found in sodium casein hydrolysate 34 followed by whey 
protein hydrolysate 20 and the lowest was found m whey protein hydrolysate 46 Only a few 
studies have addressed the issue of DH% One in vitro study indicated that the degree of 
hydrolysis had no effect on both the cytotoxic and immunomodulatory properties of NaCas m 
human Jurkat cells (Lahart et al 2011) However, a recent study found that whey samples 
induced TNFa and IL-10 in a DH dependent manner in human PBMCs (Kiewiet et al 2017) 
They found lower DH, was associated with enhanced immunoregulatory effects Hence, the
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thorough evaluation of the bioactivity of individual hydrolysates generated under different 
physico-chemical conditions is essential, as the findings cannot be generalised. The samples 
highlighted in yellow below were the five hydrolysates chosen for further evaluation in ThI, 
Th2, ThI 7 and T -R eg assays, to specifically examine immunomodulatory effects.
Table 3.2 Characteristics of milk protein hydrolysates tested
Sample Description DH% Starting Substrate Enzyme Source
20 39.4 WPC Aspergillus
21 12.9 WPC Bacillus
23 15.9 NaCas Bacillus
24 19.8 NaCas Bacillus
33 29.3 NaCas Bacillus
34 48.2 NaCas Aspergillus
35 18.8 NaCas Aspergillus
37 33.5 NaCas Aspergillus
38 14.5 NaCas Aspergillus
40 2 3 WPC Aspergillus
41 2.0 WPC Aspergillus
42 15.3 WPC Bacillus
43 1.9 WPC Aspergillus
46 0.0 WPC Aspergillus
47 12.8 NaCas Bacillus




Table 3.3 List of Whey protein and Sodium Caseinate hydroiysates and their 
regenerated samples
S a m p le
D escrip tio n
DH% R egen S ta rt in g
S u b s tra te
E n zym e
So urce
42 15-3 79 W P C Bacillus
40 15-3 77 W P C Bacillus
23 15.9 80 NaCas A sperg illus
3 4 48.2 84 NaCas A sp erg illu s
35 18.8 85 NaCas A sp erg illu s
3.5. SPECIFIC HYDROLYSATES ARE PROTOLOEROGENIC/ANTI-
INFLAMMATORY WITHOUT ANY EFFECTS ON T CELL PROLIFERATION
The results available thus far suggest that milk peptide hydroiysates may have 
immunomodulatory properties, with the potential to dampen pro-inflammatory responses 
(inflammation or allergy) and promote regulatory responses (anti-inflammatory) in a certain 
direction. In order to assess the potential of milk protein hydroiysates to alter/modulate an 
unbalanced immune status, such as that representative of CMPA five of the hydroiysates (42,40, 
23, 34,35) and their regenerates (79, 77,80, 84, 85) (Table 3.3) were re-screened for their 
proliferative/suppressive potential as described previously (see section 3.2). In the presence of 
whey and casein hydroiysates the proliferation of CD3+T cells with a whole PBMC population
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PBMC did not change significantly (Figure 3 3) Overall the five hydrolysates and their 
optimized regenerate sample did not negatively or positively effect T cell proliferation driven 
by CD3/CD28 beads
Although there was no influence on T cell proliferation, hydrolysates may have 
influenced the cytokine production by the PBMC population Levels of IFN-y, IL-2, IL-6, IL- 
10, IL-17 and IL-4 were examined In this assay no IL-4 was detected In the PBMC+bead 
population there was a significant increase in the levels of IL-6, IL-10 and IL-17 (Figure 3 4) 
None of the hydrolysates or controls had any significant effect (either increase or decrease) on 
IFN-y or IL-2 All hydrolysates and controls (except 42 and 84) significantly reduced the levels 
of pro-inflammatory cytokine IL-6 Only pepti and NaCN (controls) and hydrolysate 35 and its 
regenerate 85 significantly reduced the levels o f IL-17 Importantly only hydrolysate 35 and its 
regenerate 85 significantly increased the levels of the anti-inflammatory cytokine IL-10
In summary, hydrolysate 35 and its regenerate 85 significantly reduced the production 
of the pro-inflammatory cytokine IL-6 and IL-17 and significantly increased the anti­
inflammatory cytokine IL-10 The purpose of this study is to find a hydrolysate that can 
outperform the current treatment formula options (Pepti) with regards to immunomodulatory 
ability The data supported a potential enhanced immunomodulatory ability for hydrolysate 35 
over and above pepti High levels of anti-inflammatory (IL-10) and low levels of Th 17 cytokine 
have been identified and found to be important in gut homeostasis (Langrish et al 2005) In 
healthy individuals, low numbers of Th 17 cells are present, mainly in the lamina propria (Huber 
et al 2012) Several studies have also demonstrated a role for hydrolysates in increasing the IL- 
10 production in T cells (Lahart et allD W , Cian et al 2012) The overall suppression of IL-17 
and upregulation of IL-10 with hydrolysate 35 and its regenerate 85 could not be explored
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further as the enzyme preparation needed to make the hydrolysate could no longer be supplied 
by the manufacturer Unfortunately, this excluded hydrolysate 35 from the rest of the study 
Based on this screen summarized in Table 3 3 and on a similar screen completed with mouse 
cells within FHI by our collaborators at DCU, whey hydrolysate 42 and it’s regenerate 79, and 
sodium caseinate hydrolysate 34 an it’s regenerates 84 and 132 and were chosen for further 
testing in Thl, Th2, Thl7 and Treg polarization assays
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Figure 3.3 Hydrolysates and their regenerates do not impair T cell 
proliferation. PBMC (5 x 104 per well) were labelled with CFSE in a 96 well 
round bottom plate and co-cultured with anti-CD3/CD28 beads m the 
presence or absence of hydrolysates (1 mg/ml) On Day four, cells were 
harvested and stained with fluorescent antibody CD3 and fluorescent 7AAD 
viability dye to analyse CD3+ proliferation using flow cytometry The assay 
was performed on three PBMC donors (n=3) Statistical analysis was carried 
out using one-way ANOVA Tukey Multiple Comparison Test where **** 
p<0 0001 Stars are in comparison to the PBMC+ beads group
h=hydrolysate R=Regenerate
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Figure 3.4 Hydrolysate 35 increased the anti-inflammatory cytokine IL-10 and 
suppressed the levels of IL-17. T cell proliferation assays were carried out exactly as 
described before in figure 3 1 On day four, supernatant was collected for detection of IL- 
2, IL-6, IFN-y, IL-10 and IL-17 There was no change detected in the Thl cytokines but a 
number of the hydrolysates and their regenerates decreased pro-inflammatory IL-6 and IL- 
17 levels and increased the anti-inflammatory IL-10 level The assay was performed on 
three PBMC donors (N=3) Statistical analysis was earned out using one-way ANOVA 
Tukey Multiple Comparison Test where *<0 05, **<0 01 and ***<0 001 ****<0 0001 
Stars are in comparison to the PBMC+ beads group.
<0 001 Stars are in comparison to the PBMC+ beads group
Table 3.4 Proliferation and Cytokine Screen 2
LFC Prolif IFN-y IL-6 IL-10 IL-17 IL-2
NACN uc uc 4 ★ ★ ★ ★ 4 4  * ★ *
PEPTI 4> * 4 ★  ★ ★ ★ * 4  ★ ★ ★ ★ *
WPC80 ♦ 4> 4 ★ ★ ★ ★ 4 4 4*
56 uc * 4 ★  ★ ★ ★ * uc 4>
56R * 4« 4 ★ ★ ★ ★ * * 4>
41 uc t * uc t *
79 4 t 4 ★ ★ ★ ★ 4 uc *
40 4> 4> 4 ★  ★ ★ ★ * t *
77 * * 4 ★ ★ ★ ★ 4« t t
J3 uc 4 4 ★  ★ ★ ★ 4 4 t
80 uc uc 4 ★ ★ ★ ★ 4 * t
34 uc * 4 ★  ★ ★ ★ 4> 4 t
84 4- * 4 * 4> *
35 uc * 4 ★ ★ ★ ★ 4» ★ ★ ★ ★ 4 * 4 4 *
85 * * 4 ★ ★ ★ ★ ★ ★ ★ 4 4 4 4»
^  Indicates increased proliferation/production above PBMC +beads 
^ Ind ica tes  decrease proliferation/production compared PBMC +beads 
★  ★  Indicates level o f  significance when compared to PBMC +beads 
UC/ND= unchanged/ no difference compared to PBMC+ beads
3.6. HYDROLYSATE DO NOT NEGATIVELY IMPACT CELL VIABILITY
As a quality control procedure, the possible effect of hydrolysates on T cell viability in a 
T cell proliferation assay was assessed This is a colorimetric assay that measures the reduction 
of yellow 3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by 
mitochondrial succinate dehydrogenase The MTT enters the cells and passes into the 
mitochondria where it is reduced to an insoluble, coloured (dark purple) formazan product The 
cells are then solubilised with an organic solvent (eg DMSO) and the released, solubilised 
formazan reagent is measured spectrophotometrically Since reduction of MTT can only occur 
m metabolically active cells the level of activity is a measure of the viability of the cells 
Cytotoxicity of the hydrolysates was determined on CFSE labelled PBMC using 3-(4,5- 
dimethylthiazol-2-yl)-2-5-diphenyltetrazoliumbromide (MTT) Notably, the PBMC only group 
that did not receive activation (survival) signals had significantly reduced viability The level 
of MTT activity in the culture medium was similar in the presence and absence of the 




Figure 3.5. Hydrolysates have no negative impact on cell viability. PBMC (5 x 
104 per well) were labelled with CFSE in a 96 well round bottom plate and co­
cultured with anti-CD3/CD28 beads in the presence or absence of hydrolyates (h) 
or the regenerates (R) (1 mg/ml) On Day four, CFSE stained PBMC were harvested 
into a 96 well round bottom plate , washed with PBS and incubated with 20pi of 
MTT solution (0 5mg/ml) for 3 h at 37 °C The media was removed and the 
formazan crystals were dissolved m 200pl of DMSO, incubated at 37 °  C for 5 
minutes and centrifuged for 5 minutes at 300 x g The absorbance (optical density 
(OD)) of the samples was measured at 570nm using a microplate reader The assay 
was performed on three PBMC donors (n=3) Cell viability was determined as a % 
of control cells (PBMC + beads) Statistical analysis was carried out using one way 
ANOVATukey Multiple Comparison Test where ****<0 0001
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3.7 HYDROLYSATES IMPAIR TH1 AND TH2 DIFFERENTIATION
Although the above results show no effect of hydrolysates on number of proliferating 
CD3+ T cells response, hydrolysates may prevent or inhibit an allergic response by skewing 
Th2 responses towards a Thl phenotype (Tang et al 2001). Thl immune activation is defined 
by a distinct pattern of cytokine expression characterized by the secretion of IFN-y and 
expression of the transcription factor T-bet. The differentiation and expansion of Th2 cells is 
characterized by the secretion of 1L-4, IL-5 and 1L-13 and expression of the master transcription 
factor Gata-3. Despite the obvious potential benefit for peptide hydrolysates to promote a 
Thl/Th2 skew, few studies have examined this effect. Therefore this study assessed the 
potential of milk protein hydrolysates to drive immune responses in a certain direction. Sodium 
caseinate hydrolysate, 47 displayed an anti-inflammatory profile in murine T cell subsets (Thl, 
Th2, T h l7 and Treg) within the infant nutrition group in FHI (data not shown. Hense 
hydrolysate 47 and the regenerate of 34 (132) were examined in T helper polarisation assays.
For the Thl and Th2 polarisation assays, isolated human naive CD4+ T cells (purity> 95%) 
were transferred to 96 round bottom plates and stimulated with plate bound anti-human 
CD3/anti-CD28 antibody and incubated for 3 days in the presence or absence of polarising 
cytokines Thl(IL-2 (10 ng/ml), IL-12 (lOng/ml) and neutralising antibody anti-IL-4 (5pg/ml)) 
and for Th2 . ((IL-2) (10 ng/ml) IL-4 (12.5 ng/ml)) and neutralising antibody (anti-IFN-y 
(5pg/ml)). Hydrolysates (1 mg/ml) were added on Day 3 and cells were re-stimulated with IL- 
2 (lOng/ml). On day 6 cells were harvested and intracellular cytokine staining for T-bet (Thl) 
and Gata-3 (Th2) and cytokine production of IFN-y, IL-2 (Thl) and IL-4 (Th2) was examined. 
Figure 3.8 outlines the gating strategy for the identification of CD4+ T-bef Thl cells. Figure
3.9 shows that hydrolysates 132 and 47 significantly decreased T-bet transcription factor
109
expression (MFI & number) in polarized Th 1 cells after addition of hydrolysates on Day 3 (P 
<0 01) however regenerate 79 significantly increased the number of CD4+ cells producing T- 
bet (P< 0 05) Unexpectedly, there was no change detected in IFN-y or IL-2 in the Thl culture 
supernatants after 6 days of culture
All the hydrolysates including the whey protein control (wpc80) significantly decreased 
Gata-3 transcription factor expression in polanzed Th2 cells after the addition of hydrolysates 
on Day 3 (Figure 3 8)(P< 0 001) However addition of hydrolysates had no effect on the levels 
of 1L-4 in the supernatants after 6 days of culture (Figure 3 7)
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Figure 3.6 Representative example of gating strategy used to identify human 
CD3+T-bet+ Thl cells. (A) Cells were gated first on FSC against SSC to select the 
live lymphocyte population (B) Illustrates the gating position for human CD3+ (FITC) 
expression (C) represents the gating position for human CD3+ (FITC) CD4+ (APC) T 
cells within the lymphocyte population, (D) and (E) illustrates the gating position for 
CD3+ (FITC) and T-bet (PE) expression in unstimulated (CD3/CD28) and stimulated 
(CD3/CD28 +IL-2 (10 ng/ml), IL-12 (lOng/ml) and anti-IL-4 (5pg/ml) cells within 
the CD3+ (FITC) CD4+ (APC) T cell population. All other gating positions were 
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Figure 3.7. Hydrolysates 132 and 47 significantly decrease T-bet transcription 
factor expression in polarised Thl cells. Isolated human naive CD4+ T cells (punty> 
95%) at 1 0 x 106 cells/ml were transferred to 96 round bottom plates coated with 
lOOpl of plate bound anti-human CD3 (lpg/ml) antibody 20pl of anti-CD28 (2pg/ml) 
was then added to cells CD4+ T cells were incubated for 3 days in the presence or 
absence of polarising cytokines IL-2 (10 ng/ml), IL-12 (lOng/ml) and neutralising 
antibody anti-IL-4 (5pg/ml)) and hydrolysates (1 mg/ml) were added on Day 3 Cells 
were re-stimulated with IL-2 (lOng/ml) on Day 3 On Day 6, cells were harvested and 
stained with CD4 (APC) CD3 (FITC) and fixed, permeabilised and stained 
intracellularly with fluorescent antibody for T-bet (PE) to analyse (A) MFI of T-bet 
and (B) No of CD4+T-bet+ cells (PE) using flow cytometry Supernatant was collected 
and analysed by ELISA for the detection of (C) IFN-y and (D) IL-2 The assay was 
performed on three different PBMC donors (n=3) Statistical analysis was carried out 
with one way ANOVA Tukey Multiple Comparison Test where**** significant to 
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Figure 3.8. Representative example of gating strategy used to identify human 
CD4+Gata-3+ Th2 cells. (A) Cells were gated first on FSC against SSC to select the live 
lymphocyte population (B) Illustrates the gating position for human CD4+ (APC) expression 
(C) represents the gating position for human CD3+ (FITC) CD4+ (APC) T cells within the 
lymphocyte population, (D) and (E) illustrates the gating position for CD4+ (APC) and Gata- 
3 (PerCP) expression in unstimulated and stimulated (CD3/CD28 + IL-2 (10 ng/ml) IL-4 
(12.5 ng/ml) and IFN-y (5pg/ml) cells within the CD3+ (FITC) CD4+ (APC) T cell 


















Figure 3.9. All hydrolysates decreased Gata-3 expression in polarised Th2 cells 
after addition of hydrolysates on Day 3 Isolated human naive CD4+ T cells (punty> 
95%) at 1 0 x 106 cells/ml were transferred to 96 round bottom plates coated with 
lOOpl of plate bound anti-human CD3 (lpg/ml) antibody 20pl of anti-CD28 (2pg/ml) 
was added to cells CD4+ T cells were incubated for 3 days m the presence or absence 
of polarising cytokines, IL-2 (10 ng/ml) IL-4 (12 5 ng/ml) and neutralising antibody 
(anti-IFN-y (5pg/ml) Hydrolysates (lmg/ml) were added on Day 3 Cells were re- 
stimulated with IL-2 (lOng/ml) on Day 3 On Day 6, cells were fixed, permeabihsed 
and stained mtracellularly with fluorescent antibody for Gata-3 (PerCp) to analyse Th2 
polarisation using flow cytometry (A) MFI and (B) no of CD4+ Gata-3+ cells 
Supernatant was collected and analysed by ELISA for the detection of IL-4 The assays 
were performed on three different PBMC donors (n=3) Statistical analysis was carried 
out with one way ANOVA where **** *p<0 0001 ***p<0 001 **p < 0 01
3.8. HYDROLYSATES IMPAIR TH17 DIFFERENTIATION BUT HAVE NO IMPACT 
ON T-REGULATORY EXPRESSION
Although food allergy was classically thought to be a Th2-type response, recent 
studies have shown that the Thl/Th2 paradigm is an oversimplified view of the real situation 
Besides Thl and Th2 cells, other T-cell subtypes, such as T-Reg and Thl7 have been identified 
and found to be important in maintaining balance in the immune system (Dang et al 2016, 
Stelmaszczyk-Emmel et al 2013, Dhubanehal et al 2013) Because IL-10 producing T-reg cells 
can inhibit Th2 cells, another way to dampen the Th2 response is to promote the differentiation 
of Treg cells by administration of peptides (Palomares et al 2010) Vanous studies have shown 
an effect of hydrolysates on Treg formation by showing an IL-10 upregulation after treatment 
of lymphocytes with a hydrolysate obtained from the seaweed Porphyra columbina (Cían et al 
2012) or casein hydrolysate (Lahart et al 2011) Other studies suggest that Thl7 cells are 
important in maintaining homeostasis in the intestine and thus protect the state of tolerance 
(Huber et al 2012) Differentiation of T h l7 cells is controlled by a “master regulator” of 
transcription the orphan nuclear receptor Ror gamma t (Roryt) whereas differentiation of T-Reg 
is controlled by the transcription factor FoxP3 Despite the apparent opposite effects of T-Reg 
and T h l7 immunity, there are very few studies that have addressed the issue of T helper cell 
differentiation skewed by peptides Therefore this study sought to assess the potential of milk 
protein hydrolysates to promote Treg differentiation or modulate T h l7 differentiation Human 
CD4+ naive T cells were polarized under T-reg (IL-2 (5pg/ml) and TGF-P (2ng/ml)) or T h l7 
(IL-ip(10pg/ml), IL-6 (20ng/ml), IL-23 (10ng/ml), TGF-P (2ng/ml) anti-IL-4 (10pg/ml),anti- 
IFN-y (10pg/ml), conditions for 3 days before addition of hydrolysates on day 3 On day 6 cells
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were harvested and intracellular cytokine staining for Foxp3 and Roryt was performed The 
mean fluorescence intensity (MFI) ofRor-yt (Thl7) and FoxP3 (T-reg) and cytokine production 
of IL-10 (T-reg) and IL-17 recovered from the supernatants were examined after 6 days in 
culture in presence or absence of hydrolysates Figure 3 10 outlines the gating strategy for the 
identification of CD4+ Roryt+ Th 17 cells All hydrolysates and the control (wpc80) significantly 
decreased Roryt expression (P< 0 0001) m comparison to the positive control (lpg/ml plate 
bound CD3/CD28 plus cytokines) m polarized Thl7 cells after addition of hydrolysates on Day 
3 In terms of IL-17 cytokine production, all hydrolysates significantly hampered the production 
of Thl7 in the supernatants after 6 days of culture (Figure 3 9)
In the case of T-regulatory Foxp3 expression, as can be seen in figure 3 12 only the whey 
control sample (wpc80) significantly (P<0 05) reduced the percentage of CD4+CD25+Foxp3+ 
cells in comparison to the positive control (lpg/ml plate bound CD3/CD28 plus cytokines) 
This effect was mirrored m the amount of IL-10 secreted in the supernatants on day 6 Both 
hydrolysate 47 and wpc80 control significantly down-regulated IL-10 cytokine production 
after addition of the hydrolysates on day three of culture (P<0 001) in comparison to the positive 
control (lpg/ml plate bound CD3/CD28 plus cytokines) Whereas hydrolysate 42 and its 
regenerate 79, 34 and its regenerates 84 and 132 did not enhance or reduce the levels of IL-10 
secreted in the supernatants on day 6
In summary, all hydrolysates significantly decreased the percentage of the master 
regulator transcription factor Roryt with a corresponding downregulation of IL-17 detected in 
the supernatants However, the presence of hydrolysate 47 and intact protein wpc80 control in 
the Treg polarisation assays hampered production of IL-10 The remaining hydrolysates do not 
negatively impact Treg Foxp3 expression or IL-10 cytokine production This data suggest that
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hydrolysates may use different mechanisms to regulate these T cell subsets and depending on 
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Figure 3.10. Representative example of gating strategy used to identify human 
CD3+Roryt+ Thl7 cells (A) Cells were gated first on FSC against SSC to select the live 
lymphocyte population (B) Illustrates the gating position for human CD4+ (FITC) expression 
(C) represents the gating position for human CD3+ (PerCp) CD4+ (FITC) T cells within the 
lymphocyte population, (D) and (E) illustrates the gating position for CD4+ (FITC) and Roryt+ 
(APC) expression in unstimulated and stimulated (IL-ip(10pg/ml), IL-6 (20ng/ml), IL-23 
(10ng/ml), TGF-p (2ng/ml) anti-IL-4 (10pg/ml),anti-IFN-y (10pg/ml) cells within the CD3+ 
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Figure 3.11. Hydrolysates reduce the MFI and number of CD4+Roryt+ cells and 
suppress the levels of IL-17 production in polarised Th 17 cells. Human naive 
CD4+ T cells were activated with anti-CD3/CD28 exactly as described in figure 3 10 
CD4+ T cells were incubated for 3 days in the presence or absence of polarising 
cytokines, IL-ip (10 pg/ml), IL-6 (20 ng/ml), IL-23 (lOng/ml), TGF-P (2ng/ml) and 
neutralising antibodies, anti-IFN-y (lOpg/ml), anti-IL-4(10pg/ml) Hydrolysates 
(1 mg/ml) were added on Day 3 and re-fed with cytokines On Day 6, cells were 
harvested and stained with CD4 (APC) CD3 (FITC) and these cells were fixed, 
permeabilised, and stained intracellularly with fluorescent antibody for Roryt (PerCp) 
and analysed by flow cytometry Supernatant was collected and analysed by ELISA 
for the detection of IL-17 The assay was performed on three different PBMC donors 
(n=3) Statistical analysis was earned out with one way ANOVA Tukey Multiple 
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Figure 3.12. Intact whey protein (wpc80) significantly decreased the Foxp3 expression 
and IL-10 production in a Treg polarisation assay. Purified human naive CD4+ T cells 
(punty> 95%) at 1 0 x 106 cells/ml were transferred to 96 round bottom plates coated with 
lOOpl of plate bound anti-human CD3 (lpg/ml) antibody 20pl of anti-CD28 (2pg/ml) was 
added to cells CD4+ T cells were incubated for 3 days m the presence or absence of 
polarising cytokines (IL-2 (5pg/ml) TGF-0 (2ng/ml) and hydrolysates (1 mg/ml) were added 
on Day 3 On Day 6, cells were harvested and stained with CD4 (FITC) CD25 (APC) and 
these cells were fixed, permeabilised, and stained intracellularly with fluorescent antibody 
for Foxp3 (Pe) to analyse T-Reg cytokine production using flow cytometry and supernatant 
was collected and analysed by ELISA for the detection of IL-10 The assay was performed 
on three different PBMC donors (n=3) Statistical analysis was earned out with one way 
ANOVATukey Multiple Comparison Test where **** <0 0001 ***p<0 001 and* <0 05
3.9. HYDROLYSATES IMPAIR DC MATURATION AND CYTOKINE
PRODUCTION
Dendritic cells (DC) initiate primary and drive secondary T cell- mediated immune 
reactions against a wide range of antigens (Banchereau et al 1998, Lanzavecchia et al 2000) 
This property is due to their ability to capture antigens at the immature stage and to present 
processed antigens to naive T lymphocytes at the mature stage in secondary lymphoid organs 
(Celia et al 1997) The transition from immature to mature DC is characterised by a number of 
changes, including the increased expression of MHC class II and costimulatory molecules 
(CD80, CD83, CD86), increased secretion of 1L-12 which are necessary to deliver accessory 
signals required for the activation and the differentiation of naive T cells into type 1 (IL-2, IFN- 
y) or type 2 (IL-4,IL-5, IL-13) cytokine-producing cells (Thl and Th2) (Narala et al 2007) The 
level of IL-12 secretion by DC induced by some microbial constituents such as 
lipopolysaccharide (LPS) is a key factor m the outcome of immune responses Hydrolysates 
have been shown to inhibit inflammatory responses and even stimulate tolerogemc responses 
in other antigen presenting cells (macrophages) (Oseguera-Toledo et al 2011) Very few studies 
have examined the effect of hydro lysates on human monocyte- derived dendritic cells Thus the 
ability of hydrolysates to interfere with DC maturation, was examined Human monocyte 
derived DC were generated using human CD 14 microbeads (Miltenyi) and MACS columns 
CD14+ cells were supplemented with 50ng/ml GM-SCF and 70ng/ml IL-4 and grown for three 
days On day 3 they were re-fed with cytokines and on day 6 harvested and stimulated with 
LPS in the presence or absence of hydrolysates for 24 h After 24 h, the expression of 
costimulatory molecule CD86 was analysed on DC by flow cytometry (Fig 3 13) Supernatants
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from these cultures were collected at 24 h and cytokine secretion was analysed by ELISA (Fig 
3 13) Maturation of DC with LPS for 24 h resulted m a significant increase increase in 
maturation marker expression, CD86 (96%) and (173606 MFI) by flow cytometry (Fig 3 13 B) 
However addition of hydrolysates and control samples (WPC80, NaCN) significantly reduced 
the expression of CD86 The most significant decrease in CD86 was observed in DC cultures 
in presence of 132 and 47 (Fig 3 13) P <0 0001 Following addition of hydrolysates and 
control samples, DC secreted significantly less pro-inflammatory IL-12p40 (p<0 01) These 
data suggested that hydrolysates disrupt the maturation of DC significantly reducing the 
upregulation of CD86 expression, in conjunction with a significant decrease in IL12-p40 
production These data are consistent with a hypothesis suggesting that hydrolysates maintain 






Figure 3.13. Hydrolysates reduce LPS driven dendritic cell maturation and 
cytokine production in human monocyte derived dendritic cells. On day 6,
immature DC (iDC) were stimulated with LPS (200 ng/ml) (mDC) and cultured in 
the presence or absence of hydrolysates for 24 h. On day 7, DC were harvested and 
stained with CD1A (FITC) and CD86 (PE) for the expression of maturation marker 
by flow cytometry. (A) Percentage positive CD86 presented as representative 
histograms, (B) protein expression levels were expressed as mean fluorescent 
intensity (MFI) and (C) supernatants were collected after 24 h for cytokine analysis 
by ELISA of four independent experiments (n=4) Statistical analysis was carried 
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Figure 3.14.Summary of findings on the effect of hydrolysates on Thl, Th2, 
Thl7, Treg and DC cultures.
Table 3.5 List of whey protein samples and their optimised samples
Sample
Description
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3.10 OPTIMISED HYDROLYSATE 147 HAS ALLERGY SUPPRESSING 
PROPERTIES
Thus far we have identified hydrolysates which promote an anti- inflammatory /anti­
allergy T cell and DC phenotype summarised in Fig 3.14. There was no clear choice of 
hydrolysate for further evaluation in an in vivo setting as many of the hydrolysates exerted anti­
inflammatory effects but based on other bioassays within FHI, hydrolysate 42 was chosen. For 
the purpose of hydrolysates going forward for in vivo testing , 2 upscaled samples of whey 
hydrolysate 42 (147 3 hr and 147 6 hr) (Table 3.5) were screened to confirm their
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immunomodulatory role in vitro before they were tested in vivo 147 3 hrs and 147 6 hrs refers 
to the amount of time the hydrolysate was treated with the digestive enzyme preparation during 
hydrolysis as longer hydrolysis times can change the immunoreactivity of protein allergens 
(Nongomerma & Fitzgerald 2014, Wroblewska B et al 2004)
The proliferative ability of increasing doses (0 5 mg/ml 1 0 mg/ml, 2 0 mg/ml) of 
hydrolysates (147 3 hr and 147 6hr) was assessed by measuring the proliferation of activated 
and labelled peripheral blood mononuclear cells (PBMC) in the presence or absence of 
hydrolysates, as detailed in section 2 3 3 Adding increasing doses of hydrolysates had no effect 
on the proliferation of CD3+ T cells (with a whole PBMC population stimulated with 
antiCD3/CD28 (Figure 3 15)
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Figure 3.15. Hydrolysate 147 had no impact on T cell proliferation. PBMC (5 
x 104 per well) were labelled with CFSE in a 96 well round bottom plate and co­
cultured with anti-CD3/CD28 beads in the presence or absence o f hydrolysates (0 5, 
lmg or 2mg/ml) On Day four, cells were harvested and stained with fluorescent 
antibody CD3 and fluorescent 7AAD viability dye to analyse CD3+ proliferation 
using flow cytometry The assay was performed on three PBMC donors (n=3) 
Statistical analysis was earned out using one-way ANOVA Tukey Multiple 
Comparison Test where **** <0 0001 Stars are in comparison to the PBMC+ beads 
group
3.11. OPTMISED HYDROLYSATE 147 ENHANCES TH1 DIFFERENTIATION
The results so far suggest that specific hydrolysates impair or enhance Thl 
differentiation However when the two new fractions of optimized hydrolysates 147 (3 hr) 147 
(6 hr) were tested in a polarized Thl assay a more enhancement effect was observed (Figure 
3 16 A) Hydrolysates 147 3 hr and 6 hr and whey control protein (WPC80) significantly 
increased the T-bet transcription factor expression (P <0 001, P<0 01) Previously there was no 
change found with the levels of IFN-y in the supernatants after 6 days of culture under Thl 
polarising conditions with ELISA (Figure 3 7) A more sensitive read-out utilizing intracellular 
flow cytometry was carried out to detect the percentage of CD4+ cells producing IFN-y On day 
6, Thl cells were harvested and stimulated with PMA and lonomycin for 4 hrs, and stained 
intracellularly for IFN-y Hydrolysate 147 (6hrs) significantly mcreased the mean fluorescent 
intensity of CD4+T-bet+cells and the percentage of CD4+ cells producing IFN-y in Thl 
polarised cells (P<0 05) (Figure 3 16 B)
As whey hydrolysate 42 was the original hydrolysate this data suggests that hydrolysate 146 





















Figure 3.16. Hydrolysate 147 (6 hrs) significantly increases T-bet 
transcription factor expression and percentage CD4+ IFN-y+ cells in 
polarised Thl cells after addition of hydrolysates on Day 3. Isolated human 
naive CD4+ T cells (punty> 95%) were set up exactly as described in figure 
3 9 Cells were recovered on Day 6 and stained with CD4 (APC) CD3 (FITC) 
and fixed, permeabilised and stained intracellularly with fluorescent antibody 
for T-bet (Pe) or stimulated with lOOng/ml PMA, 1 pg/ml lonomycin and IX 
Brefeldin A for 4 h and stained intracellularly with fluorescent antibody for IFN- 
y (pe) (A) Graphical representation of protein levels of transcription factor t- 
bet (M FI) and percentage of human CD4+ IFN-y+ cells is represented in (B) 
respectively The assay was performed on three different PBMC donors (n=3) 
Statistical analysis was carried out with one way ANOVA Tukey Multiple 
Comparison Test where**** significant to control (lpg/ml plate bound 
CD3/CD28) plus cytokines***p < 0 001** p <0 01* p <0 05
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3.12. BOTH FRACTIONS OF HYDROLYSATE 147 IMPAIRS TH2
DIFFERNTIATION.
Thus far the results suggest that specific hydrolysates impair Th2 differentiation The two 
new fractions of optimized hydrolysates (147 3 hr, 147 6 hr) were tested in a Th2 polarised 
assay and the same effect was seen (Figure 3 17 A) Hydrolysates 147 3 hr and 6 hr significantly 
decreased the Gata-3 transcription factor expression (P <0 05, P<0 01) Previously there was 
no change found with the levels of IL-4 in the supernatants after 6 days of culture under Th2 
polarising conditions with ELISA (Figure 3 9) A more sensitive assay of intracellular flow 
cytometry was carried out to detect the percentage of CD4+ cells producing IL-4 On day 6 Th2 
cells were harvested and stimulated with PMA and lonomycm for 4 hrs, and stained 
mtracellularly for IL-4 The capacity of the new fractions (147 3 hr, 147 6 hr) to impair Th2 
differentiation were examined using a Th2 polarisation assay There was a significant decrease 
m the percentage of CD4+ cells producing IL-4 when the Th2 polarised cells were cultured in 
the presence of hydrolysate 147 3 hr, 147 6 hr and WPC80 (P<0 001) (Figure 3 17 B)
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Figure 3.17. Hydrolysate 147 significantly decrease Gata-3 expression and 
IL-4 cytokine production in polarised Th2 cells. Isolated human naive CD4+ 
T cells (punty> 95%) were set up as described in figure 3 11 On Day 6, cells 
were fixed, permeabilised and stained mtracellularly with fluorescent antibody 
for Gata-3 (PerCp) or IL-4 (PE) to analyse Th2 cytokine production using flow 
cytometry or cells were stimulated with 100ng/ml PMA, 1 pg/ml îonomycin and 
lx Brefeldin A for 4 h and analysed by intercellular flow cytometry (A) 
Graphical representation of protein levels of transcription factor Gata-3 (MFI ) 
and percentage of human CD4+ IL-4+ cells is represented in (B) respectively 
The assay was performed on three different PBMC donors (n=3) Statistical 
analysis was carried out with one way ANOVA Tukey Multiple Comparison 
Test where *<0 005 **p<0 01***p < 0 001
3.13. HYDROLYSATES 147 AND WHEY PROTEIN CONTROL INHIBIT TH17 
DIFFERENTIATION WITHOUT ANY CHANGE IN T-REGULATORY 
EXPRESSION
Human CD4+ naive T cells were polarized under T-reg and Thl7 conditions for 3 days 
before addition of hydrolysates on day 3. The mean fluorescence intensity (MFI) of Roryt 
(Thl7) and Foxp3 (T-reg) and cytokine production of IL-17 recovered from the supernatants 
after 6 days in culture in presence or absence of hydrolysates was examined. All hydrolysates 
and control (wpc80) sample significantly decreased Roryt transcription factor expression (P< 
0.0001) in comparison to the positive control ( lpg/ml plate bound CD3/CD28 plus cytokines) 
in polarized Thl7 cells after addition of hydrolysates on Day 3 (Figure 3.18 A). In terms of IL- 
17 cytokine production, all hydrolysates and whey control sample slightly reduced the 
production ofT hl7 in the supernatants after 6 days of culture (P<0.05) (Figure 3.18B).
In the case of T-regulatory Foxp3 expression, there was a slight increase in the mean 
fluorescent intensity of Foxp3 with hydrolysate 147 6 hr but this increase was not significant. 
(Figure 3.19). Overall hydrolysate 147 and wpc80 did not positively or negatively impact on 
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Figure 3.18. Hydrolysate 147 and whey protein control reduce the MFI of 
CD4+Roryt+ cells and suppress the levels of IL-17 in polarised Th 17 cells. Isolated 
human naive CD4+ T cells (punty> 95%) at 1 0 x 106 cells/ml were isolated as described 
before in figure 3 13 On Day 6, cells were harvested and surfaced stained with CD3 
(APC) CD4 (FITC) and then cells were fixed, permeabilised and stained mtracellularly 
with fluorescent antibody for Roryt (PerCp) and analysed by flow cytometry (A) 
Graphical representation of protein levels of transcription factor Roryt (M FI) and (B) 
Supernatant was collected and analysed by ELISA for the detection of IL-17 The assay 
was performed on three different PBMC donors (n=3) Statistical analysis was carried 
















Figure 3.19. No change detected in Foxp3 with hydrolysate 147. Purified naive 
CD4+ T cells were prepared as descnbed in Fig 3 14 On Day 6, cells were harvested 
and stained with CD4 (FITC) CD25 (APC) and these cells were fixed, permeabilised, 
and stained intracellularly with fluorescent antibody for Foxp3 (Pe) to analyse (A) MFI 
(B) percentage and (C) total no of CD4+Foxp3 + cells using flow cytometry The assay 
was performed on three different PBMC donors (n=3) Statistical analysis was earned 
out with one way ANOVA Tukey Multiple Comparison Test where **** <0 0001
3.14. NEW OPTIMISED HYDROLYSATES INHIBIT DC MATURATION AND 
CYTOKINE PRODUCTION
Th2 cells and its associated cytokines (IL-4, IL-5, IL-13) produce many of the 
pathological features of allergic disease however they depend on the instruction from antigen- 
presenting DCs to differentiate and act. DCs provide the first step of the immune recognition 
of allergens and thus represents the decision maker of the immunological outcome. Hense in 
the absence of activation signals, allergen challenged DC induce the proper T cell 
unresponsiveness and tolerance. In contrast in the presence of these signals the outcome may 
result in the induction of T cell activation, division and Th2 differentiation. The maintenance 
of balance between tolerance and immunity is a complex process and hydrolysates have been 
shown to maintain the balance towards tolerance (Oseguera-Toledo et al 2011). Previously, 
hydrolysate 42 and it’s regenerate 79 significantly reduced the LPS driven dendritic cell 
maturation and cytokine production in human monocyte derived DC. To assess whether the 
new fraction 147 6hr has an impact on DC maturation, human monocyte derived DC were 
stimulated with LPS in the presence or absence of hydrolysate 147 6hr for 24 h. After 24 h, the 
expression of co-stimulatory molecule CD86 was analysed on DC by flow cytometry and the 
cytokine secretion in the supernatants was analysed by ELISA. Following addition of 147 
hydrolysate, there was a significant decrease in the expression of the co-stimulatory molecule 
CD86 (Figure 3.20A) and DC secreted significantly less pro-inflammatory IL-12 in presence 
of hydrolysate 147 and wpc80 (Figure 3.20B). This data provides further evidence that 
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Figure 3.20. Optimised 147 hydrolysate inhibits the LPS driven dendritic 
cell maturation and reduces the cytokine production in human monocyte 
derived DC. On day 6, immature DC (lDC) were stimulated with LPS (200 
ng/ml) (mDC) and cultured in the presence or absence of hydrolysates for 24 h 
On day 7, DC were harvested and stained with CD1A (FITC) and CD86 (PE) 
for the expression of maturation marker by flow cytometry (A) protein 
expression levels were expressed as mean fluorescent intensity (MFI) and (B) 
supernatants were collected after 24 h for cytokine analysis by ELISA of four 
independent experiments (n=2) Statistical analysis was carried out using the 
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Figure 3.21. Summary of findings on the effect of hydrolysate 147 on 
T h l, Th2, T hl7, Treg and DC cultures.
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3.15. HYDROLYSATE 147 INCREASED THE EXPRESSION OF PEROXISOME 
PROLIFERATOR—ACTIVATED RECEPTOR GAMMA IN HUMAN 
MONOCYTE- DERIVED DENDRITIC CELLS
Although many immunoregulatory effects of hydrolysates have been described, the 
underlying mechanisms to explain the aforementioned effects are still unknown Peroxisome 
proliferator-activated receptors (P-PAR) are ligand-activated transcription factors belonging to 
the nuclear receptor superfamily They exercise homeostatic functions in the intestine at the 
interface between nutrient metabolism and immunity, and their main functions are related with 
the regulation of genes involved in glucose and lipid metabolism and m cellular differentiation 
(Tenenbaum et al 2003, Desverhgne et al 2004, Feige et al 2006) P-PARy is activated by both 
natural ligands, such as polyunsaturated fatty acids (PUFAs) or by synthetic ligands, such as 
thiazolidinediones—a class of antidiabetic drug and both have been investigated for their anti­
inflammatory effects (Tyagi et al 2011) Although P-PARy is expressed in various tissues and 
cell types, including pancreas, liver, kidney, immune cells (eg, lymphocytes, monocytes, and 
macrophages), it is also expressed in dendntic cells (Gosset et al 2001, Letellier et al 2008) 
Synthetic P-PARy agonists including troglitazone and rosiglitazone were shown to suppress 
production of inflammatory cytokines by these cells (Letellier et al 2008) However some 
agonists in clinical use have series side effects such as weight gam, increased bone fracture and 
heart failure (Rizos et al 2009) Conversely, natural products like milk derived peptides which 
so far display anti-inflammatory effects may also activate P-PAR
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P-PARy is of particular interest to the food industry beacuse P-PAR-y activators and their 
precursors e g lmolemc and linoleic acid are abundant in several foods
To assess whether P-PARy has a role in the immunomodulatory effect of hydrolysates, 
on DC, human monocyte derived dendritic cells were stimulated with LPS (in the presence and 
absence of hydrolysate 147) and the expression of P-PARy mRNA was examined P-PARy 
mRNA expression was significantly higher in the presence of hydrolysate 147 (P<0 01) and 
less so with wpc80 (P < 0 05) in comparison to negative control (immature dendritic cell) 
(Figure 3 21)
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Figure 3.21. Expression of P-PARy in vitro in human monocyte derived 
dendritic cells Monocytes were cultured in the presence of GM-CSF (50ng/ml) 
and IL-4 (70ng/ml) to generate DC On Day 6, immature DC (iDC) were seeded 
at 2 x 105 per well in a 24 well plate and left alone or stimulated with LPS (200 
ng/ml) and cultured in the presence or absence of 147 and WPC80 (1 mg/ml) for 
24 h After 24 hours the cells were collected for quantitative PCR (qPCR) 
analysis RNA from each sample was extracted, cDNA was synthesised and used 
as a template for qPCR P-PARy mRNA expression was relative to the 
housekeeping gene GAPDH Hydrolysate 147 and whey control significantly 
increased the mRNA expression of P-PARy after 24 hours These experiments 
were repeated using 3 PBMC donors to generate human monocyte derived 
dendritic cells (n=3) and the results shown are representative of this Statistical 
analysis was carried out using unpaired student t-test where *<0 05 and**< 0 01
3.16. WHEY PROTEIN-DERIVED PEPTIDES MODULATE THE EXPRESSION 
OF PRO-INFLAMMATORY PHENOTYPE OF MDDC
The demonstration that P-PARy activators like milk protein hydrolysates may regulate the 
synthesis of cytokines and /or surface molecules by vanous immunocompetent cells (Fitzgerald 
et al 2015, Clark et al 2000) raised the possibility that P-PARy could play a role in hydrolysate 
modulation of DC activation and cytokine production
P-PARy is a nuclear receptor that supresses inflammatory gene expression when 
activated m the inflammatory response in DC (Gosset et al 2001) P-PARy also acts as a 
transcription factor to suppress the signal transduction and consequent activation of pro- 
inflammatory transcription factors such as NFkB ( Letellier et al 2008) Therefore, it is 
postulated that as P-PARy is expressed on DC and hydrolysates activate P-PARy, addition of 
147 hydrolysate to activated DC may result in inhibition of NFkB signaling Specifically in 
order to test whether the effects of whey protein hydrolysate in suppressing the inflammatory 
phenotype of activated DC was blocked, a synthetic P-PARy inhibitor BADGE was used DC 
were treated for 24 h with the hydrolysate or with a synthetic P-PARy agonist troglitazone (25 
juM) m the presence or absence of BADGE (lOpM) and then activated with LPS (200ng/ml) 
P-PAR-y agonist (p-pary+) significantly reduced the MFI of the maturation marker CD86 
(P<0 001) and simultaneously inhibited the production of IL-12 (P< 0 0001)(Figure 
3 23) Similarly, the whey hydrolysate 147 significantly reduced the MFI of the maturation 
marker CD86 (P<0 01) and simultaneously inhibited the production of IL-12 (P< 0 0001) In 
the presence of antagonist BADGE (P-PARy-), the effects of both troglitazone and the whey 
hydrolysate 147 were prevented This data suggest that the modulation of LPS monocyte
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derived dendritic cells response by whey derived bioactive peptides is mediated by the 
activation of P-PARy (Figure 3 23)
In summary, the activation of P-PARy in MDDC decreased secretion of IL-12, a pivotal 
cytokine in Thl polarisation The P-PARy agonist, troglitazone decreased CD86 expression 
The net effect of these changes appeared to be an inhibition o f DC immunogenicity marked by 
diminished T-cell activation capacity Fitzgerald et al (2014) found a similar effect with a casein 
hydrolysate in TNF-a activated endothelial cells where the modulation of TNF-a induced 
adhesion molecules response by casein derived bioactive peptides was mediated by activation 
of PPAR-y
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Figure 3.23. The anti-inflammatory effects of whey hydrolysate 147 can be mimicked 
in the presence of a P-PARy agonist troglitazone or reversed in the presence of a P- 
PARy antagonist, BADGE On Day 6, immature MDDC (5  X 106 cells/ml) were 
harvested The P-PARy antagonist Badge (lOpM) was added 1 h before the stimulation of 
MDDC with LPS (200 ng/ml) (mDC) and troglitazone (25 pM) agonist added 10 min before 
stimulation MDDC were cultured in the presence or absence of agonist /antagonist or with 
hydrolysates +/- antagonist for 24 h On Day 7, DC were harvested and stained with CD86 
(PE) for the expression of maturation marker by flow cytometry (B) Supernatants were 
collected after 24 h for cytokine analysis by ELISA These experiments were repeated using 
three PBMC donors (n=3) Hydrolysates and P-PAR y agonist troglitazone significantly 
decreased the maturation marker CD86 and inhibited the production of IL-12p40 by DC 
while the P-PARy antagonist restored the maturation marker CD86 and cytokine level of IL- 
12p40 back to a mature MDDC phenotype Statistical analysis was carried out with one way 
ANOVA Tukey Multiple Comparison Test where **** < 0 0001, **<0 01
3.17. WHEY HYDROLYSATE 147 EXERTS ITS ANTI-INFLAMMATORY EFFECTS 
BY SUPPRESSING NF-kB PATHWAY ACTIVATION THROUGH P-PARy 
DEPENDENT MECHANISMS
NF-kB (nuclear factor kappa-light-cham-enhancer of activated B cells) is a 
protein complex that controls transcription of DNA, cytokine production and cell survival The 
DC maturation process is known to depend on the activation of NF-kB following LPS 
stimulation To explore the hypothesis that the hydrolysate exerts it effects in DC via NF-kB 
through activation of P-PARy, DC were treated for 24 h with the hydrolysate (147) or whey 
protein control (wpc80) or troglitazone (25pM) in the presence or absence of BADGE (lOpM) 
and then activated with LPS (200ng/ml for 10 mins) and the resulting DC lysates were analysed 
by western blotting Phosphorylation of the p65 subunit of NF-kB was used as an index of NF- 
kB activation As shown in Figure 3 24, LPS activates the NF-kB pathway inducing the 
phosphorylation of NF-kB p65 (P <0 0001, Figure 3 24 A, B) Phosphorylation of the NF-kB 
p65 was significantly reduced by hydrolysate 147 (P<0 01), by whey protein control wpc80 (P 
<0 01) and by the P-PARy ligand (p-pary+) troglitazone (P<0 01) In the presence of BADGE 
(p-pary-), the effects of both the whey hydrolysate, whey control and troglitazone on NF-kB 
p65 phosphorylation were completely suppressed, demonstrating that the modulation of NF-kB 




Figure 3.24. Whey hydrolysate 147 and wpc80 exert there anti-inflammatory effects by 
suppressing NF-kB pathway activation through PPAR-y dependent mechanism.
Phosphorylation of the p65 subunit of NF-kB was used as an index of NF-kB activation (A) 
DC were treated with whey hydrolysate 147, WPC80 or troglitazone (p-pary+ (25 pM)) for 24 
h and with or without BADGE (p-pary- (10 pM)) followed by 10 nun stimulation with LPS 
(200ng/ml) Phosphorylation of p65 was estimated by Western Blotting experiments (10 pg of 
total proteins) and (3-actin was used as a loading control (B) Protein levels (assessed as ratio of 
protein OD normalized to the OD of P-actin) were shown as a percentage of control (LPS 
activated cell) (n=2) Statistical analysis was carried out using unpaired student t test where 
**** <0 0001 DC vs LPS and **<001 treatment vs BADGE
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3.18. SUMMARY
The main objectives of this chapter were to 1) to identify hydrolysates that have 
immunosuppressive effects on T cell proliferation and cytokine production in vitro 2) to 
determine the effects of hydrolysates on Thl, Th2, Thl7 and T Reg differentiation 3) to 
determine the effects of hydrolysates on DC maturation and cytokine production and 4) to 
identify a mechanism by which hydrolysates can influence key signal transduction events 
involved in inflammatory processes The addition of hydrolysates to PBMC cultures had 
differential effects on T cell proliferation however for the most part, hydrolysates did not 
significantly interact with T cell proliferation In terms of immunomodulatory ability, a number 
of whey and casein hydrolysates reduced the levels of the Thl cytokine (IFN-y), while other 
hydrolysates significantly increased the levels of IFN-y after 4 days in PBMC activated cells 
Several hydrolysates inhibited the Th2 response by decreasing the signature cytokine of allergy 
IL-4 and some hydrolysates significantly decreased the pro-inflammatory cytokine IL-6 Two 
casein hydrolysates increased the level of IL-10 Based on these results two whey hydrolysates 
and three casein hydrolysates and their optimised regenerates were selected for further analysis 
to build the body of evidence that hydrolysates may have immunomodulatory properties with 
the potential to dampen pro-inflammatory responses and promote regulatory responses These 
selected hydrolysates and their regenerates had no.effect on the number of proliferating CD3+ 
T cells Differential modulation was again evident m this second screen where several 
hydrolysates and their regenerates decreased both pro-inflammatory IL-6 and IL-17 with little 
or no effect on Thl cytokines IFN-y, or IL-2
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Unfortunately, the most promising hydrolysate 35 and it’s regenerate 85 with an enhanced 
immunomodulatory ability over and above Pepti had to be excluded from the study 
Hydrolysates were then chosen for further screening based on the results of this screen and a 
screen performed with mouse cells within FHI
In terms of suppression in polarized Thl cells, upscaled hydrolysate 132 and 47 
significantly decreased T-bet transcription factor expression, however addition of upscaled 
hydrolysate 79 to Thl polarised cells, significantly increased the number of CD4+ T-bet+ cells 
All hydrolysates significantly decreased the master transcription factor of Th2 cells, Gata-3 in 
polarized Th2 cells while both the original hydrolysates 42 and 47 significantly reduced the 
number of Gata-3+ cells, but there was no change detected in the Th2 culture supernatants 
(Figure 3 9) When hydrolysates were added to T h l7 polarised cells, all hydrolysates 
significantly reduced the protein expression of the transcription factor Roryt, number of CD4+ 
Roryt + cells and suppressed the levels of IL-17 (Figure 3.11) Adding WPC80 control to Treg 
polarised cells, hampered the production of IL-10 and protein expression of Foxp3 (Figure 
3 12)
The third part of this study was to determine the effects of hydrolysates on DC maturation 
and cytokine production Human monocyte derived DC stimulated with LPS in the presence or 
absence of hydrolysates (42, 79, 132 and 47) disrupted the maturation of DC and significantly 
prevented the upregulation of CD86 co-stimulatory molecule expression in conjunction with a 
significant decrease m IL-12p40 cytokine production (Figure 3 13)
The last part of this study was to identify a mechanism by which hydrolysates can influence 
key signal transduction events involved m inflammatory processes P-PAR-y a member of the 
nuclear receptor superfamily, has recently been described as a modulator of macrophage and
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dendritic functions, are activated by natural ligands (PUFAs) or by synthetic ligands 
(Troglitazone) and both have been investigated for their anti-inflammatory effects P-PAR-y are 
expressed in spleen and in Peyer’s patches (Braissant et al 1996, Greene et al 1995) and are 
also expressed in DC (Gosset et al 2001) Many anti-inflammatory natural products activate P- 
PAR therefore natural immunomodulatory milk protein hydrolysates may activate or modulate 
P-PAR-y to exert there anti-inflammatory effects This was first investigated by examining the 
P-PAR-y mRNA expression in MDDC in the presence or absence of hydrolysate 147 P-PAR-y 
mRNA expression was significantly higher in the presence of hydrolysate 147 (Figure 3 22) 
Probing this further, lead us to test whether the effects of whey hydrolysate 147 in suppressing 
activated DC was blocked, by treating DC with hydrolysate or with a synthetic P-PAR-y agonist 
troglitazone in the presence or absence of a synthetic P-PAR-y inhibitor BADGE In the 
presence of the antagonist BADGE the anti-inflammatory effect of hydrolysate 147 and the 
synthetic agonist troglitazone was prevented (Figure 3 2) In the DC lysates obtained from 
activated DC treated with hydrolysate or agonist m the presence or absence of BADGE 
phosphorylation of NF-kB p65 was significantly reduced by hydrolysate 147 and by P-PAR-y 
agonist However m presence of BADGE the NF-kB p65 protein levels were significantly 
reduced This suggests that the inhibition is direct and is dependent on activation of NF-kB by 
hydrolysate 147 mediated through a P-PARy dependent mechanism This mechanism could 
provide information for a more efficient application of specific lmmunomodulating milk 
peptides to induce anti-allergic /anti-inflammatory effects in infants with food allergy
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CHAPTER 4
COMPARISON OF THE 
ENGRAFTMENT OF HUMAN IMMUNE 
POPULATIONS IN NSG-SCF VERSUS 
NSG-SGM3 MICE
4.1 Introduction
Development o f ‘humanized’ mice, which involves transplantation of human 
hematopoietic stem cells in immunodeficient animals, has provided a promising 
platform to study human immune responses in vivo (Legrand et al 2009). The 
humanised mouse system, a xenogenic transplantation and engraftment model for 
hematopoietic stem cells (HSCs) and peripheral blood mononuclear cells (PBMCs) 
facilitates the investigation o f human immune systems in vivo (Manz 2007, Shultz et al 
2007). Mice with functional human immune systems have potential to serve as a novel 
platform to test functional foods. Evaluation o f functional foods i.e. anti-inflammatory 
milk protein hydrolysates in a humanised mouse models brings us one step closer to 
validate their biological activity in a human relevant system. Mast cells and basophils 
play a critical role in allergy and this makes them attractive candidates for targeting 
allergic diseases. To this end, mice need to fully support the development o f human 
myeloid immune cells especially granulocytes like mast cells and basophils in order to 
be capable o f mounting effective human allergic responses.
As explained in Chapter 1, there are numerous issues with regards the current 
animal mouse models o f food allergy that make the prospect o f a humanised mouse 
model attractive. Humans and mice display numerous discrepancies in both innate and 
adaptive immunity. The immunological limitations o f these models were increasingly 
being realized which prompted the development o f mice that fully support human 
hematopoiesis in vivo. NSG or NOD-.sc/i/ IL2Rgnul1 mice are the most common strain of 
immunodeficient mice currently being used for the generation of humanised mice but 
the differentiation of human HSC into functional myeloid cells requires the delivery of 
human cytokines in vivo. Thus, to facilitate this a number o f strains have been engineered
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to allow the expression of human genes that are relevant in human allergy for example 
SCF, IL-3, GM-SCF, and TPO.
Despite, or perhaps because of the continuous efforts to improve the currently 
available models, the development o f humanised mice remains complicated by the fact 
that there is no consensus on how it should be approached. Although some investigators 
use peripheral blood leukocytes to reconstitute mice, human hematopoietic stem cells 
(HSCs) have been shown to provide better engraftment, and present less risk o f the mice 
developing graft vs host disease. However factors that must be considered when 
developing these models include the following: 1) a number of different human cell 
types can be used to engraft mice, 2) NSG mice are available on a number o f background 
strains, 3) mice can be irradiated or not to achieve higher levels o f engraftment, 4) mice 
can be engrafted both as adults and neonates and 5) both male and female mice can be 
used (Shultz et al 2015). To date there have been few studies on the engraftment of 
humanised mice that have directly compared these factors.
The development o f animal models that mimic human allergic responses is crucial 
to study the pathophysiology o f disease and to generate new therapeutic methodologies. 
In Chapter 1, the rational for choosing NSG-SCF and NSG-SGM3 was discussed. Based 
on this discussion, CD344 stem cells derived from UCB were chosen to repopulate 
immunodeficient mice with human immune cells in this study. The engraftment levels 
o f two strains o f immunodeficient mice, both with the IL2ry -/- mutation, were compared 
after adoptive transfer o f human CD34+ cells derived from umbilical cord blood (UCB). 
The two strains used were as follows: NOD.Cg-Prkdc scld IL-2rg tmIWJ1 Tg (PGK1- 
KITLG*220) 441Daw/J; human membrane bound stem cell factor (NSG-SCF) and 
triple transgenic NOD.Cg-Prkdc scld Tg; human stem cell factor (hSCF), granulocyte-
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macrophage colony-stimulating factor (GM-CSF) and interleukin -3 (IL-3) mice (NSG- 
SGM3) We chose to compare the engraftment levels of hHSCs in irradiated NSG- 
SGM3 versus non-irradiated NSG-SCF mice to study the development o f human 
myeloid, T, B cells, basophils and mast cells in these two strains of mice as no study has 
directly compared these models In this chapter the engraftment levels of human 
immune cells in NSG-SCF and NSG-SGM3 mice were compared, various methods of 
CD34+ cell isolation from UCB were tested, purified cells were transferred into 
conditioned NSG-SGM3 and non-conditioned NSG-SCF and the engraftment of these 
mice was characterised In summary the objectives of this chapter were,
1) To identify which strain o f mouse provided the best host for engraftment of 
human immune cells involved in the allergy response (T, B , myeloid mast 
cells and basophils)
2) To identify the conditions facilitating the optimal development o f humanised 
mice,
• Engraftment in male versus female mice
• Engraftment with fresh versus frozen CD34+ HSC
• The dose o f CD34+ required for optimal engraftment levels of T, B, 
myeloid mast cells and basophils in NSG-SCF and NSG-SGM3 mice
4.2. TH REE HSC SOURCES FO R HUMANISATION OF M ICE
There are several factors to address before commencing with the generation of
humanised mice but none are more important than the source o f HSC We choose three 
sources o f HSC 1) fresh umbilical cord blood (UCB) provided by the cord blood bank 
Anthony Nolan Trust Nottingham, UK, 2) UCB donated from consented women who 
underwent planned caesarean sections at the national maternity hospital (NMH), Holies
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St, Dublin and 3) frozen cord blood - derived flow sorted human CD34+ cells purchased 
from Lonza (Basel, Switzerland).
4.3 ISOLATION OF CD34+ CELLS FROM FRESH UMBILICAL CORD 
BLOOD.
Clinical standard UCB was obtained from the Anthony Nolan Trust, Nottingham, 
UK. It was shipped overnight (by air) and the next morning the CD3+ T cell were 
depleted from the UCB using the RosetteSep system (Stem cell Technologies , Grenoble 
France)(Section 2.8.2) before enrichment for CD34+ cells was performed with the 
positive selection kit II (Stem cell Technologies) as detailed in section 2.8.3. Flow 
cytometry staining for CD34+ was used to determine the purity of the cell preparations. 
After using the Easy Sep human cord blood kit, which involves two separate isolation 
steps, the cell suspension contained only 4.2 % CD34+ cells (Figure 4.1). The flow 
through containing the cells that were not magnetically labelled and thus were poured 
off was also examined to ensure no CD34 cells that could be collected by an extra 
purification step remained. No CD34+cells were present in the flow through highlighting 
a problem with either the kit used to isolate the cells or the blood obtained from Anthony 
Nolan Trust. However, it was suspected that the UCB was X-rayed at customs in transit 
despite having an X-ray exempt form on the packaged cells (private communication 
Kam Varma, PdP couriers, UK) which killed the cells (Figure 4.1). Thus new fresh cord 
was obtained again from the Anthony Nolan Trust shipped overnight (non-irradiated) 
and enrichment for CD34+ cells was performed again with the positive selection kit II 
(Stem cell Technologies). The new Easy Sep kit produced a cell suspension with 90.9% 
CD34* cells (Figure 4.2). Furthermore the yield was acceptable (3.8 x 106 cells total,
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enough to engraft approximately 36 mice) (Table 4.1). Table 4.1 summarises the various 
attempts to purify CD34+ cells from fresh cord blood from Anthony Nolan. O f the 3 
attempts to isolate CD34+ cells from the Anthony Nolan Trust sufficient purity (> 90% 
CD34+ cells) was only achieved once (Table 4.1).
The next source o f UCB was obtained from consented women volunteers at the 
NMH Holies St, Dublin. Human UCB samples were obtained according to institutional 
guidelines approved by the NMH ethics committee. The major challenge here was to get 
a yield o f UCB sufficient to permit injection into a number o f mice. Based on our 
experience o f 11 UCB samples obtained from consented donors from the NMH (Table 
4.1) 4 out o f 11 times we received volumes o f 80-140ml which resulted in sufficient 
yields (1.2 x 106- 2.78 x 106) and purity (> 90%) to permit injection into mice. However 
2 out o f 11 times UCB blood volume were very low (6-9ml) which resulted in very low 
yields and purity (Table 4.1). There were several times when we got sufficient volumes 
of UCB (65-85ml) but for some unforeseen reason, also resulted in low yields and purity. 
Several factors may affect the CD34+ cell yield. First, one needs to find a density 
gradient matrix that works well for UCB, which is not necessarily the same as is 
efficacious for adult peripheral blood. Moreover, during the purification o f UCB cells 
away from red blood cells, performed on lymphoprep gradient medium (Axis Shield 
PoS, AS, Oslo, Norway) retention o f red blood cells occurred at the interface or just 
below when there was a delay o f several hours between withdrawal o f blood from the 
cord (due to emergency caesarean sections) and its collection which could not be 
controlled which resulted in the low yields and purity detailed in Table 4.1.
The third source of HSC; frozen cord blood - derived flow sorted human CD34+ cells 
purchased from Lonza (Basel, Switzerland) allowed for greater flexibility in terms of 
planning experiments and therefore were the most stable source as they were already
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purified and contained sufficient cell numbers and purity o f CD34+ cells to perform 
expenments (Figure 4 3) In this chapter, some experiments were completed with UCB 
obtained from Anthony Nolan, some with NMH but most were completed with purified 
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Figure 4.1. CD34+ cell purification from fresh UCB. Using the Easy Sep system 
CD34+ cells were isolated from 24-36 hr old cord blood obtained from the Anthony 
Nolan Trust. Analysis for surface expression o f CD34+(PE) by flow cytometry was 
used to determine the purity o f the cell preparations. (A) Illustrates the gated HSC 
population from SCC against FSC plot, (B) represents the gating position for human 
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Figure 4.2. CD34+ cell purification from fresh UCB. Using the Easy Sep system 
CD34+ cells were isolated from 24-36 hr old cord blood obtained from the Anthony 
Nolan Trust. Analysis for surface expression o f CD34+ (PE) by flow cytometry was used 
to determine the purity o f the cell preparations. (A) Illustrates the gated HSC population 
from SCC against FSC plot, (B) represents the gating position for human CD34+ (PE) 
and (C) purity (blue open histogram) and red peak represents isotype control. Data is 
from Donor 100544 (170ml) and is representative of one experiment.
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FSC-A
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Table 4.1 List of CD34*celi purifications
Cord Blood 
Sample voi
Source of Cells Total cell yield 
CD34+
Purity of CD34+ cells 
(%)
114ml Anthony Nolan 2 x 10s 4.2
127 ml Anthony Nolan 6.4 x 10s 82.0
170ml Anthony Nolan 3.8 X106 90.9
80ml NMH 6.6 x 10s 68.0
120ml NMH 1.2x 106 93.0
85ml NMH 6 x10s 78.0
80 ml NMH 1.6 x 106 95.6
80ml NMH
.... ............ . . .....
4.4 xlO5 74.0
65 ml NMH 2.19 X 10s 76.0
9ml NMH
Li ........ ............................. ...........
5.8 x 10s 81.0
6ml NMH 2 x10s 86
140 ml NMH
- ............ .... .. ............  .................
2.78 x 106 94.0
100ml NMH 7 x10s 83.0
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Figure 4.3. Purity analysis of CD34+ stem cells by flow cytometry. Isolated 
hematopoietic CD34" cells obtained from Lonza were thawed as in section 2.1 and were 
analysed for surface expression of CD34+ (PE) by flow cytometry to determine the purity 
o f the cell preparations. (A) Illustrates the gated HSC population from SCC against FSC 
plot, (B) represents the gating position for human CD34+ (PE) and (C) purity (black open 
histogram) and red peak represents isotype control.
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Fig 4.4. Timeline of the CD34+ stem cell reconstitution in NSG, NSG-IL- 
3/GM-SCF/SCF (SGM3) and NSG- membrane bound SCF mice (mSCF).
NOD-SCID IL-2ry"ull(NSG) and human stem cell factor, granulocyte- 
macrophage colony-stimulating factor and interleukin -3 expressing NOD-SCID 
IL-2ryllull(NSG-SGM3) mice were exposed to a sub-lethal dose (2.4Gy) o f gamma 
irradiation. 1 x 105 CD34+HSCs was then administered intravenously (300 pi) via 
the tail vein on day 0 into NSG, NSG-SGM3 and NOD-SCID IL-2ry nuU human 
membrane bound stem cell factor (NSG-SCF). Engraftment was monitored in 
samples of peripheral blood using flow cytometry at 6 weeks and engraftment was 
monitored in bone marrow, liver, spleen thymus and peripheral blood at 12, 16 
and 20 weeks post reconstitution with human CD34+ HSCs.
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4.4. 3-WEEK OLD NSG AND NSG-SGM3 MICE WERE RADIOSENSITIVE 
AT SUB-LETHAL DOSES
Neonatal mice classically show better engraftment compared to adults (Ishikawa et 
al 2005) but injecting them with HSCs is delicate work In contrast, weanmg and 1 v 
tail injection o f 3-4 week old mice is an easier procedure and they have been shown to 
display better engraftment than adult mice (Shultz et al 2016) To determine the effect 
of using 3 week old mice instead o f adult mice (6 week +), NSG and NSG-SGM3 mice 
were conditioned with low dose whole body irradiation (2 4 Gy) whereas NSG-SCF 
mice were not irradiated 4 hrs later human HSC (1 x 105 CD3+ cell depleted CD34+ 
cells) obtained from the Anthony Nolan Trust were injected into the tails veins of 3 
strains o f NSG mice (Figure 4 4) After HSC administration, weight loss and survival of 
each mouse was monitored 3 times a week The administration o f HSC to non-irradiated 
NSG-SCF mice had no effect on survival throughout the study (Figure 4 5) However, 
unexpectedly at approximately week 8 post HSC transplantation NSG and NSG-SGM3 
mice that were generated displayed an increased rate of mortality compared to NSG- 
SCF mice that were not irradiated (Figure 4 5) Hense, all mice were subsequently 
monitored every day until the end o f the experiment Autopsy results revealed gross 
abnormalities in the thymus o f these mice which resembled radiation damage It is 
known that sublethal irradiation causes damage to neurons in the developing brain 
(Kameyama et al 1994) For e g radiation damage of newborn mice increases numbers 
o f binucleated neuron heterokaryons consisting o f Purkinje cells fused to bone marrow- 
denved cells (Espejel et al 2009) On closer examination the deaths in the NSG and 
NSG-SGM3 mice may have been as a result o f their young age (3 weeks) in conjunction 
with too high a irradiation dose (240 cGy) because non-irradiated NSG-SCF mice did 
not become moribund after 20 weeks after HSC transplantation (Figure 4 6) After
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consultation with a senior staff member from Jackson laboratories a lower dose of 
radiation o f 140cGy for NSG and 100 cGy for NSG-SGM3 was recommended for these 
radiation sensitive strains instead o f the 240 cGy dose administered previously (personal 
communication, Dr Ralph Gareus, Jackson Laboratories, Maine, USA). All subsequent 
experiments were performed with 3 week old mice and reduced radiation doses for NSG- 
SGM3 mice.
All remaining mice (NSG, NSG-SGM3, NSG-SCF) were compared for their 
engraftment levels o f immune cells in the three strains o f immunodeficient mice, all with 
the IL2Rynul1 mutation. 20 weeks after adoptive transfer o f human CD34+ cells, spleens, 
bone, liver, peripheral blood and thymus were harvested and stained with human 
antibodies to examine the overall engraftment in these organs. The percentage of human 
CD45+ cells was first examined in all three strains o f mice. Comparable percentages of 
human CD45+ cells were present in the spleen, bone marrow, livers, thymus and in the 
circulation o f all mice tested (Figure 4.6). Reconstitution was considered to be successful 
if the percentage o f human CD45+ cells in organs tested was more than 25% (Shultz et 
al 2016). Furthermore, there were considerably more human leucocytes present in the 
bone marrow of NSG-SCF mice than in the bone marrow o f NSG-SGM3 and NSG mice 
(Mean 73.5% vs 55.9% vs 41.5% ) (Figure 4.6). This increase in engraftment kinetics 
between strains was also observed with the myeloid cells. Notably there were 
significantly more CD33+ myeloid cells found in the spleen in NSG-SCF mice than in 
the spleen o f NSG-SGM3 mice (Mean 59.5% vs 33.2% P< 0.05). This trend also 
continued in the B cell lineage where there were significantly more CD20+ B cells found 
in the liver and bone marrow o f NSG-SCF mice than in the other two strains (P 0 .001 , 
P<0.05) (Figure 4.6). There were little or no CD3+ T cells present in the spleen, bone 
marrow or liver of NSG mice at 20 weeks post transplantation of HSCs but this lack of
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T cell development may be a direct result o f the damage to the thymus in these mice 
There were more CD3+ T cells found in the spleen and bone marrow of NSG-SCF mice 
than the spleen and bone marrow o f NSG-SGM3 and NSG mice but the difference was 
not significant The highest level was again found in the liver (Mean 12 17 ) (Figure 
4 6) The engraftment o f the effector cells o f allergy (mast cells and basophils) were 
analysed in the spleen, bone marrow and livers Fluman cells expressing the phenotypic 
markers of mast cells and basophils (FcsRl and CD203c) were present at slightly higher 
levels in spleen and bone marrow o f NSG-SCF (Figure 4 7) No mast cells or basophils 
were detected in any of the tissues o f NSG mice over the course o f this experiment (Data 
not shown) Mast cells and basophils were further distinguished by assessing human c- 
kit expression As shown in figure 4 7B there was an increase in the total number of 
mast cells and basophils recovered in the spleen, bone marrow and liver of NSG-SCF in 
comparison to NSG-SGM3 tissues but this difference was not significant In addition 
the numbers o f basophils and mast cells m the vanous tissues was investigated -3770 
m the spleen, 2290 in the bone marrowand 9112 o f FceR f CD203c+ cells in the liver 
were mast cells in NSG-SCF mice In comparison, fewer mast cells were recovered in 
the spleen and bone marrow o f NSG-SGM3 mice but higher numbers were recovered in 
the liver of these mice (Figure 4 7)
In summary there was higher engraftment of immune cells in the tissues of non- 
lrradiated NSG-SCF mice in comparison to the reduced hematopoiesis found in 
irradiated humanised NSG and NSG-SGM3 mice which was possibly caused by the 
radiation dose which resulted in a decreased ability o f transplanted and irradiated human 
HSC to repopulate following radiation injury
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Figure 4.5. NSG and NSG-SGM3 3 week old male and female mice were 
susceptible to sub lethal irradiation. 1 x 105 human CD34+ HSCs were 
isolated from 24-36 hr old cord blood from Antony Nolan Trust UK and 
administered to irradiated NSG and NSG-SGM3 (2.4 Gy) and non­
irradiated NSG-SCF mice on day 0. Transplanted mice were monitored 
twice a week until day 55 and then every day for the duration o f the 
experiment. n=12 for each group. Statistical analysis was carried out using 
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Figure 4.6. Human CD45, CD33, CD20 and CD3 cells m spleen, bone marrow, liver
and peripheral blood and thymus at 20 weeks post engraftment with HSC from
Anthony Nolan Trust cord blood a) human CD45+,b) human C33+ and c) human
CD20+ cells and d) human CD3+T cells as a % o f human CD45+ cells m NSG versus
NSG-SCF versus NSG-SGM3 mice (n=3 at week 20) NSG mice were set up exactly
as described in figure 4 1 Tissues were harvested on week 20 and cells were recovered
and stained with CD45 (PerCp), CD33 (FITC), CD20 (APC) and CD 14 (PE) and
analysed by flow cytometry Graphical representation o f the percentage o f (A) human
CD45+ cells (B) myeloid (C) B cells and (D) T cells recovered in the spleen, bone
marrow, liver and peripheral blood n=3 per group (1 HSC donor) at week 20
Statistical analysis was earned out using one-way ANOVA Tukey with multiple
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Figure 4.7. Higher engraftment of mast cells and basophils in NSG-SCF mice 
compared to NSG-SGM3 mice after adoptive transfer of HSCs from Anthony 
Nolan Trust. The mice were set up as described in figure 4 4 Cells were recovered 
at week 20 from spleen, bone marrow and liver and surface stained with hCD45+ 
(fitc) hFCeRl+ (ape), hCD203C+ (pe) cells and anti-human c-kit Ab (PerCp) (A) 
Graphical representation of the percentage o f human mast cells 
(hFCeRl+hCD203C+hCD45+ cells) recovered from spleen, bone marrow and liver 
of NSG-SCF and NSG-SGM3 mice (B) Total number of basophils 
(hFCsR 1 +hCD203C+hCD45+c-kit") and mast cells (hFCeRl+hCD203C+hCD45+ c- 
kit+) recovered in the indicated tissues The total number o f cells was assessed using 
counting beads during flow cytometry n=4 per group, 1 HSC donor
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4.5. HUMANISED M ICE POSSESS SIM ILAR LEVELS OF HUMAN CELLS 
AT 12,16 AND 20 W EEKS POST ENGRAFTM ENT W ITH HSCs
Using protocols created by Billerbeck et al. (2012) and Brehm at al. (2012) as a 
guideline and starting point, a humanised mouse model was developed. The majority of 
studies using humanised mice assess engraftment 12 weeks post transfer o f HSCs 
(Shultz et al 2007, Ishikawa et al 2017, Billerbeck et al 2011) whereas 16 to 22 weeks 
are required for functional development of mast cells and basophils ( Ito et al 2013, 
Takagi et al 2011). NSG-SGM3 mice were conditioned by low dose total body 
irradiation o f 1.0 (Gy). 1 x 105 CD34+ stem cells obtained from Lonza (characterisation 
, Figure 4.3 ) were injected intraveneously into three week old NSG-SGM3 and non­
irradiated NSG-SCF mice and the engraftment o f leucocytes was examined using flow 
cytometry at 6, 12, 16 and 20 weeks (Figure 4.1). At the outset it is important to note 
that any mouse with more than 25% human CD45+ cells is considered successfully 
humanised (Shultz et al 2016). NSG-SGM3 mice engrafted with isolated CD34+ stem 
cells had lower levels o f human CD45+ cells in their circulation at 6 weeks (16.3% +/- 
1.8 versus 30.8 % +/- 1.3) than NSG-SCF mice (Figure 4.8). Notably, NSG-SCF mice 
achieved the level o f engraftment (25%) associated with successful humanisation at 6 
weeks. Importantly in NSG-SGM3 the average percentage of human CD45+ cells more 
than doubled between 6 and 12 weeks (16.2% vs 42%) and the average percentage of 
human CD45+ cells in NSG-SCF also increased to 56% (Figure 4.9). NSG-SCF and 
NSG-SGM3 mice engrafted with CD34+ stem cells from Lonza on average had high 
levels of human CD45+ cells in the bone marrow, liver, thymus and peripheral blood at 
12 weeks. Low levels o f CD45+ cells were found in the spleen o f NSG-SCF at 12 weeks 
in comparison to the significantly higher levels found in the spleen o f NSG-SGM3 mice
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(15% +/- vs 41% +/- P<0 05) However by 20 weeks comparable levels of human CD45+ 
cells were found in both strains o f mice (Figure 4 9) Over the 12 week engraftment 
period, human CD45+ cells levels remained high in the liver and bone marrow o f NSG- 
SCF mice Whereas over time the levels of CD45+ cells decreased in the thymus and in 




Figure 4.8 NSG-SCF mice have higher leucocyte engraftment in the 
circulation at 6 weeks post reconstitution with HSC. Comparison o f NSG- 
SCF and NSG-SGM3 PB engrafted with CD34+ Lonza cells. Tail bleeds were 
performed 6 weeks after HSC injection into the tail vein. The blood was lysed 
and stained with CD45 (PerCp) antibody and analysed by flow cytometry. (A) 
Illustrates the viable gated lymphocyte population o f NSG-SCF from SSC 
against FSC plot (B) Percentage of human CD45+ cells in the peripheral blood 
o f one NSG-SCF mouse (C) Illustrates the viable gated lymphocyte population 
ofNSG-SGM3 from SSC against FSC plot (D) Percentage of human CD45+ 
cells in the peripheral blood o f one NSG-SGM3 mouse (E) Graphical 
representation o f the percentage o f CD45+ cells in the peripheral blood at 6 
weeks. Images A-D are representative o f one tail bleed from each mouse. n= 
11 per group using one HSC Lonza donor. Statistical analysis was carried out 














Figure 4.9. Time course of engraftment of human CD45+ using CD34+ cells 
obtained from Lonza in NSG-SCF versus NSG-SGM3 mice. NSG mice 
were set up exactly as described in figure 4 4 Tissues were harvested on week 
12, week 16 and week 20 and cells were recovered and stained with CD45 
(PerCp) antibody and analysed by flow cytometry Graphical representation of 
the percentage of human CD45+ cells recovered in the spleen, bone marrow, 
liver, thymus and peripheral blood n=4 per group (1 HSC donor) at weeks 12 
(A) and (B) week 16, n=3 at (C) week 20 Statistical analysis was earned out 
using one-way ANOVA Tukey with multiple comparison test where * <0 05
4.6. NSG-SCF/NSG-SGM3 MICE RECONSTITUTED WITH CD34+ STEM 
CELLS HAD ENHANCED HUMAN T CELLS IN THE BONE MARROW  
AND LIVER.
Having demonstrated that human CD45+ cells repopulate conditioned NSG-SGM3 
and non-conditioned NSG-SCF mice that received human HSCs, the human lymphoid 
and myeloid cells present were further characterised By 20 weeks, the frequency of 
human myeloid cells within the total CD45+ population was higher in spleen and livers 
o f NSG-SCF and NSG-SGM3 mice (Figure 4 10) than in bone marrow or PB There 
was no difference observed between the strains in the B cell population across all tissues 
tested at 20 weeks, however there were significantly more T cells in the bone marrow of 
NSG-SCF than NSG-SGM3 and significantly more T cells m PB m NSG-SGM3 than 
NSG-SCF by 20 weeks (Figure 4 10) B cell frequencies decreased over time in spleen, 
bone marrow and liver in NSG-SCF mice from 27% at week 12 to approximately 19% 
at Week 20 in spleen, (figure 4 11) from 23% at week 12 to 16% at week 20 in bone 
marrow (Figure 4 12) and from 19% at week 12 to 9% at week 20 in liver (Figure 4 13) 
Similar decreases in B-cell frequencies were observed in spleen, bone marrow 
and liver o f NSG-SGM3 mice This overall reduction in B cells was paralleled by a 
proportional increase in CD3+ T cell frequencies in bone marrow in NSG-SCF mice 
Notably, there were significantly more CD3+ T cells found in the bone marrow o f NSG- 
SCF mice than m the bone marrow of NSG-SGM3 mice at 16 and 20 weeks (P < 0 01, 
Figure 4 12) This significant change in the lymphocyte population has been described 
previously (Billerbeck et al 2013) To further characterise the increased T-cell 
population m NSG-SCF mice, CD4+ to CD8+ T cell ratios were compared in both mouse 
strains In the spleens o f NSG-SCF mice, the ratio of CD4+ to CD8+ T cells was
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approximately 5 1 (P<0 01) and 4 1 in the spleens o f NSG-SGM3 mice (Figure 4 14) 
In the bone marrow o f NSG-SCF mice the ratio o f CD4+ to CD8+ T cells was slightly 
higher at 6 1 (P<0 01) in comparison to the ratio of 3 1 in the bone marrow of NSG- 
SGM3 mice Lower ratios of 4 1 (P < 0 01, NSG-SCF) and 3 1 (P < 0 05, NSG-SGM3) 
were found in the livers of these mice Together the results show that the transgenic 
expression o f human SCF, IL-3 and GM-CSF significantly promotes the expansion of 
human CD4+ T helper cells in these mice which are vital cells in the generation o f 
immune responses
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Figure 4.10 Human Myeloid, B and T cells present in spleen, bone marrow, liver and 
peripheral blood at 20 weeks post engraftment a) human CD33+,b) human CD19+ and 
c) human CD3+ cells as a % of human CD45+ cells in NSG-SCF versus NSG-SGM3 
mice reconstituted with CD34+ Lonza cord blood cells NSG mice were set up exactly 
as described m figure 4 1 Tissues were harvested on week 20 and cells were recovered 
and stained with CD33 (FITC), CD 19 (PE) and CD3 (APC) and analysed by flow 
cytometry Graphical representation o f the percentage o f (A) human CD33+ (B) human 
CD 19 + (C) CD3+ recovered in the spleen, bone marrow, liver and penpheral blood 
n=3 per group (1 HSC donor) at week 20 Statistical analysis was carried out using one­
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Figure 4.11 Time course of spleen engraftment o f human B cells 
(CD19+), T cells (CD3+), myeloid cells (CD33+) and mast 
cells/basophil cells (CD203C+FC sR l+) as a % o f human CD45+ cells 
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Figure 4.12. Time course o f bone marrow engraftment o f human B cells 
(CD19+), T cells (CD3+), myeloid cells (CD33+) and mast cells/basophil 
cells(CD203C+FCeRl+)as a % o f human CD45+ cells in NSG-SCF versus 
NSG-SGM3 mice using Lonza CD34+ cord blood cells Statistical analysis 
was earned out by one way ANOVA Tukey with multiple companson test 
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Figure 4.13. Time course o f engraftment in the liver Human B cells 
(CD19+), T cells (CD3+), myeloid cells (CD33+) and mast cells/basophil 
cells(CD203C+FC£Rl+)as a % o f human CD45+ cells in NSG-SCF versus 
NSG-SGM3 mice using Lonza cord blood cells (n=4 at weeks 12 (A) and 
























Figure 4.14. Increased frequencies of CD4+lymphocyte in SCF and SGM3 
mouse tissues at 20 weeks. Analysis o f human CD4+ to CD8+ T-cell ratios in 
spleen, bone marrow and liver The mice were set up as described in figure 
4 1 Cells were recovered from the spleen (A), bone marrow (B) and liver (C) 
and surface stained with CD45 (fitc), CD3 (APC), CD4 (PerCP) and CD8(PE) 
and analysed by flow cytometry Graphical representation o f the percentage 
of cells that were CD4+CD8+ (gated on human CD45+ CD3+ T cells), n=l 1 per 
strain Statistical analysis was carried out using one way ANOVA Tukey with 
multiple comparison test where * <0 5, **<0 01
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4.7. DEVELOPMENT OF HUMAN MAST CELLS/BASOPHILS IN HSCF
VERSUS SGM3 NSG RECIPIENTS
We next investigated the development of human mast cells and basophils in the 
membrane-bound hSCF expressing NSG mice versus the triple transgenic hSCF, hGM- 
CSF and hIL-3 expressing mice. Using the gating strategy as described in figure 4.15, 
the engraftment of mast cell and basophils was analysed by flow cytometry. The cell 
surface marker, CD203c, has been identified as specific for basophils and mast cells 
among cells o f hematopoietic lineage. CD203c is an ecto-nucleotide 
pyrophosphatase/phosphodiesterase expressed on resting cells at low levels and its 
expression is rapidly up-regulated following activation (Buhring et al 1999). The high 
affinity IgE receptor Fc epsilon receptor 1 (FceRl) is expressed on mast cells and 
basophils and plays a central role in the IgE mediated allergic response. The stem cell 
factor receptor c-kit (CD117), a tyrosine-protein kinase that acts as cell-surface receptor 
for the cytokine KITLG/SCF and is expressed on mast cells independent o f tissue site 
maturation or activation status (Metcalfe eta l 2016) and it’s presence distinguishes mast 
cells from basophils.
As we have seen previously in figure 4.11, 4.12, 4.13 comparable percentages o f 
mast cells had engrafted in the spleen, bone marrow and liver in both strains o f mice by 
week 20 (Figure 4.16 A). Overall similar numbers o f mast cells
(CD45+CD203C+FCeRT) were recovered in spleen and bone marrow in both strains of 
mice however there was a significant increase in mast cells in the livers o f NSG-SGM3 
in comparison to NSG-SGM3 (Figure 4.16B). When these cells were further stained 
with human c-kit antibody (CD117), the majority o f cells recovered in the spleen ,bone 
marrow and livers of NSG-SCF mice were mast cells. However in the bone morrow 
and livers o f NSG-SGM3 mice significantly more basophils (CD45+CD203C+FC8RI+c-
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kit ) had engrafted than mast cells (Figure 4 16C) Strikingly, there were over -4000 
basophils recovered m the livers of NSG-SGM3 mice (P<0 0001) Mast cell progenitors 
and mature mast cells reside in high frequencies m the spleen and bone marrow of 
normal immunocompetent mice (Annobu et al 2005) so transgenic expression of human 
membrane bound SCF influenced the mast cell development in the hematopoietic organs 
of NSG-SCF mice In companson, the expression o f SCF, IL-3 and GM-CSF resulted 
m significantly increased number o f basophils found in the liver o f these lmmuno- 
deficient mice
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Figure 4.15.Representative example of gating strategy used to identify human mast ceils and basophils. (A) llustrates the gated 
lymphocyte population from SSC against FSC plot,(B) represents the gating position for human CD45+ (FITC ) expression within the 
lymphocyte population, (C) illustrates the gating position for CD203C+ (PE) and FCeRT (APC) expression within the CD45+ 
population and (D) represents the gating position for mast cells (CD45+ CD203C+c-kit+) and basophils (CD45+ CD203C+Ckit ‘ ). All 
gating positions were determined using matching isotype controls.
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Figure 4.16. Differential distribution of mast cells and basophils in tissues of 
humanised mice. The mice were set up as described in figure 4 4. Cells were recovered 
at week 20 from spleen, bone marrow and liver and surface stained with hCD45+ (fitc) 
hFCsRl+ (ape), hCD203C+ (pe) cells and anti-human c-kit Ab (PerCp) (A) Graphical 
representation o f the percentage of human mast cells (hFCsRl+hCD203C+hCD45+ cells) 
recovered from spleen , bone marrow and liver (B) the number o f mast cells 
(hFCeRl+hCD203C+hCD45+) and (C) the number o f mast cells 
(hFCeR 1 +hCD203C+hCD45+c-kit+) and basophils (hFC£Rl+hCD203C+hCD45+ c-kif ) 
recovered m the indicated tissues from hSCF and hSGM3 mice The total number of cells 
was assessed using counting beads during flow cytometry Statistical analysis was earned 
out using one way ANOVA and 2 way ANOVA Tukey with multiple comparison test 
where **** < 0 0001 n=4 per group
4.8. FEMALE NSG-SCF ENGRAFTED WITH CD34+ STEM CELLS HAD 
ENHANCED LEUCOCYTE, MYELOID AND T AND B CELL 
RECONSITUTION WHEN COMPARED WITH MALE NSG-SCF MICE.
In order to explore the use o f humanized mice (transplanted with human 
hematopoietic stem cells as in vivo models) to evaluate the effects of functional foods 
and immune therapies on adaptive immune responses, the question o f possible gender 
aspects need to be considered Notta et al (2010) reported that female non-obese 
diabetic/severe combined immunodeficient (NOD/SC ID)/IL2Ryc-/- (NSG) mice 
transplanted with limiting numbers o f human CD34+ CD 38- cord blood hematopoietic 
stem cells (CB-HSCs) showed better engraftment of human CD45+ hematopoietic cells 
than males Subsequent work reported faster growth of human tumor lines in NSG male 
mice, further supporting differences o f xenograft cell engraftment and growth in female 
and male hosts (Padura et al 2010) Here, we evaluated if engraftment o f CD34+ CB- 
HSC into 6-week-old NSG-SCF mice was affected by gender
Umbilical cord blood was obtained from volunteers who were undergoing 
elective c-sections from the national maternity hospital (NMH) Dublin in accordance 
with the ethical committee guidelines for heath related research studies Cord blood (2 
hrs old) samples were first processed for isolation o f mononuclear cells (MNC) using 
lymphocyte separation medium (Lymphoprep) Cord blood MNCs were then enriched 
for human CD34+ cells using Easy Sep Human Cord blood CD34 positive selection KIT 
II (section 2 8 3) Purity o f the CD34+separated cells was > 90% (Table 4 1) NSG- 
SCF male and female mice were injected with a moderate dose (1x10 5 HSCs) via the
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tail vein on day 0 (Figure 4.4). 20 weeks later, flow cytometry was used to determine 
the levels o f CD45+ cell chimerism in the spleen, bone marrow, liver, peripheral blood 
and thymus. When 1x10s HSCs were transplanted, the percentages of human CD45+ 
were comparable across all tissues but the absolute numbers o f human CD45+cells in the 
spleen of non-irradiated NSG-SCF mice were significantly higher (~ 6- fold higher) than 
that observed in male mice (P< 0.0001, Figure 4.18). Female NSG mice displayed a 
trend toward higher numbers of human CD45+ cells compared with males in the Liver 
(female vs male: 235143 vs 104387, P<0.05). This trend continued with the myeloid 
compartment. Females displayed a 10 fold increase (85645 vs 8603.5) in the number of 
CD33+ myeloid cells in the spleen compared with males (P< 0.0001, 4.18(C)). There 
were also differences in lineage distribution o f human T and B cells engrafted in male 
or female recipients (Figure 4.15). The percentages and absolute numbers o f CD3+ T 
cells in the spleen and liver were significantly increased when compared with males. 
Females displayed 3-fold (24.5 vs 6.95) and 6-fold (32.6 vs 5.1) percentage increase in 
the spleen and liver and 11- fold (66001 vs 5827) and 15- fold (90,317 vs 6002) increase 
in the absolute numbers (P< 0.0001, Figure 4.15). The absolute numbers o f CD20+ B 
cells in the spleen o f female mice also increased 6 -  fold (301,207 vs 45,879) compared 
with males. These results are consistent with Notta et al (2010), who found that the 
recipient gender played a critical role in the engraftment and proliferation o f human 
HSCs. Therefore, CD34+ cord blood cells repopulate at higher numbers in spleens and 
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Figure 4.18 The total number of leucocyte and myeloid cells engrafted in the spleen 
of NSG-SCF mice were significantly increased in female mice NSG mice were set up 
exactly as descnbed in figure 4 4 Tissues were harvested on week 20 and cells were 
recovered and stained with CD45 (PerCp) and CD33 (F1TC) antibody and analysed by 
flow cytometry Graphical representation o f the percentage(A) and number o f human 
CD45+ cells (B) percentage (C) and number (D) o f myeloid cells recovered in the spleen, 
bone marrow, liver, thymus and peripheral blood The total number o f human cells was 
assessed using counting beads during flow cytometry n=6 per group (1 HSC donor) at 
week 20 Statistical analysis was carried out using one-way ANOVA Tukey with multiple 


















































i + B .
Sp le e n  B M  Liv e r
(C)















S p le e n  B M  L iv e r












L iv e r
■  Male 
□  Female
0 .
S p le e n B M L i v e r
Figure 4.19. Engraftment of T and B cells in the spleen was significantly increased 
in female NSG-SCF mice NSG mice were set up exactly as described in figure 4 4 
Tissues were harvested on week 20 and cells were recovered and stained with CD3 
(APC) and CD20 (FITC) antibody and analysed by flow cytometry Graphical 
representation o f the percentage (A) and number of human T cells (B) cells and 
percentage (C) and number (D) of B cells recovered in the spleen, bone marrow, and 
liver The total number o f human cells was assessed using counting beads during flow 
cytometry n=6 per group (1 HSC donor) at week 20 Statistical analysis was earned out 
using one-way ANOVA Tukey with multiple comparison test where **** <0 0001* 
<0 05
4.9. EVEN AT LIMITING DOSES OF HSC FEMALE NSG-SCF 
MICE CONTINUE TO DISPLAY HIGHER NUMBERS OF 
HUMAN CHIMERISM COMPARED TO MALE MICE
As we have already shown in section 4. 8, female NSG-SCF mice are far superior hosts 
for the engraftment o f higher numbers o f leucocytes, myeloid T cells and B cells, in the 
spleen and livers o f NSG-SCF mice. To explore this further, engraftment levels with a 
lower dose (5xl04) of HSCs was examined in female versus male NSG-SCF mice.
Cord blood (6 hrs old) was obtained from donors at the NMH and CD34+ cells were 
obtained as detailed in section 2.6.3. CD34+ cell purity was > 95% (Table 4.1). Non­
irradiated NSG-SCF male and female mice were injected with 5xl04 HSCs via the tail 
vein on day 0. After 12 and 20 weeks, flow cytometry was used to determine the levels 
o f CD45+ cell engraftment in peripheral blood. High levels o f CD45+ cells at 12 weeks 
(37.1%) and 20 weeks (45.7%) were observed in the peripheral blood o f female NSG- 
SCF mice (Figure 4.20). In a side by side comparison experiment, male NSG-SCF mice 
had lower levels o f CD45+ in the circulation at 12 and 20 weeks (7.7% and 17.5 %) 
(Figure 4.20). Comparable percentages o f CD33+ myeloid cells were detected across all 
tissues at week 20 (Figure 4.21). In the bone marrow and livers o f female NSG-SCF 
mice significantly increased percentages o f CD3+ T cells had engrafted compared to 
male mice (P<0.001,P<0.05, Figure 4.20 ). In addition there was a significant increase 
in the percentages o f CD20+ B cells in the livers o f female mice compared to male mice 
(P<0.05) (Figure 4.21). This gender differential increase in lineage cells continued 
through to the mast cells where there was a dramatic increase in the number of CD45+Fce 
Rl + CD203c+ cells in the spleens o f female mice (P< 0.0001, Figure 4.22).
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In summary, engraftment levels o f  high (1 x 105) and low (5 x 104) HSC doses 
was superior in female NSG-SCF mice providing better multihneage engraftment than 
their male equivalents Importantly this gender bias must be taken into account when 
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Figure 4.20. Enhanced T cell engraftment in peripheral blood of female mice at 
lower dose of HSC compared to male mice. Comparison o f Female and male NSG -  
SCF mice engrafted with CD34+ HSCs isolated from UCB from NMH. Tail bleeds were 
performed and the blood was lysed and stained with CD45 (PerCp) antibody and 
analysed by flow cytometry. (A) Illustrates the viable gated lymphocyte population of 
NSG-SCF from SSC against FSC plot (B) Percentage o f human CD45+ cell in the 
peripheral blood of one female NSG-SCF mouse. (C) Illustrates the gated lymphocyte 
population of male NSG-SCF from SSC against FSC plot and (D) Percentage o f human 
CD45+ in the peripheral blood of one male NSG-SCF mouse. Image representative of 
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Figure 4.21 Female NSG-SCF mice display increase in engraftment compared to 
male mice. 20 weeks after adoptive transfer o f 5 x 104 CD34+ HSC from UCB from NMH 
Dublin, male versus female SCF mice were analysed for human CD45+ (Leucocyte)(A), 
CD33+ (Myeloid) (B), CD3+ (T cells) (C) and CD20+ (B cells) (D) engraftment Graphical 
representation o f the percentage and numbers of leucocytes myeloid T cells and B cells m 
each organ The flow cytometry data are representative of 4 ammals/group Statistical 
analysis was earned out by one way ANOVA Tukey with multiple comparison test where 
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Figure 4.22. Increased number o f mast cells engrafted in the spleens o f female NSG- 
SCF mice injected with lower dose of HSCs compared to male mice. Cells were 
isolated from spleen, bone marrow and liver from hSCF mice at 20 weeks after HSC 
transplantation and were stained with anti-hCD45 (fitc), anti-hCD203C (pe) and anti- 
hFCeRI (ape) antibodies Graphical representation o f the percentage (A) and numbers
(B) o f hCD203C+FCeRl+ CD45+ mast cells in each organ The flow cytometry data are 
representative of 4 animals/group Statistical analysis was carried out by one way 
ANOVA Tukey with multiple comparison test where **** < 0 001
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4.10 SUMMARY
The mam aims o f this chapter were to (1) isolate viable haematopoietic stem cells 
from umbilical cord blood cells and (2) to repopulate conditioned and non-conditioned 
NSG-SGM3/NSG-SCF mice with human immune cells using haematopoietic stem cells 
and to (3) identify the optimal strain o f mice that best supported the development of 
human myeloid cells especially mast cells and basophils
As discussed in Section 4 1 human umbilical cord blood was chosen to repopulate NSG- 
SCF and NSG-SGM3 mice with human cells Thus establishing a source o f human HSCs 
was the first step in the generation o f humanised mice While awaiting ethics approval 
for procuring cord blood samples directly from women from NMH, umbilical cord blood 
was sourced from the Anthony Nolan non-profit cord blood bank, Nottingham, UK O f 
the three attempts to obtain CD34+ HSC from Anthony Nolan cord blood sufficient 
purity and yield (enough cells to engraft mice) was only achieved once In the initial 
experiment CD34+ HSCs were injected into 3 week old irradiated NSG, NSG-SGM3 
and non-irradiated (NSG-SCF) mice to compare the engraftment levels of human cells 
However by week 20 only 25% of NSG and 58% of NSG-SGM3 mice had survived 
(Table 4 2) The deaths in mice was related to the high dose irradiation and engraftment 
o f the human HSCs because 100% of un-irradiated transplanted NSG-SCF mice 
survived till the end of the study As a result there were lower levels o f engraftment of 
human cells in the circulation and tissues o f these two strains o f mice than that seen in 
the tissues o f NSG-SCF mice In terms of mast cell and basophil cell numbers, NSG- 
SCF mice had higher levels of mast cells in the spleen, bone marrow and liver in 
comparison to levels found m NSG-SGM3 mouse tissues
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Procuring UMB from consented volunteers in NMH proved to be very unreliable 
both m terms of volumes and quality of UCB However sufficient volumes and yields 
o f UCB were achieved on 4 occasions to allow investigations into if  dose o f HSC or 
gender have any effect on engraftment levels in NSG-SCF mice Overall, CD34+ cord 
blood cells repopulated at higher numbers in spleens and livers of females compared 
with age-matched male NSG-SCF mice There was also increased engraftment o f T cells 
and B cells in the bone marrow and liver at the lower dose o f HSC Importantly, there 
was increased numbers o f mast cells in the spleens of female NSG-SCF mice at this 
limiting dose
Due to the unreliability o f both Anthony Nolan and NMH UCB, it was decided 
to purchase frozen vials o f flow sorted CD34+ HSCs were purchased from Lonza which 
allowed greater control over the timing o f sample and processing and there were no 
issues with yield as each vial had a defined number of cells In this side by side 
comparison experiment with irradiated (1 0  cGy) NSG-SGM3 and non-irradiated NSG- 
SCF mice, the leucocyte engraftment levels in blood was significantly increased at 6 
weeks in NSG-SCF mice compared with NSG-SCF mice (Figures 4 8) Both strains of 
mice had comparable myeloid engraftment across all tissues tested (Table 4 10A) but 
NSG-SCF had significantly increased CD3+ T cells m the bone marrow and liver while 
NSG-SGM3 mice had significantly higher T cells in the circulation (4 10C) Similar 
percentages o f mast cells and basophils were detected in spleen, bone marrow and liver 
in both mouse strains but there were differences in the distribution o f these cells m the 
tissues o f humanised mice In the spleen, bone marrow and livers o f NSG-SCF and NSG- 
SGM3 mice, there were comparable % and number of mast cells across the tissues but 
when the c-kit expression was analysed there were more basophils detected in the bone 
marrow and livers of NSG-SGM3 mice
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Isolating viable hematopoietic stem cells from umbilical cord blood was an arduous 
and unpredictable process SCF, also known as steel factor or kit ligand may serve as a 
guidance cue that directs HSCs to their stem cell niche and it plays an important role in 
HSC maintenance GM-CSF and IL-3 stimulate the differentiation o f HSCs in myeloid 
progenitor cells and IL-3 stimulates proliferation o f all cells in the myeloid lineage 
(erythrocytes, thrombocytes, granulocytes and monocytes) All of these cytokines are 
species specific and expression o f human SCF, IL-3 and GM-CSF in NSG-SGM3 
resulted in moderate levels o f human CD45+ engrafitment in the spleen and bone marrow 
with higher engraftment in the livers o f NSG-SCF and NSG-SGM3 mice Comparable 
total numbers o f human leukocytes were detected in liver, spleen and bone marrow in 
both mouse strains 20 weeks after transplantation with lower levels detected in the PB 
and thymus m both strains (Table 4 2 ,4  3)
There were no remarkable differences in the engraftment kinetics between NSG- 
SCF and NSG-SGM3 (summarised in table 4 2, 4 3) with the exception o f higher 
engraftment o f T cells in the bone marrow o f NSG-SCF versus higher engraftment in 
the circulation o f NSG-SGM3 and higher numbers of basophils in the bone marrow and 
livers o f NSG-SGM3 Ideally more screening with multiple donors would have re­
confirmed our findings but due to limited time and budget and to avoid the unnecessary 
complications with irradiation, the NSG-SCF strain was chosen as the host for the 
engraftment of human immune cells involved m the allergy response for future 
experiments By comparing male and female engraftment kinetics we found that gender 
does play a role at low and high doses o f HSC in NSG-SCF mice Female NSG-SCF 
transplanted with lover dose of HSC had significantly higher numbers o f T and B cells 
and mast cells than their male equivalents and at 20 weeks had higher levels of CD45+
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across all tissue tested (Table 4 4) and this was taken into consideration going forward 
to in vivo testing
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CHAPTER 5
DEVELOPMENT OF A HUMANISED 
MOUSE MODEL OF OVALBUMIN 
INDUCED ALLERGY AND 
INFLAMMATION AS A PLATFORM TO 
TEST FUNCTIONAL FOODS
5.1 Introduction
The ability o f milk protein hydrolysate 147 to suppress immune responses in vitro 
and some o f the associated mechanisms through which this occurs were identified in 
chapter 3 However the findings that hydrolysate 147 can modulate the immune 
response (Chapter 3) needs to be proven in an in vivo setting In Chapter 4 mice were 
developed with a humanised adaptive immune system complete with tissue 
engraftment by human mast cells In this chapter, the next step was to utilise our 
humanised mouse system in a relevant food allergy (ovalbumin) model with 
functional human immune systems capable of mounting T helper specific responses 
against the common food allergen ovalbumin This study sought to test the capacity 
o f the functional food component hydrolysate 147 as an anti-inflammatory agent in a 
food (OVA) driven allergic inflammatory humanised mouse model
Mouse models for human allergies including atopic dermatitis (Kotani et al 
2000), asthma (Iwata et al 2003) and food allergies (Li et al 2001, Dearmann et al 
2005, Bowmann et al 2009, Kmppels et al 2009) have allowed researchers to elucidate 
important fundamental principles o f the cellular and molecular mechanisms o f these 
diseases These studies, together with the development o f methods for the creation of 
transgenic, knockout, and knockin mice, have provided added impetus and powerful 
tools for mouse research, and have led to a dramatic increase m the use of mice as 
model organisms Studies on mice have contributed immeasurably to our 
understanding o f human biology All too often, however, mice respond to 
experimental interventions in ways that differ markedly from humans Endostatin, the 
anticancer drug, is but one of many treatments that cure cancer in mice but have
195
limited effectiveness in humans (Perlman et al 2016) Interestingly, allergy is one field 
in which the transcriptional analysis approach has shown remarkable consistency 
between murine and human samples For example, a recent study using a murine 
model o f atopic dermatitis (AD) included comparisons with data from affected human 
skin and showed a high degree o f homology in the gene expression profile (Ando et al 
2013) Using genetically modified mice the authors definitively showed key roles for 
T cells and mast cells in disease pathogenesis Similarly, m a murine model o f severe 
asthma, Yu et al (2013) performed transcriptional comparison analysis between the 
murine lung and patient lung biopsy specimens Their data elegantly showed a highly 
significant association in gene expression patterns that was lost in mast cell deficient 
mice but restored if  mast cells were reconstituted by means o f adoptive transfer There 
is no doubt that such validation approaches will be an important aspect o f mechanistic 
studies moving forward, especially given that researchers in the field o f allergy 
possess a strong collection o f tools to study the diseases
One such tool that can be exploited are humanised mouse models that bring us 
one step closer to the human situation Mice that are administered human stem cells 
develop a human immune response, as opposed to the immune response which a 
mouse would normally display Humanised mouse models can be adapted to provide a 
humanised model that would better mirror human immune responsiveness, and 
therefore potentially provide more meaningful information m terms o f treating allergic 
disease m humans rather than the information provided by the current mouse model 
Humanised mouse models o f inflammation and food allergy provide a platform from 
which novel therapies can be assessed and their performance o f alleviating allergic 
conditions can be investigated in a clinically relevant manner Recently in a 
humanised mouse model o f peanut allergy, Burton et al (2016) used NSG-SCF mice
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to successfully predict the allergenic potential o f peanut proteins and demonstrated the 
human food allergic sensitisation/ allergic response could be abolished by anti-IgE 
(omahzumab) treatment They elegantly showed that in animals receiving omalizumab 
treatment before sensitisation were completely protected from loss o f core body 
temperature (symptom of anaphylaxis) m response to peanut challenge which resulted 
in a significant increase in serum levels o f total IgE, an effect that is commonly 
observed m human subjects treated with the antibody that is attributed to the 
persistence o f stable circulating omalizumab IgE complexes (Burton et al 2016) In a 
similar manner we propose to generate a humanised mouse model o f OVA allergy to 
successfully predict the allergenic potential o f ovalbumin (egg) proteins and 
demonstrate that the inflammatory/allergic response can be deviated by a milk peptide 
hydrolysate treatment
Therefore the objectives o f this chapter were,
• To assess the immunomodulatory capacity o f novel milk whey derived protein 
hydrolysate 147 in a humanised mouse model o f OVA inflammation against 
whey protein concentrate control
• To determine if milk protein hydrolysate 147 has anti-mflammatory/anti- 
allergic effects in the humanised model o f OVA inflammation
197
5.2. HUMANISED MICE POSSESS SUFFICIENT LEVELS OF HUMAN 
CELLS AT WEEK 12 BEFORE ALLERGEN SENSITISATION
The first step in the development o f the model was to ensure sufficient engraftment of
human CD34+ cells as variability can exist across hCB CD34+ stem cells donors
Human umbilical cord blood-denved CD34+ cells were purchased from Lonza (Basel,
Switzerland) After thawing the frozen vials o f cells according to the manufacturer’s
protocol, all the cells (over 90% viability) were used for transplantation 5 x 104 cord
blood CD34+ hHSC were transplanted i v via the tail vein into 84 female NSG-SCF
on day 0 (Figure 5 1) 12 weeks later a small group o f NSG-SCF mice were analysed
to determine levels o f engraftment o f human hematopoiesis in the spleen, bone
marrow, liver, thymus and peripheral blood to check that there was sufficient levels of
engraftment o f human cells present before a sensitisation regimen could commence
Flow cytometry was performed to evaluate the engraftment levels o f human CD45+
cells Engraftment levels o f human CD45+ leucocytes in the spleen, liver, bone
marrow, thymus and peripheral blood were high (mean 72 4%, 75 37%, 79 63%,
32 17% and 53 3% respectively) (Figure 5 2A) The development o f human lymphoid
and myeloid cells in the engrafted human CD45 hematopoietic cell populations by
flow cytometry using antibodies against hCD3, hCD19 and hCD33 was next
examined The percentage o f human CD33+ myeloid cells within the total human
CD45+ population was high in the spleen, bone marrow and liver o f NSG-SCF mice
(Figure 5 2 B, C, D) Comparable percentages of CD19+ B cells were also found in all
three organs (19 6%, 22 85%, and 28 24% respectively) (Figure 5 2 B,C,D) In the
spleen, bone marrow and liver a similarly moderate human CD3+ T cell chimerism of
approximately 22% was achieved (Figure 5 2 B, C, D) Mast cells and basophils are
the primary effector cells in allergic responses thus so it was important to examine the
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development o f human mast cells and basophils in each CB CD34+ before 
commencement o f an immunisation regime Overall the percentages o f CD45+ 
CD203c+ ckit+ (mast cell) or CD45+ CD203C+ ckit' (basophils) within the spleen and 
bone marrow were similar (Figure 5 2 B, C, D) However, a higher percentage o f 
human mast cells was achieved m the liver of NSG-SCF mice (Mean 24%) 
Previously m chapter 4, higher percentage and numbers o f human mast cells had 
engrafted in the spleen, bone marrow and livers o f female NSG-SCF mice by 20 
weeks (Figure 4 6) It is very promising for the success o f the model that even at 12 
weeks post transplantation o f CD34+ cells mast cells and basophils had engrafted and 
at sufficient levels
In summary, NSG-SCF mice had sufficient levels o f immune cell engraftment of 
leucocytes, myeloid, T, B, mast cells and basophils in the spleen, bone marrow and 
liver, 12 weeks post transplantation o f CD34+ HSCs This equates to engraftment of 
a functional human immune system for use in investigating the therapeutic effect of 
hydrolysates in a model o f OVA induced allergy and inflammation
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Figure 5.1. Development of humanised mouse model of OVA allergy. 6-8 week old 
female NSG-SCF mice were injected by tail vein injection with 5 x 104 HSC on day 0. 
Tissues were harvested on week 12 to check engraftment in spleen, bone marrow, liver, 
peripheral blood and thymus. Sensitisation: Mice were sensitised by intraperitoneal 
injection o f either OVA (100ug/ml) with alum or saline with alum once a week for two 
weeks (week 12 and week 13). Tail bleeds were performed to check the levels o f IgE 
antibody production by ELISA. Treatment: 147 hydrolysate or whey protein control was 
delivered by oral administration for 5 doses (50mg/ml per dose) once a week for 5 weeks 
from week 15 to week 19. Challenge: One week later (week 20) all mice were challenged 
with OVA antigen (50mg/ml) via oral delivery. The development o f OVA allergy was 
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Figure 5.2. Engraftment of human cells in female NSG-SCF mice 12 weeks after 
transplantation of CD34+ ceils. Mice were set up exactly as described in figure 5 1 
Tissues were harvested on week 12 and cells were recovered and stained with antibodies 
and analysed by flow cytometry Graphical representation o f the (A) percentage of human 
CD45+, cells recovered in the spleen, bone marrow, liver, thymus and peripheral blood of 
mouse (B) percentage o f B cells (CD19+), T cells (CD3+), myeloid cells (CD33+) and 
mast cells/basophils (CD45+CD203+FcsR l+) recovered in the spleen (C) percentage o f B 
(CD19+), T (CD3+), myeloid (CD33+) and mast cells/basophils (CD45+CD203+FcsR l+) 
recovered in the bone marrow (D) percentage o f B (CD19+), T (CD3+), myeloid (CD33+) 
and mast cells/basophils (CD45+CD203+FceRl+) recovered in the liver o f OVA sensitised 
mice n=2 per group (4 HSC donors) at week 12
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5.3 MICE SENSITISED TO OVA IN THE PRESENCE OHYDROL Y SATE 
147 AND WHEY PROTEIN CONTROL ARE PROTECTED FROM  
SYSTEMIC ANAPHYLAXIS-LIKE SYMPTOMS AFTER SUBSEQUENT 
ORAL CHALLENGE WITH OVA.
Depending on the route of exposure, dose o f allergen and the presence o f a suitable 
adjuvant, the immune response can result in either sensitisation or mucosal tolerance 
induction (Perrier et al 2010, Mine et al 2007 and Repa et al 2008) An effective 
approach to overcome the oral tolerance induction is pretreatment o f mice by systemic 
mtrapentoneal (l p ) administration o f allergen with aluminium hydroxide (alum) a 
potent Th2 adjuvant followed by repeated intra-gastnc treatments (Dearman et al 
2007) Brandt et al (2009) used a modification o f the widely used munne model of 
asthma to induce small intestinal allergic inflammation After two systemic 
administrations of OVA m alum, exposure of mice to OVA by the oral route resulted 
in the generation o f an acute antigen-specific diarrhea and allergic inflammation o f the 
small intestine This study utilised a modification o f the latter food allergy model by 
including a treatment regimen after sensitisation and before challenge Specifically 
this study sought to determine if  allergy specific immunotherapy in the form o f milk 
peptide hydrolysate 147 could prevent the allergic response NSG-SCF mice were 
divided into four groups, OVA sensitised, PBS (control), OVA sensitised plus 
hydrolysate (147) and OVA sensitised plus whey protein control (wpc80) (Table 5 1) 
All groups o f NSG-SCF mice (6-11 per group) were transplanted with 5 x 104 cord 
blood CD34+ hHSC i v via the tail vein on day 0 After checking for engraftment of 
human immune cells at 12 weeks mice were sensitised by mtrapentoneal injection of 
either OVA (lOOug/ml) with alum or saline with alum once a week for two weeks 
(week 12 and week 13) 147 hydrolysate or whey protein control was delivered by
oral administration for 5 doses (50mg/ml per dose) once a week for 5 weeks from
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week 15 to week 19 (Figure 5.1). One week later (week 20) all mice were challenged 
with OVA antigen (50mg/ml) via oral delivery and the systemic anaphylactic 
symptoms were evident within 15 to 30 minutes. The severity o f anaphylaxis was 
scored as indicated in Table 5.2. The most severe reactions were observed in mice 
sensitized with OVA plus alum and challenged with OVA antigen (50mg/ml). In the 
OVA treated group systemic anaphylaxis-like symptoms developed within 30 mins in 
four o f seven mice. Mice responded with laboured respiration (marked change in 
breathing) and lethargy and were huddled. Control mice (PBS) challenged with OVA 
antigen (50mg/ml) did not respond with any of the symptoms. In contrast, the 
symptoms were significantly reduced in mice o f the hydrolysate 147 and wpc80 
control group. 5 o f 12 (147 treated) and 6 o f 11 (wpc80) mice responded with 
scratching around the nose and head and the remainder o f mice displayed no 
symptoms (Figure 5.3). Our experimental regime (one oral challenge) o f OVA 
however, did not induce any acute responses such as allergen-induced diarrhea as all 
mice had normal faeces.
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Table 5.1 Experimental groups
Table 5.2
Experim ental groups Sensitisation Treatm ent Challenge 1
S e n sitise d  O V A /A lu m O V A - O V A
N o n -se n s itise d  P B S /A lu m PBS - O V A
S e n sit ise d  O V A /A lu m O V A 1 4 7 O V A
S e n sitise d  O V A /A lu m O V A W P C 8 0 O V A
Anaphylaxis scoring system
I Score Symptoms
0 N o S ym p to m s
1 Scrathing around 
nose and mouth
2 Swelling around the 




3 Shortness of breath; 
blue rash around the 
mouth and tail; higher 
breathing rate
4 No activity after 
stim ulation, shivering 
and muscle 
contractions
5 Death by shock
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Figure 5.3 Hydrolysate 147 and wpc80 control significantly reduced the systemic 
anaphylactic (symptom) scores in OVA sensitised mice. 6-8 week old female NSG- 
SCF mice were injected by tail vein injection with 5 x 104 HSC (Lonza) on day 0 
Tissues were harvested on week 12 to check engraftment in spleen, bone marrow, 
liver, peripheral blood and thymus Mice were sensitised by mtrapentoneal injection 
of either OVA (100ug/ml) with alum or saline with alum once a week for two weeks 
(week 12 and week 13) and on week 14 tail bleeds were performed to check the levels 
o f IgE antibody production by ELISA 147 hydrolysate or whey protein control was 
delivered by oral administration for 5 doses (50mg/ml per dose) once a week for 5 
weeks from week 15 to week 19 Mice (n = 6 to 11) were challenged intragastrically 
with OVA (50mg/ml) Thirty mins later, the symptoms o f anaphylaxis were scored on 
a scale from 0 (no symptoms) to 5 (death), closed circles, closed square, closed 
triangles indicate individual mice Statistical analysis was earned out by one way 








Weeks Post HSC IV
Figure 5.4,Ova sensitised mice had reduced survival in comparison 
to 147 and wpc80 treated mice. 5 x 104 human HSC were 
administered i v to female NSG-SCF mice on day 0 Mice were 
sensitised by 1 p injection o f either (lOOpg/ml) with alum or saline with 
alum once a week for two weeks (week 12 and week 13) 147 
hydrolysate or whey protein control was delivered by oral 
administration for 5 doses (50mg/ml per dose) once a week for 5 weeks 
from week 15 to week 19 One week later (week 20) all mice were 
challenged with OVA antigen (50mg/ml) via oral delivery Mice were 
monitored three times a week for the duration of the experiment n=6 for 
PBS and OVA groups, n= 11 for 147 and wpc80 treated groups
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5.4. HYDROLYSATE 147 AND WPC80 SIGNIFICANTLY IMPROVED OVA- 
DRIVEN ALLERGIC GI PATHOLOGY
The pnmary target organs for allergic reactions are the skin and the respiratory system 
but the main immune inflammatory events occur in the gastrointestinal tract and these 
events are central to the pathophysiology o f food allergy (Knight et al 2007) OVA 
sensitisation hampered the survival of NSG-SCF mice (75% survived) whereas 100% 
of the mice survived in 147 and wpc80 treated groups (Figure 5 4) It is hypothesised 
that feeding hydrolysates between the sensitisation and challenge phase may alter the 
“inflammatory” status o f the gastrointestinal tract Therefore histological analysis was 
earned out to compare hydrolysate 147 efficacy against the efficacy o f it’s parent 
control wpc80 m alleviating OVA-dnven pathology m the small intestine NSG-SCF 
mice received HSC (5 x 104) on day 0 After two systemic administrations o f OVA in 
alum (Week 12 & 13), 147 hydrolysate and whey protein control 80 (wpc80) were 
administered once a week for 5 weeks (50mg/ml) via oral gavage in the humanised 
OVA model (Figure 5 2) One week after treatment with 147 hydrolysate or wpc80, 
oral challenge with 50mg/ml o f OVA antigen was performed 18 hrs later the OVA 
target organ (small intestine) was harvested and placed in formalin for histological 
analysis Tissue sections were stained with H&E and the histological score was 
evaluated for each treatment group according to the criteria described in section 2 10 4 
(Erben et al, 2014) Histological analysis o f the jejunum in the small intestine showed 
that OVA sensitised mice exhibited characteristics o f allergic inflammation which 
included lymphocyte infiltration (I) or blunting (v) (Figure 5 5 A&B) PBS control 
mice exhibited normal small intestinal tissue morphology with no accumulation of 
infiltrating cells However OVA sensitised mice that received no therapy displayed 
frequent villi destruction and blunting accompanied by infiltrating lymphocytes
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(Figure 5 5 A &B) OVA sensitised mice that received 147 hydrolysate and whey 
protein control (wpc80) were shown to have similar effects in improving small 
intestine pathology (Figure 5 5B) 147 significantly reduced the level of villi 
destruction and lymphocyte infiltration into the lamina propria (Figure 5 5 A&B) 
However both 147 and wpc80 had infiltrating lymphocytes m the connective tissue 
wpc80 displayed more inflammatory changes such as villous atrophy, (A) crypt 
elongation (E) and thickened basal layers (T) in comparison to 147 hydrolysate 
treatment Fhe histology findings suggest that hydrolysate 147 and whey protein 
control mediate significant protection in the jejunum of the small intestine as 
illustrated by less inflammatory pathology in this organ
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Figure 5.5: Milk peptide whey hydrolysate 147 and whey protein 
concentrate control (WPC80) treatment significantly reduced villi 
destruction in the jejunum of OVA mice. The OVA model was set up
exactly as described in figure 5 2 Tissue samples were harvested 18 hr after 
the OVA challenge on week 20, formalin fixed, paraffin embedded and 
stained with H&E (A) Represented images were analysed for lymphocyte 
infiltration (I) and villi destruction and displayed for each group Images 
were captured at 100X and 400X A well defined histology scoring system 
as descnbed in section 2 10 4 was carried out blinded and used to determine 
the level of allergic inflammation between the groups in the small intestine
(B) n= 6-ll per group (4 HSC donors) Statistical analysis was earned out 
using one way ANOVA Tukey where ****<0 0001
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5.5. MAST CELLS WERE RESIDENT IN THE CONNECTIVE TISSUE OF
OVA SENSITISED NSG-SCF MICE.
Animal and clinical studies have revealed that sensitisation to allergens and 
subsequent mast cell activation by cross-linking of FceRI with IgE and food antigen 
are critical for the induction of food allergy (Brandt et al 2003, Lin et al 2002) As we 
have already observed, the engraftment of human mast cells in the spleen, bone 
marrow and liver at 12 weeks (Figure 5 2) it was important to investigate the presence 
o f mast cells in the gastrointestinal tissues Many o f the symptoms are mediated by 
mast cell activation in the GI leading to release o f inflammatory mediators that drive 
much o f the allergic reaction with pathological consequences (Karra et al 2009) As 
in the previous experiment on day 141, 18 hrs after OVA challenge small intestine 
was harvested and placed in formalin for histological analysis Tissue sections were 
stained with toluidine blue to identify the presence of mast cells Mast cells are often 
classified according to their location or protease subtype and typically are grouped as 
mucosal or connective tissue-type subpopulations o f mast cells (Galli et al 1984) No 
mast cells were identified m the jejunum of PBS, 147 hydrolysate treated or wpc80 
treated mice (Figure 5 6) However on closer examination o f the connective tissue in 
the submucosa o f OVA sensitised mice, small numbers o f mast cells were present 
(Figure 5 6) Toluidine blue stained mast cells red- purple or violet (metachromatic 
staining) and the background blue (orthochromatic staining) Connective tissue mast 
cells contain numerous granules rich in histamine and serotonin (Friend et al 1996) 
Mast cells appeared to be mtact and elongated in form and were purple in colour but 
appeared to have weak purple granules which indicates an intermediate level of 
sulfation o f heparin monomers It is known that the level of sulfation o f heparin 
determines its functional activity (Faarberg et al 2001) Overall there were limited 
numbers of mast cells present and no mast cells revealed features o f de-granulation in
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the connective tissue o f OVA sensitised mice The enzyme histochemical detection of 
chloroacetyl esterase was also used to try and detect mast cells in the jejunum of these 
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Figure 5.6. Mast cells were only visible in connective tissue of 
OVA sensitised NSG-SCF mice that received no therapy. The
OVA model was set up exactly as described in figure 5.2. Tissue 
samples were harvested on day 141 (18h after the OVA challenge) 
formalin fixed, paraffin embedded and stained with toluidine blue.
(A) Representative images of P-metachromasia mast cells in the 
connective tissue in the submucosa o f the small intestine. 
Images were captured at 100X and 600X. n= 6 per group (4 
HSC donors).
(C) Representative images o f Toluidine blue stained jejunum with 
no mast cells present in PBS, OVA, 147 and WPC80 treated 
tissue.
5.6 HYDROLYSATE 147 TREATMENT ALTERS THE OVA-SPECIFIC IgGl 
ANTIBODY LEVELS IN A HUMASISED MOUSE MODEL OF OVA 
ALLERGY
IgE antibodies can play an important role in conferring immunologic specificity 
to effector cell activation in patients with allergic disease (Galli et al 2012) IgE is the 
isotype found at by far the lowest concentrations in the circulation (50-200 ng/ml total 
circulating IgE m healthy subjects vs approx 10mg/ml for IgG) (Dullaers et al 2012) 
However IgE can be found at much higher levels in patients with allergic diseases 
(Platts et al 2016) Ova sensitisation in mice is known to induce IgE and a powerful 
T h2 response Therefore it was important to explore whether oral treatment with whey 
hydrolysate 147 could decrease total IgE antibody concentrations in OVA sensitised 
mice After transplantation o f human CD34+ HSCs on day 0 and checking for 
engrafted human immune cells at week 12, mice were sensitised by intraperitoneal 
injection o f either OVA (100ug/ml) with alum or salme with alum once a week for 
two weeks (week 12 and week 13) One week later, tail bleeds were performed and 
serum IgE antibody levels were determined by ELISA Low levels o f total IgE 
antibody were detected m the serum of control mice whereas there was a significant 
increase in IgE antibody produced m the serum of OVA sensitised mice (Mean 79 85 
vs 651 15 P<0 0001) one week after the last sensitisation (Figure 5 7A)
In contrast, levels o f IgE detected in the sera o f all groups at week 20 (after 
treatment and challenge) were similar (Figure 5 7B) It is important to note that PBS 
mice were challenged with OVA and this is likely to result in the increase from 
100ng/ml to 400ng/ml seen between figure 5 7 A and B Clearly IgE levels alone do 
not explam susceptibility to allergic disease Many patients can experience near-fatal 
anaphylaxis despite having low or undetectable levels of circulating IgE (Simons et al
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2007) Thus, in addition to IgE there is an important humoral response generated 
during primary sensitization that leads to production of allergen-specific IgGl 
Qualitative changes in the OVA-specific IgG antibody response may possibly be an 
important mechanism underlying the clinical efficacy o f 147 hydrolysate 
immunotherapy As in the previous experiment, blood samples were collected at 
sacrifice on day 141 Total serum IgGl and OVA specific serum IgGl levels were 
determined by ELISA There were low levels o f total IgGl detected in control mice 
compared to significantly high levels m OVA sensitised and wpc80 treated mice, 
(P<0 01, P<0 05) (Figure 5 8 A) Significantly higher levels o f OVA-specific 
IgGl were induced in the OVA and OVA and wpc80 treated groups (POOO l, 
P<0 05) However there was a significant reduction in OVA specific IgGl produced in 
the sera o f OVA and 147 hydrolysate treated mice (P < 0 01) (Figure 5 8B)
In summary, treatment with hydrolysate 147 and its control wpc80 had little or 
no effect in changing the levels o f total IgE levels However the ability of 147 to 
dampen T h2 associated OVA-specific IgGl may give an indication of the potential 
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Figure 5.7 Oral treatment with milk protein hydrolysate 147 or WPC80 
does not change total IgE antibody responses to sensitising allergen. Tail 
bleeds were performed 1 week after the final sensitisation (week 14), serum 
was processed and frozen at -80°C until analysis o f total IgE by ELISA (Ready 
Set-GO kit, eBioscience San Diego ,USA) In the same way at end of study on 
day 141, facial bleeds were performed, processed and frozen at -80°C until 
analysis o f total IgE by ELISA (A) Levels of IgE detected in the serum in PBS 
and OVA sensitised mice at 14 weeks and (B) Levels o f IgE detected in serum 
of PBS, OVA sensitised, OVA sensitised and 147 treated and OVA sensitised 
and wpc80 treated mice at 20 weeks IgE levels were calculated by reference to 
a human IgE standard curve Statistical analysis was earned out using unpaired 
student t-test where **** <0 0001
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Figure 5.8. Hydrolysate 147 treated mice exhibit a significant suppression of 
anti-ova IgGl antibody response. The OVA model was set up exactly as 
described m Figure 5 2 On day 141, mice were bled through the facial vein and 
200gl o f blood was collected Serum was processed and frozen at -80°C until 
analysis Levels of total IgGl and OVA-specific IgGl in serum were determined 
by ELISA (Ready-SET-GO, eBioscience, San Diego, USA) Briefly, 96-well 
plates were coated either with OVA (5pg/ml) or anti-human IgGl (lOpg/ml) 
overnight Serum samples were diluted 1/100 for IgGl and 1/10 for OVA specific 
IgGl Anti-human IgGl were applied followed by HRP-conjugated anti-human 
IgG antibody (1/250) for detection (A) Total IgGl antibody level and (B) OVA 
specific IgGl detected in sera o f PBS, OVA, 147 treated and wpc80 control treated 
mice IgGl levels were calculated by reference to a human IgGl standard curve 
Statistical analysis was carried out with one way ANOVA Tukey with multiple 
comparison test where ***<0 001, **<0 01, *<0 05
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5.7 EX VIVO CYTOKINE PRODUCTION BY MLN REDUCED BY
HYDROLYSATE 147 TREATMENT.
Mesenteric lymph nodes (MLNs) are an important site o f T cell activation in the 
small intestine and activation within the MLNs is likely a key event in the 
development o f Tn2-biased inflammation within the gastrointestinal tract (Knight et al 
2007) As there were differences detected in antibody responses between the groups of 
mice the question was posed if the differences in antibody responses were also 
associated with cytokine milieu Mesenteric lymph nodes (MLN) were removed at 
sacrifice (day 141) Single cell suspensions were prepared in RPMI-1640 containing 
10% fetal bovine serum and 1% penicillin-streptomycm Cells (2 x 105/well) were 
cultured in flat- bottom 96-well plates without any stimuli or in presence of OVA 
(lOOpg/well) for 72 hrs (37°C, 5% CO2) Supernatants were collected and stored at - 
20°C until analysis IL-4, IL-5 and IL-13 were determined by ELISA (R&D) Local 
and systemic cell responses to PBS, OVA, OVA plus 147 treated and OVA plus 
wpc80 were evaluated in all 4 groups o f mice as in vitro cytokine production by MLN 
after exposure to corresponding allergen IL-4 production from controls (PBS group) 
was low in response to OVA stimulation, however the levels o f IL-4 were 
significantly increased in MLN cells exposed to OVA (P<0 001) Importantly, IL-4 
cytokine production was significantly reduced in the OVA plus wpc80 and OVA plus 
147 groups (Figure 5 9)
In summary, on the local level in MLNs, a significantly higher production of 




Figure 5.9. Oral administration of milk peptide hydrolysate 147 and 
parent control wpc80 inhibits the ex vivo cytokine production of IL- 
4 by Mesenteric Lymph nodes (MLN) in OVA treated mice. Mice 
were set up exactly as described in Figure 5 2 Mesenteric lymph node 
cells were recovered on Day 141 and prepared from all four groups of 
mice (PBS, OVA sensitised, 147 and WPC80 fed mice) using a cell 
strainer MLN cells (2 x 105/well) were cultured with or without 
100ug/ml OVA for 72 h m culture medium in triplicate Supernatants 
were frozen at -20°C until determination of IL-4 concentration by 
ELISA n= 6 per group and plated in duplicate Statistical analysis was 
earned out using one way ANOVA Tukey with multiple companson 
test where ****< 0 0001
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5.8.147 HYDROLYSATE TREATMENT SIGNIFICANTLY REDUCED 
THE TH2 AND PROINFLAMMATORY CYTOKINES IN THE GI AND 
SPLEEN OF OVA MICE
The main driver of OVA induced inflammation are T h2 cells Given the 
capacity of hydrolysates to potentially alter the T h1/Th2/T h17 balance or enhance 
TReg function, it was important to investigate whether hydrolysate 147 anti­
inflammatory/ immunomodulatory activity would impact the systemic and GI 
organs o f OVA sensitised mice Therefore cytokines profiles for the small intestine, 
spleen and liver were determined Using the same model set up as described in 
figure 5 2, small intestine, spleen and liver were harvested, snap frozen and 
homogenates were used to detect the o f levels o f T h2 (IL-4, IL-13) T hI (IFN-y, 
IL-12) pro-inflammatory (IL-6, IL-17) and anti-inflammatory (IL-10) cytokines by 
ELISA
As expected, in the small intestine there was a significant increase in the levels 
of the Th2 cytokine IL-4 m the mice that were sensitised with OVA antigen (Figure 
5 10) However, both 147 and wpc80 treatment significantly decreased the levels of 
the Th2 cytokine IL-4 There was a trend for reduction in IL-13 in the small 
intestine o f mice treated with 147 m comparison to OVA sensitised mice (Figure 
5 10) 147 treatment significantly reduced the levels o f the T hI cytokine IL-12 in 
comparison to high levels of the cytokine detected in both OVA sensitised mice 
and wpc80 treated mice There was a significant reduction in the levels o f pro- 
inflammatory cytokines IL-6 and IL-17 in the small intestine of 147 treated mice in 
comparison to OVA sensitised mice and wpc80 treated mice (Figure 5 10) 
However the most significant finding was the increase in the levels of the anti­
inflammatory cytokine IL-10 m the small intestine o f 147 treated mice in
2 2 1
comparison to OVA mice In the small intestine of wpc80 treated mice there was a 
significant increase in the levels of IL-10 in comparison to OVA mice but not as 
high as 147 treated mice The cytokine profile is broken down in Table 5 3
The cytokine profile in the spleen was very similar to the cytokine profile 
found in the small intestine 147 treatment significantly decreased the levels o f the 
T h2 cytokine IL-4 in comparison to OVA sensitised mice (Figure 5 11) However 
the levels of the T h2 cytokine IL-13 after treatment with wpc80 were similar to the 
levels detected in the spleens o f OVA sensitised mice compared to 147 treatment 
(Figure 5 11) There was a significant ~5 fold decrease in the T hI cytokine IL-12 
in both spleens o f 147 treated and wpc80 treated mice in comparison to OVA 
sensitised mice (Figure 5 11) 147 treatment again significantly decreased the levels 
of pro-inflammatory 1L-6 and IL-17 in comparison to OVA sensitised mice with 
less of a decrease found in the spleens o f wpc80 treated mice However similar to 
effect m the small intestine, treatment with 147 resulted in a ~2 fold increase in IL- 
10 levels in comparison to OVA sensitised mice The data is summarised in Table 
5 4
IL-4 changes in the liver did not reach statistical significance, however both 
147 and wpc80 treatment significantly reduced the T h2 cytokine IL-13 in 
comparison to OVA sensitised mice (Figure 5 12) The level o f the ThI cytokine 
IL-12 was reduced with 147 treatment however there were no changes detected in 
the levels of the pro-inflammatory cytokines (IL-6, IL-17) with either 147 
hydrolysate or wpc80 control However, in keeping with the anti-inflammatory 
trend seen in the small intestine and spleen there was a significant increase m the 
levels o f IL-10 in the livers o f 147 and wpc80 treated mice (Figure 5 12) Table 5 5 
summarises this data
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Collectively these results demonstrate further that 147 hydro lysate is anti­
inflammatory/ anti-allergic as it provides protection in both systemic and GI tissues 
above that provided by it’s parent control (wpc80) This was characterised by the 
overall reduction in T h2 cytokines, Thl cytokines and pro-inflammatory cytokines 
and increase in anti-inflammatory cytokines in systemic and G l tissues m the 
humanised OVA model
223
IW IL-12 U IL-10
/  /  * /
Figure 5.10 Hydrolysate 147 significantly reduced TH1, TH2, pro- 
inflammatory (IL-4, IL-6, IL-17) and increased the anti-inflammatory 
cytokines (IL-10) detected in the small intestine of OVA mice. The OVA
model was set up exactly as described in figure 5.2. Tissue samples were 
harvested on Day 130, immediately snap frozen and stored at -80 °C. 
Homogenates were prepared and ELISA was used to detect TH1 (IFN-y, IL- 
12), TH2 (IL-4, IL-13) pro-inflammatory (IL-6, IL-17) and anti-inflammatory 
(IL-10) cytokines. Concentration o f cytokine is expressed as pg cytokine per 
ml tissue n=l 1 per group. Statistical analysis was carried out using one way 
ANOVA Tukey with multiple comparison test where * <0.05, **< 0.01 
***<0.001.
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147 i  IL4,11-6,11-12 & t  11-10 
WpcSO i  11-4,11-12 & f  11-10
Figure 5.11: Hydrolysate 147 significantly reduced pro-inflammatory (IL-4, IL-6, 
IL-17 and increased anti-inflammatory IL-10 cytokines detected in the spleen of 
OVA mice. The OVA model was set up exactly as described in figure 5.2. Tissue 
samples were harvested on day 141, immediately snap frozen and stored at -80 0 C. 
Homogenates were prepared and ELISA was used to detect TH1 (IFN-y, IL-12), TH2 
(IL-4, IL-13) pro-inflammatory (IL-6, IL-17) and anti-inflammatory (IL-10 ) 
cytokines. Concentration of cytokine is expressed as pg cytokine per ml tissue n=l 1 
per group. Statistical analysis was carried out using one way ANOVA Tukey with 
multiple comparison test where * <0.05, **< 0.01 ***<0.001.
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Figure 5.12. Hydrolysate 147 significantly reduced pro-inflammatory (IL-13, 
IL-12) and increased anti-inflammatory cytokine IL-10 detected in the liver 
of OVA mice. The OVA model was set up exactly as described in figure 5.2. 
Tissue samples were harvested on day 141, immediately snap frozen and stored at 
-80 °C. Homogenates were prepared and ELISA was used to detect TH1 (IFN-y, 
IL-12), TH2 (IL-4, IL-13) pro-inflammatory (IL-6, IL-17) and anti-inflammatory 
(IL-10 ) cytokines. Concentration of cytokine is expressed as pg cytokine per ml 
tissue n=l 1 per group. Statistical analysis was carried out using one way 
ANOVA Tukey with multiple comparison test where * <0.05, **< 0.01 
***<0.001.
Table 5.3 Cytokine profile in the 
Small intestine
Table 5.4 Cytokine profile in the 
Spleen
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5.9. REGULATORY T CELLS IN OVA MICE WERE NOT SIGNIFICANTLY 
ALTERED BY 147 HYDROLYSATE OR WPC80 TREATMENT.
Food allergy is a type 2 helper T cell (Th2) dependent disease whose prevalence is 
increasing in industrialized countries as a direct consequence of reduced tolerance to 
food antigens The generation o f regulatory T cells (TReg) is a key component of oral 
tolerance, and compelling experimental evidence has demonstrated that functional 
allergen-specific TReg cells play a major role in healthy immune responses to allergens 
and clinically successful allergen-specific immunotherapy (Palomares et al 2013) 
Since IL-10 producing TReg cells can inhibit Th2 cells, another way to dampen the Th2 
response is to promote the differentiation of Treg cells by administration of specific 
peptides (Palomares et al 2010) To date few studies have shown an effect of 
hydrolysates on TReg formation in vivo Duan et al (2012) showed an upregulation of 
IL-10 production in splenocytes obtained from mice treated with p-lactoglobulin 
trypsin hydrolysates, while mtact P-lactoglobulin on the contrary downregulated IL- 
10 Based on these findings, the effect that 147 hydrolysate treatment has on TReg 
cells during OVA driven allergy was investigated in the humanised mouse model
All four groups of mice (PBS, OVA, OVA plus 147, OVA plus wpc80) were 
sacrificed on day 141 and the spleens were harvested for analysis Human TReg cells 
were defined as CD4+CD25+CD127 low FoxP3+ after gating on the human CD45+ cells 
recovered from the spleens and determined by intracellular flow cytometry Figure 
5 13 outlines the 8- colour gating strategy to identify these cells on the Attune NxT 
flow cytometer
Very small populations o f TReg cells were present m the spleens harvested The 
highest percentage and numbers of TReg cells were found in the PBS control group
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(Figure 5 14) The total numbers of human TReg cells were significantly decreased in 
the spleens treated with 147 or wpc80 in comparison to PBS control mice These 
results suggest that 147 or wpc80 has no effect on the number and percentage o f TRegs 
(CD 127 low CD25+ Foxp3+TReg found in the spleen it may suggest that TReg may have 
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Figure 5.13. Representative example of gating strategy used to identify human 
CD45+CD3+CD4+ T cells producing Foxp3+ (A) Illustrates the gated population 
from SSC against FSC plot, (B) represents the gating position for single cells (C) 
illustrates the gating position for human CD45+ (Pacific orange) cells and mouse 
CD45+ (Pe) cells within the single cells (D) represents the gating position for Live 
/Dead stain (E-Flour 780) versus hCD45+ expression. (E) represents the CD3+ 
(Alexa Flour) CD4+ (FITC) T cells within the CD45+ population. (F) Illustrates the 
gating position for Foxp3+ (BV421) CD 127 low (PerCP) within the CD3+CD4+ 
population (G) represents the gating position for the total Foxp3+ CD25+ (PE/CY7) 































Figure 5.14. Hydrolysate 147 and WPC80 treatment had no significant effect 
on the number and percentage of Treg cells in the spleens of OVA driven 
mice The OVA model was set up exactly as decnbed in figure 5 2 Cells were 
recovered on day 141 Human Treg cells were defined as CD 127 low 
CD25+Foxp3+ after gating on the human CD45+ CD3+ CD4+ T cells and analysed 
by intracellular flow cytometry Graphical representation o f the total number and 
percentage o f human Treg cells recovered from the spleen N=6 per group (2 
HSC donors) Statistical analysis was earned out in companson to the PBS group 
using one way ANOVA Tukey Multiple Comparison Test where *<0 05 
****<0 0001
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5.10. HYDROLYSATE 147 SKEWS THE T-CELL DIFFERENTIATION 
FROM A TH2 SUBTYPE TOWARD TH1 WHICH IS BENEFICIAL IN 
FOOD ALLERGY
Th I and T h2 cells are not 2 distinct CD4+ T-cell subsets, but they simply 
represent polarized forms o f the highly heterogenous CD4+ T h cell-mediated 
immune response (Romagnani 1999) T hI cells are characterized by the 
prevalent production of IL-2 and IFN-y, without IL-4, IL-5, and IL-13 
production By contrast, T h2 cells are charactenzed by the prevalent production 
o f IL- 4, IL-5, and IL-13 in the absence of IFN-y production Some bioactive 
peptides from hydrolysates have the ability to modulate the immune response in 
a hypoallergenic way by balancing the T h 1/Th2 response (Moller et al 2008) 
However few studies have addressed the issue o f T-cell differentiation skewed 
by hydrolysates in vivo Wu et al (2006) demonstrated that the IFN-y/IL-4 ratio 
increased in spleen T cells from mice fed with chitosan hydrolysate, suggesting 
a change toward a more THl-like phenotype We have previously shown in vitro 
that hydrolysate 147 decreases IL-4 production in a T h2 polarisation assay 
(Figure 3 18b) Therefore to build on this finding, the effect that 147 hydrolysate 
has on the development o f human CD4+T cells producing either IFN-y (T hI) or 
IL-4 (T h2) during OVA driven inflammation was analysed in the spleen using 
intracellular flow cytometry 
On day 141, human CD4+ T cells were examined in the spleen from all groups 
of mice Using the gating strategy as described in figure 5 15, the T h I and T h2 
cytokine production was analysed in these cells by intracellular flow cytometry 
(Figure 5 16) In OVA mice, there was increased percentage and number of 
CD45+CD4+ T cells producing IL-4 and decreased percentage and number of
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CD45+CD4+ T cells producing IFN-y compared to PBS control mice (Figure 
5 16) In contrast, treatment with 147 (but not wpc80) in OVA mice reduced the 
percentage and number of CD45+CD4+ T cells producing IL-4 and increased 
percentage and number o f CD45+CD4+ T cells producing IFN-y (Figure 5 16) 
Table 5 3 summaries the data m figure 5 16 and displays the ratio of IFN-y/IL-4 
(T h 1/Th2) between the groups o f mice There was a lower IFN-y/IL-4 ratio 
(both in the percentage and number) in OVA mice compared to PBS mice 
Treatment with 147 (but not wpc80) increased the ratio (both in percentage and 
number) o f IFN-y/IL-4 in the spleen compared to OVA mice This data 
demonstrates further that 147 has immunomodulatory ability as it is capable of 
skewing the T-cell differentiation from a T h2 subtype toward T h I,  which is 
beneficial in allergic inflammation
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Figure 5.15. Representative example of gating strategy used to identify human 
splenic CD45+CD4+ T cells producing IL-4 (Th2) or IFN-y (Thl) (A) Illustrates 
the gated splenic population from SSC against FSC plot (B) represents the gating 
position for single cells (C) illustrates the gating position for human CD45+ (Pacific 
Orange) and mouse CD45’ (PE) population (D) represents the gating position for the 
unstimulated CD45+ CD4+ (FITC) IL-4 +(PE Dazzle) population (E) Illustrates the 
stimulated CD45+ CD4+ (FITC) IL-4 +(PE Dazzle) population (F) represents the 
unstimulated CD45+CD4 IFN-y+ (APC) and (G) Illustrates the stimulated 










































Figure 5.16 Increased IFN-y/IL-4 ratio in splenocytes o f 147 treated mice The
OVA model was set up exactly as described in figure 5 2 Spleens were recovered on 
day 141 and single cell suspensions o f splenocytes were stimulated with 100ng/ml 
Phorbal 12-mynsate 13-acetate, 1 pg/ml lonomycin and lpg/ml brefeldin A for 4 hrs 
and analysed by intracellular flow cytometry Graphical representation o f the 
percentage (A) and total number o f human CD4+ IFN-y cells (B) recovered in the 
spleen and percentage (C) and total number of human CD4+IL-4 cells (D) recovered 
in the spleens N=6 per group (2 HSC donors) Statistical analysis was carried out 
using one way ANOVA Tukey with Multiple Comparison test
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PBS 22.72 2021 12.3 1356 1.84 1.49
OVA 11.51 12.51 22.47 2010 0.51 .62
147 20.93 2305 13.56 1349 1.54 1.70
WPC80 13.66 1821 h24.3 1893 0.56 0.96
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5.11 HYDROLYSATE 147 REDUCED THE MAST CELL LOAD IN THE 
BONE MARROW OF HUMANISED MICE
Mast cells are viewed as key players in IgE-dependent allergies and anaphylaxis 
(Voehnnger 2013) and several lines o f evidence suggest that basophils participate in 
allergic disease (Schroeder 2011) However, allergic inflammation reflects a complex 
interplay between several inflammatory cells, including mast cells, basophils, 
lymphocytes, dendritic cells, eosinophils and neutrophils (Barnes 2011) In a recent 
humanised mouse model study o f anaphylactic peanut allergy, anaphylaxis in peanut 
fed humanised NSG-SCF mice was mediated by engrafted human mast cells through 
production o f human IgE antibody produced by engrafted B cells and omalizumab 
(anti-IgE) treatment completely protected the mice from anaphylaxis (Burton et al 
2017) However this study failed to show what effect the treatment had on the 
development o f mast cells in these mice As we have previously found that mast cells 
and basophils engraft in the bone marrow o f NSG-SCF mice (Figure 5 2) the next step 
was to investigate if 147 hydrolysate treatment would affect the development of the 
mam effector cells in allergy, mast cells and basophils
Using the same model set up as described in figure 5 1, on day 141, femurs were 
removed from all groups of mice and bone marrow was harvested Human mast cells 
were defined as CD203c+FCsRI+ c-kit+ after gating on the human CD45+ cells 
recovered from the bone marrow and determined by flow cytometry Figure 5 17 
outlines the 6- colour gating strategy to identify these cells on the Attune Nxt flow 
cytometer As expected, the highest percentage o f  mast cells (CD45+ CD203c+ c-kit+ 
cells) was found in the bone marrow of OVA sensitised mice that received no 
treatment compared to PBS mice (Figure 5 18A) Treatment with 147 and wpc80 
significantly decreased the percentage and number of mast cells present (Figure 5 18
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B and C) When these mast cells were further analysed for their expression o f c-kit 
there was significantly lower numbers of mast cells (CD45+ CD203c+ FcsRl+ c-kit+) 
and basophils (CD45+ CD203c+ FcsR l+ c-kit ) present in the bone marrow o f 147 and 
wpc80 mice (Figure 5 18 E) Overall 147 and wpc80 had a similar profile to PBS mice 
(Figure 5 18, A,B,D) however there were significantly less numbers of mast cells and 
basophils present with 147 and wpc80 treatment
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Figure 5.17. Representative example of gating strategy used to identify 
human mast cells and basophils. (A) Illustrates the gated population from SSC 
against FSC plot, (B) represents the gating position for single cells (C) illustrates 
the gating position for human CD45+ (Pacific orange) cells and mouse CD45+ 
(Pe) cells within the single cells (D) represents the gating position for Live /Dead 
stain (E-Flour 780) versus hCD45+ expression. (E) Illustrates the CD33+cells 
within the CD45 + population (F) represents the CD203C+ (PE) FCsRl+ (APC) 
cells within the CD33+ population. (G) Illustrates the gating position for 
CD203C+ c-kit+ (mast cell) and CD203C+ c-kit'(basophils) within the 
FCeR1+CD203C+ population. All gating positions were determined using FMO 
controls.
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Figure 5.18. Percentage and num ber of mast cells were significantly reduced 
in the bone m arrow  of 147 hydrolysate & wpc80 mice. The OVA model was 
set up as described in Figure 5.1. Cells were recovered on day 141 and analysed 
by flow cytometry. (A) Flow cytometry plots of CD45+ (Pacific Orange) 
CD203c+ (PE) c-kit+ cells (BV521) in bone marrow of PBS, OVA, OVA +147 
and OVA+WPC80 mice. (B) percentage and (C) number of engrafted CD45+ 
CD203c+ c-kit+ in bone marrow and (D) percentage and (E) number of mast cell 
(CD45+ CD203c+ FcsRC c-kit+ ) and basophils (CD45+ CD203c+ FcsRC c-kif ) 
in bone marrow of engrafted mice. N=6 per group for PBS and OVA and N=11 
for 147 and WPC80 treated groups. Statistical analysis was carried out with one 
way ANOVA Tukey with Multiple Comparison Test where * < 0.05, **< 
0.01***< 0.001
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5.12 DIFFERENTIAL DISTRIBUTION OF LYMPHOCYTES, MONOCYTES 
AND GRANULOCYTES IN BONE MARROW OF 147 TREATED MICE ARE 
ACCOMPANIED BY REDUCTIONS IN T-LYMPOCYTES
The coordinated production o f leukocytes in bone marrow is crucial for innate and 
adaptive immunity Inflammation alters normal leukocyte production by promoting 
granulopoiesis over lymphopoiesis (Ueda et al 2005) Developing granulocytes and 
lymphocytes compete for a bone marrow niche where reductions in one compartment 
result m expansion by the other (Ueda et al 2005) As outlined before, milk 
hydrolysates consist o f mixtures o f smaller peptides with different properties that can 
influence the immune response to be more suppressive/tolerogenic (Korhonen et al 
2003) Herein, we used a model o f OVA driven inflammation to investigate if 
ingesting a novel hydrolysate after sensitisation and before challenge would result in 
differential expression of lymphocyte, granulocyte or monocyte populations in OVA 
mice
As before, all groups o f NSG-SCF mice were set up as described in figure 5 1 
On day 141, bone marrow and liver were harvested and differences in lymphocyte 
subtypes were analysed by flow cytometry Representative dot plots showing the 
distribution o f leucocytes by size (forward light scatter) versus granularity (side angle 
scatter) are illustrated m figure 5 19 A There was an increased frequency and number 
o f granulocytes in the bone marrow o f OVA mice compared to PBS mice (Figure 5 19 
A, B, C) Treatment with 147 (but not wpc80) in OVA mice significantly reduced the 
frequency and number o f granulocytes and concurrently increased the frequency and 
number of lymphocytes (Figure 5 19 A) There was an increased frequency and 
number of granulocytes in the liver o f OVA mice compared to PBS mice A similar 
trend of significantly increased lymphocytes in comparison to low levels of
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granulocytes was also seen in the livers o f 147 treated mice however there was no 
change in cell number between the groups (Figure 5 20 B,C) To evaluate the distinct 
phenotypic switch in the bone marrow further, absolute cell counts were performed in 
the bone marrow of all groups of mice Human myeloid, T and B cells recovered 
from the bone marrow were determined by 7 colour flow cytometry Treatment with 
147 (but not wpc80) significantly decreased the number o f CD45+ leucocytes found in 
the bone marrow o f these mice compared to OVA mice (Figure 5 21 A) Notably 
there was lower absolute number o f CD3+ CD4+ lymphocytes (but not wpc80) in the 
147 treatment group in comparison to OVA mice (Figure 5 21C) There was lower 
absolute number of CD3+ CD8+ lymphocytes (as well as wpc80) m the 147 treatment 
group in comparison to OVA mice (Figure 5 21 D) This potential for reducing the 
number o f lymphocyte phenotypes continued through to the myeloid and B cells 147 
significantly decreased the number o f human myeloid CD33+ cells (as well as wpc80) 
and B (CD19+) cells (but not wpc80) in OVA mice (Figure 5 21 B, E)
In summary, the data suggests that 147 has a big impact on the granulocyte 
populations as it significantly altered the ratio o f immune cell populations in the bone 
marrow and liver In the bone marrow and liver there was a relative increase in the 
ratio of lymphocytes compared to granulocytes However in looking at cell number 
across the populations there was no actual increase in the cell number but there was a 
significant decrease in the granulocyte cell number It is possible that 147 promoted 
the accumulation of another cell type found in the lymphocyte gate for e g natural 
killer (NK) or invariant natural killer cells (lKT) cells or innate lymphoid cells (ILCs) 
that we did not analyse here lKT are a subgroup of T cells with a immunoregulatory 
function which have recently been shown to play a role in CMPA in infants 
(Jyounouchi et al 2011) Here the authors for the first time have demonstrated that
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iNKT from children with IgE mediated food allergy especially those with milk allergy 
were reduced in number and exhibited a Th2 response to milk sphingomyelin, a type 
o f lipid found commonly in milk and eggs.
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Figure 5.19. 147 hydrolysate decreases the percentage and
number of granulocytes in the bone marrow of OVA challenged 
mice. The OVA model was set up as described in Figure 5.1. Cells 
were recovered on day 141 and analysed by flow cytometry. (A) 
Representative flow cytometry plots o f lymphocyte, monocyte and 
granulocyte distribution in bone marrow o f PBS, OVA, OVA plus 
147 and OVA plus WPC80 mice. (B) percentage and (C) number of 
lymphocytes , monocytes and granulocytes in bone marrow of PBS, 
OVA, OVA plus 147 and OVA plus WPC80 mice. N=6 per group 
for PBS and OVA and N = ll for 147 and WPC80 treated groups. 
Statistical analysis was carried out with two way ANOVA Tukey 
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Figure 5.20. 147 hydrolysate decreases the percentage of 
granulocytes in the liver of OVA challenged mice. The OVA model 
was set up as described in figure 5.1. Cells were recovered on day 141 
and analysed by flow cytometry. (A) Representative flow cytometry 
plots o f lymphocyte, monocyte and granulocyte distribution in liver of 
PBS, OVA, OVA plus 147 and OVA plus wpc80 mice. (B) percentage 
and (C) number o f lymphocytes, monocytes and granulocytes in bone 
marrow o f PBS, OVA, OVA plus 147 and OVA plus wpc80 mice. N=6 
per group for PBS and OVA and N = ll for 147 and wpc80 treated 
groups. Statistical analysis was carried out with two way ANOVA 
Tukey with Multiple Comparison Test where ***0.001.
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Figure 5.21. Significant reductions in T lymphocyte populations in bone 
marrow of OVA challenged mice treated with hydrolysate 147. The
OVA model was set up as described in Figure 5 1 Cells were recovered on 
day 141 and analysed by flow cytometry (A) absolute number of 
Leucocytes (CD45+) cells in the bone marrow (B) absolute number of 
myeloid (CD33+) cells in bone marrow and (C) absolute number of 
CD3+CD4+ (D) absolute number o f CD3+CD8+ (E) absolute number o f B 
(CD19+) cells N=6 per group for PBS and OVA and N = ll for 147 and 
wpc80 treated groups Statistical analysis was earned out with one way 
ANOVA Tukey with Multiple Comparison Test where * < 0 05
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5.13. HYDROLYSATE 147 SIGNIFICANTLY REDUCES THE 
ACTIVATION OF DENDRITIC CELLS IN THE BONE MARROW OF 
HUMANISED MICE
The prevalence of allergic diseases has increased rapidly m recent years It is well 
established that the deleterious allergic response is initiated by T-cell recognition 
o f major histocompatibility class II-peptide complexes at the surface o f antigen- 
presenting cells While this first signal gives antigen specificity to the adaptive 
immune response, a second nonspecific costimulatory signal is required by T cells 
to become fully activated This signal is provided by interactions between 
antigen-presenting cells and T cells through molecules borne at the surfaces o f the 
two cell types Depending on the type o f molecules involved, this secondary 
signal can promote the development o f an inflammatory allergic reaction or may 
favor immune regulation Several molecules of the B7 family (CD80, CD86, PD- 
1, ICOS, CTLA-4) and tumor necrosis factor receptor family (0X40, CD30, 4- 
1BB, Fas, CD27, CD40) play an important role in delivering costimulatory 
signals m early and late phases o f allergic response (Lombardi et al 2010) In 
Chapter 3, the demonstration that addition o f milk hydrolysate 147 to activated 
monocyte derived dendritic cells resulted in down regulation of co-stimulatory 
molecule CD86 expression raised the possibility that hydrolysate 147 could also 
down regulate the expression of costimulatory molecules in vivo
Using the same model as described in figure 5 1, on day 141 bone marrow 
cells were isolated from the femurs o f mice, single cells suspensions were 
analysed for the expression o f dendritic cell markers C D llc+ and co-stimulatory 
marker o f activation CD86+ by flow cytometry In the bone marrow there was 
significant reduction in the absolute number and percentage o f cells in mice
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challenged with OVA and treated with hydrolysate 147 in comparison to OVA 
challenged mice (P<0 05, P<0 001) This finding is consistent with the finding 
from Chapter 3 Treating mice with wpc80 after sensitisation and before 
challenge also significantly reduced the absolute numbers of 
CD45+CD11C+CD86+ in the bone marrow o f these mice (Figure 5 22) 
Downregulation o f the dendritic activation marker CD86 in 147 treated mice adds 
to the growing body o f evidence that hydrolysate 147 has anti-inflammatory 
capabilities in a humanised mouse mode o f OVA allergy
Next the development o f human myeloid subsets was examined in the bone 
marrow of humanised mouse model In mice sensitised and challenged with 
OVA, percentage and number CD45+CD33+ HLA-DR' granulocytes were 
increased compared to PBS mice Importantly, this subset o f cells (% and 
number) was significantly reduced m mice that were treated with 147 (P<0 001, 
Fig 5 23 A, B) However a similar effect was seen in the bone marrow o f mice 
that were treated with wpc80 (P<0 001)
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Figure 5.22. Reduction of co-stimulatory molecule CD86+ cells in the bone 
marrow of OVA mice is mediated by 147 hydrolysate treatment. The OVA model 
was set up exactly as described in figure 5.2. On day 141, bone marrow was 
harvested, mechanically digested and single cell suspensions were analysed for the 
expression of CD45+, CD86+ C D llc + by flow cytometry. (A) Representative flow 
cytometry graphs of percentage CD45+ CD86+ C D llc+ (B) percentage and (C) 
number o f CD45+ CD86 CD1 lc+ cells in bone marrow. n=6 per group for PBS and 
OVA and N =11 for 147 and wpc80 groups. Statistical analysis was carried out using 





















Figure 5.23.147 treatment significantly reduced the percentage and total number 
of CD33+ HLA-DRr granulocytes in the BM of OVA sensitised mice. The OVA
model was set up exactly as described in figure 5 2 On day 141, bone marrow was 
harvested, mechanically digested and single cell suspensions were analysed for the 
expression o f CD45+, CD33+HLA-DR+ by flow cytometry (A) percentage and (B) 
number o f CD45+ CD33+HLA-DR+ in bone marrow n=6 per group for PBS and OVA 
and N = ll for 147 and wpc80 groups Statistical analysis was earned out using one 
way ANOVA Tukey Multiple Companson Test where * <0 05 and ***< 0 001
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Throughout this chapter studies were designed to 1) assess the 
immunomodulatory capacity of novel milk protein hydrolysate 147 in a humanised 
mouse model of OVA inflammation against whey protein control and 2) to determine 
if milk protein hydrolysate 147 has anti-inflammatory/anti-allergic effects m the 
humanised model Whey 147 hydrolysate and its parent control wpc80 were tested 
after sensitisation and before the challenge/ effector phase o f the allergic immune 
response to investigate the capacity for these treatments to alter the pre-disposed Th2 
environment that already exists in these mice 30 mins after challenge with OVA 
antigen, 147 and wpc80 treated mice had reduced anaphylactic symptoms in 
comparison to OVA sensitised mice that received no intervention (Figure 5 3) 
Investigating the GI protection by hydrolysates, histological analysis revealed that 
damage in the target organ o f allergic mice was greatly diminished in mice exposed to 
147 hydrolysate and wpc80 treatment (Figure 5 6) There were limited number of 
mast cells present in the connective tissue o f OVA mice and no mast cells were 
present m the GI tissues o f 147, wpc80 or PBS mice
For further investigation, cytokines profiles in OVA mice following these 
treatments were analysed Figures 5 6-5 8 confirmed that 147 treatment significantly 
reduced the Th2 and pro-inflammatory cytokine profile in the small intestine, spleen 
and in the liver o f OVA driven mice There was a significant increase in the anti­
inflammatory cytokine IL-10 in all three tissues The source o f the IL-10 remains 
unidentified but may have been produced by telorogemc dendritic cells In terms of 
changing T cell differentiation, from an allergic Th2 to a more tolerant subtype, 
spleens that were treated with hydrolysate 147 had higher T h1/Th2 ratios This 
skewing o f the immune response is very beneficial attnbute in a food allergy model
5.14 SUMMARY
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Looking more closely at the effector cells o f allergy, mast cells were significantly 
decreased in the bone marrow o f NSG-SCF mice treated with hydrolysate 147 (and 
wpc80) and they mirrored the effect seen in the PBS control mice However the most 
striking phenotype was that 147 treatment blocked the accumulation o f granulocytes 
in the bone marrow and liver This suppression of granulopoiesis resulted in over 
production of lymphocytes However, phenotypic analysis by flow cytometry revealed 
a significant reduction in the leucocytes (CD45+), T-lymphocyte subsets (CD3+ CD4+, 
CD3+CD8+) myeloid (CD33+) and B cells (CD19+) in the bone marrow o f 147 treated 
mice, a phenomena which may be mediated by either a regulatory or suppressor type 
o f cell
Oral immunotherapy for food allergy alters the expression of the co-stimulatory 
molecules on DC (Gorelik et al 2015) There was significant reduction o f co- 
stimulatory molecule CD86 in the bone marrow o f mice receiving 147 hydrolysate 
treatment which again points to a tolerogenic type o f immune regulation There were 
significantly lower numbers o f CD33+HLA-DR~ granulocytes in the bone marrow of 
147 and wpc80 treated mice in comparison to OVA mice (Figure 5 23) Importantly 
147 hydrolysate was more anti-inflammatory than its parent control wpc80 as shown 
in summary (Figure 5 24)
Collectively, this data suggests that hydrolysate 147 has no implications for the 
risk o f inducing allergic symptoms in already sensitised mice and represents a potent 
anti-inflammatory compound that could be added as a functional food ingredient as an 
immune balancing compound Following these investigations, this chapter adds 
significant knowledge on our understanding o f the anti-inflammatory effects a novel 
milk peptide hydrolysate 147 has in reducing OVA driven allergy in a humanised 
mouse model and presents a framework from which suitable conditions for testing
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Figure 5.24: Whey milk peptide hydrolysate 147 provided additional anti­
inflammatory/pro- tolerogenic effects over it’s intact whey protein control 
in a humanised mouse model of ovalbumin induced allergy and 
inflammation. Addition o f 147 to OVA mice resulted in lower production of 
T h2 antibody IgGl in serum, lower expression o f pro-inflammatory cytokines 
IL-6, IL-17 and higher expression of the anti-inflammatory cytokine IL-10 in 
both spleen and small intestines o f OVA mice than wpc80. 147 was more potent 
than wpc80 at providing a T h 1/Th2 balance in the spleen and had a significant 
impact on reducing the granulocyte populations in bone marrow and liver of 
OVA mice in comparison to wpc80. 147 reduced the CD4+T and CD19+B 




In the last two decades many studies have demonstrated that bovine milk is a source of 
bioactive compounds These bioactive molecules are naturally contained in milk Milk- 
derived bioactive peptides are usually encrypted and kept inactive within the primary 
structure o f milk protein and they are generated by proteolysis of casein (a-, [3-, y- and k- 
casein) and whey proteins ([3-lactoglobulm, a-lactalbumin, serum albumin, immunoglobulins, 
lactoferrin and protease-peptone fractions) Both whey and casern contain a number of 
immunomodulatory peptides that are naturally present or that are part o f the primary 
sequence o f whey and casein proteins These peptide sequences can be released during 
digestion in the gut and can also be produced by in vitro enzymatic hydrolysis. Proteins that 
are pre-digested or hydrolysed into smaller protein chains outside of the body are known as 
hydrolysates These milk hydrolysates are known to possess different immunological 
properties to the whole protein and have been proven to beneficially modulate the immune 
system The increasing number of and health promoting effects attributed to milk-denved 
bioactive peptides make them potential functional ingredients These hydrolysates can be 
used to prevent or mitigate allergic reactions via the development o f targeted food products or 
functional food ingredients Although human milk is generally accepted as the feeding 
choice, more than 70% of the infants m Western Europe are formula fed from 12 weeks on 
(Bosscher et al 2009) Infant formula, which is often cow’s milk based, is the only approved 
alternative for breastfeeding However, cow’s milk proteins cause allergic symptoms in 2-3% 
of the infants (Sackwsen et al 2011) Cow’s milk is largely considered the most important 
ingredient source for infant formula, as it is made up of many up o f many o f the constituents 
found in breastmilk, such as essential amino acids that are required to support the 
developmental needs o f the infant Current milk formula on the market suitable for infants 
with CMPA, are comprised o f extensively hydrolysed cow’s milk proteins These milk 
formulae provide the infant with the high nutritional quality o f the proteins, while also
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reducing the allergenic properties, due to their small size (Terheggen-Lagro et al 2002) 
However, while these extensively hydrolysed formula are more tolerable and prevent allergic 
symptoms, they cannot induce tolerance to the allergen because extensive protein hydrolysis 
results in the loss o f lmmunogenicity This reduces stimulation to the immune system, 
inhibiting its ability to develop tolerance to these otherwise harmless milk proteins Although 
strict avoidance of cow’s milk is advised for the management o f CMP A, recent studies 
suggest that exposure to cow’s milk allergens can, in fact be beneficial for infants that are at 
nsk o f developing CMPA through targeting and influencing the immune system from birth 
(Staden 2007) Partially hydrolysed formulae however have been shown to reduce the 
prevalence o f atopic dermatitis in infants compared to whole-protein formula (Spieldenner et 
al 2011, Vandenplas et al 2014, Hemandez-Ledesma et al 2014) Partial hydrolysis of 
proteins retains the protein’s lmmunogenicity which provides the infant with an opportunity 
to develop oral tolerance to the whole protein (Henson et al 2012) Milk hydrolysates 
generated from either casein or whey protein may possess anti-inflammatory or anti-allergic 
properties and thus may be beneficial in infant formula to alleviate the symptoms of CMPA 
while promoting immune balance Based on the recommendations that infant formula should 
mimic the effects o f human milk m the infant as much as possible, several groups, including 
ours proposed to develop a nutritional product enriched with immunomodulatory peptides to 
prevent food allergy in infants
The first chapter (chapter 3), sought to identify hydrolysate’s that had 
immunomodulatory effects using in vitro screening assays Firstly, the ability of 20 
hydrolysates to suppress T cell proliferation was investigated in human PBMCs We chose to 
use human PBMCs as they are a relevant source o f human immune cells and have been used 
previously to study immunoregulatory effects o f dietary molecules (Vogt et al 2013) 
including cow’s milk proteins (Zaczynska et al 2014) Milk peptide hydrolysates isolated
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from whey and casein proteins have been shown to have inhibitory effects on T cells by 
suppressing the proliferation of PBMCs isolated from healthy donors (Sutas et al 1996) In 
this study Sutas et a l , (1996) hypothesised that the inhibitory effect o f the whey and casein 
hydrolysates was strengthened by the additional hydrolysis with the use of bacterial enzymes 
from the Lactobacillus Casei strain Similar studies using the BrdU test to assess the effect 
o f milk casein peptide on the proliferation o f PBMCs found a concentration-dependent 
stimulation o f cells after 10 hrs o f exposure of the cells to milk peptides but longer 
incubations resulted in T cell suppression (Fiedorowic et al 2011) Thus in collaboration with 
FHI, this first screening study sought to identify hydrolysates with immunomodulatory 
properties in vitro as this likely has implications in determining the outcome of an immune 
response Therefore the influence o f hydrolysates on T cell proliferation and cytokine 
production in vitro was assessed Pepti (Aptamil) a current infant milk formula on the market 
suitable for infants with CMPA (extensively hydrolysed) was included as a bench mark 
control m these assays Using a proliferation dye dilution assay both whey (20, 21) and 
sodium caseinate hydrolysates (23, 33) and their parent control (NaCn) were shown to 
suppress T cell proliferation, however there was no evidence o f enhanced suppression over 
that o f pepti control The majority o f the hydrolysates (10 out o f 16) had no effect on T cell 
proliferation but some were effective at modulating the cytokines in the supernatant The 
capacity o f T cells to produce an inflammatory reaction is largely controlled by their 
repertoire o f cytokines and food allergies have traditionally been considered to be Th2 cell- 
denved immunopathologies Therefore the inhibition o f the Th2 cytokines (such as IL-4) and 
the induction of Thl (IFN-y) and anti-inflammatory cytokines (such as IL-10) is a relevant 
approach to shift the balance in allergy A number o f whey and casein hydrolysates inhibited 
the Th2 response by decreasing the levels o f IL-4 and increasing the levels o f IFN-y and 
some casein hydrolysates reduced the pro-inflammatory cytokine IL-6 while increasing the
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anti-inflammatory cytokine IL-10 These initial results indicated the ability o f certain milk 
peptide hydrolysates to favourably balance pro-inflammatory and anti-inflammatory/pro- 
tolerogemc responses in stimulated PBMC To further confirm these immunomodulatory 
effects, a cohort o f whey (40,42) and casein hydrolysates (23,34,35) and their optimised 
regenerates (79,77,80 84,85) were re-screened for their suppressive potential and ability to 
dampen pro-inflammatory responses and promote regulatory responses These hydrolysates 
and their corresponding regenerates had no effect on T cell proliferation but they 
differentially modulated the production of pro (IL-6, IL-17) and anti-inflammatory (IL-10) 
cytokines in vitro Notably, hydrolysate 35 and it’s regenerate significantly upregulated the 
production o f IL-10 and suppressed the levels o f IL-17 over and above pepti formula Whey 
hydrolysate have been shown previously to induce TNFa or IL-10 production in resting 
PBMCs (Rodnguez-Carrio et al 2014) High IL-10 levels induced by intact whey or mildly 
hydrolyzed whey indicate an overall anti-inflammatory effect o f whey and whey 
hydrolysates Anti-inflammatory effects o f whey hydrolysates have indeed been described m 
animals using standard tests including paw edema models (Taveras et al 2013) A number of 
hydrolysates and their regenerates were anti-proliferative, increased the levels o f Thl 
cytokine (34) or significantly decreased the pro-inflammatory cytokines IL-6 (34,35,79), or 
decreased IL-17 (34,35,85) or increased anti-inflammatory IL-10 (35,85) Hydrolysate 35 and 
its regenerate 85 had to be excluded from further studies due to cessation of enzyme 
preparation by manufacturer Based on this second screen and a screen completed with 
mouse cells within FHI, whey hydrolysate 42 and it’s regenerate 79, and sodium caseinate 
hydrolysate 34 an it’s regenerates 84 and 132 were chosen for further testing in Thl, Th2, 
T h l7 and Treg polarisation assays
Although, measuring cytokine levels in supernatants provides an overall view of cytokine 
concentration, it does not provide any detail o f cytokines being produced at a cellular level by
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particular cells Therefore the next approach was to assess the effect hydrolysates have on 
T hl, Th2, Thl7 and Treg to draw further conclusions about the effect o f hydrolysates on T 
helper cell differentiation It has long been recognized that antigen presenting cells (APCs) 
guide (if not dictate) the sensitization o f allergy by directing differentiation of uncommitted 
(naive) CD4+ T helper (Th) cells towards Thl, Th2, T h l7 and Treg phenotypes For 
example, the presence of IFN-y and IL-12 in the local milieu skews towards Thl (expression 
of T box expressed in T cells (T-bet)), IL-4 towards Th2 (expression of GATA-3), 
transforming growth factor (TGF)-p and IL-10 towards Treg (expression of forkhead box P3 
(Foxp3)) and IL-6 and IL-23 towards T h l7 (expression of RORgammat) in human CD4+ T 
cells (Zang et al 2014) No study to date has addressed the topic o f T cell differentiation 
skewed by peptides using human T helper polarised cells One study investigated the effect o f 
a yak milk hydrolysate on the Thl/Th2 balance my measuring mRNA levels of Thl cytokines 
(IL-2 and IFN-y) and the Th2 cytokine IL-4 in murine spleen lymphocytes (Mao et al 2007) 
They found that yak milk casein hydro lysate increased the Thl cytokines but it did not alter 
the Th2 cytokines (Mao et al 2007) Furthermore Wu et al (2006), found that the IFN-y/IL-4 
ratio increased in spleen T cells from mice fed chitosan (shrimp) hydrolysate, suggesting a 
change toward a more Thl-like phenotype Therefore, the effect o f hydrolysates on driving 
immune responses in a certain direction was explored in Thl and Th2 polarisation assays 
Addition o f whey hydrolysate 79 on day 3 increased the number of CD4+ T-bet cells while 
addition of casein hydrolysates 132 and 47 decreased the MFI and number o f CD4+T-bet 
cells in a polarised Thl assay However no hydro lysate altered the production of the Thl 
cytokines (IL-2, IFN-y) in this Thl assay In a Th2 polarisation assay, all hydrolysates 
including wpc80 decreased the MFI Gata-3 expression however when we analysed the 
number o f CD4+ Gata-3 cells by intracellular flow cytometry only hydrolysate 42 and 47
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significantly decreased the number of Th2 cells producing Gata-3 and no hydrolysate altered 
the levels o f the Th2 cytokine (IL-4) measured by ELISA
Thl7 have been identified as a unique CD4+ T helper subset characterised by IL-17 
production that promotes tissue inflammation (Harrington et al 2005, Park et al 2005) 
Understanding their function during homeostatic and inflammatory conditions is 
continuously evolving, however, it is increasingly clear that Thl7 cells are critical in 
protecting and maintaining the homeostasis particularly in the lamina propna o f the small 
intestine (SI), where they are abundantly present (Ivanov et al 2006) In healthy individuals, 
low numbers o f Thl7 cells are present, mainly in the lamina propna (Huber et al 2012) 
During inflammatory disease, IL-17 induces the recruitment o f neutrophils and the 
chemokine CCL20 attracts more Thl7 cells (Esplugues et al 2011) CD4+ T cells from 
children with food allergies have been shown to produce lower levels o f IL-17 ex vivo In 
vitro CD4+ T cells from these allergic children showed impaired IL-17 production after 
antigen administration (Bin et al 2013) In a recent cow’s milk allergy mouse model study, 
whey sensitized animals showed an increased percentage o f total Thl, activated Thl7 and 
activated Treg cells, however, these increases were not observed in animals sensitized with 
the whey hydrolysate (Kiewiet et al 2017) Therefore the effect of hydrolysates (developed in 
FHI) on T h l7 cytokine production and transcription factor expression (Roryt) was 
investigated All hydrolysates significantly decreased the Roryt (MFI) expression and 
number o f CD4+ Roryt+ cells Importantly, hydrolysate 42 and it’s regenerate 79 significantly 
suppressed the levels o f IL-17 in polarised Thl 7 cells after 6 days o f culture in a similar 
manner to the parent control wpc80
Treg cells are a heterogeneous population of T cells with suppressive and 
immunoregulatory properties that are essential for maintaining tolerance to innocuous 
substances and preventing excessive or misguided immune responses to pathogens In
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humans, several studies show that the balance between allergen-specific Th2 and Treg cells 
recognizing the same T-cell epitopes determines whether an individual develops allergy 
(Th2) or has a healthy response (Treg) (Akdis 2012) This balance can potentially be 
maintained by administration of hydrolysates Treg cells are one o f the main producers o f IL- 
10, an anti-inflammatory cytokine that induces the down-regulation o f Thl cells and the 
enhancement o f B cell survival, proliferation and antibody production, among other actions 
Casein hydrolysates were found to stimulate IL-10 production in treated ConA stimulated 
human Jurkat T cells (Lahart et al 2011) Upregulation of IL-10 production was also 
observed in splenocytes from mice treated with the whey protein P-lactoglobulin trypsin 
hydrolysates, while intact (3-lactoglobulin on the contrary, downregulated IL-10 (Duan et al 
2012) In a similar manner in our Treg polarisation assays, intact wpc80 and casein 
hydrolysate 47 decreased Foxp3 expression and IL-10 production however the majority o f the 
hydro lysates neither enhanced or reduced the expression o f Foxp3 and IL-10 cytokine levels 
These findings are not entirely similar to the published studies above where hydrolysates 
were shown to increase levels o f IL-10 but differences in cell types (murine splenocytes, 
human Jurkat T cells) may account for these variances Our study used pure populations of 
polarised CD4+ T helper cells whereas the Lahart & O’Callaghan study used immortalised T 
lymphocyte cells
Dendntic cells (DCs) are recognized as the most potent antigen-presentmg cells, which 
are solely capable o f inducing a primary immune response Hydrolysates delivered orally 
might interact with immune cells, including DCs, in the gut-associated lymphoid tissue 
(GALT) As hydrolysates had been found to possess immune-modulating properties, it was 
hypothesized that the hydrolysates in bovine milk may stimulate tolerogenic responses in 
antigen presenting cells by interfering with DC maturation Very few studies have examined 
the effect o f hydrolysates on human monocyte derived dendritic cells therefore the capacity
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for milk-denved hydrolysates to modulate DC maturation was examined Both whey (79 42) 
and casein (34, 84) hydrolysates suppressed the effector functions o f DCs as they 
significantly reduced the expression o f the co-stimulatory molecule CD86 and levels o f IL- 
12, with casein 132 and 47 being more potent at reducing production of 1L-12 Similar to our 
findings, Li et al (2017) showed that avian- derived pepsin hydrolysate effectively inhibited 
hpopolysacchande (LPS)-mduced bone marrow derived dendritic cells (BMDCs) maturation 
through reduced expression levels o f CD86 and production o f TNF-a, IL-12p70, and 
RANTES, and enhanced production o f IL-10 Tolerogenic DC can present antigen to antigen- 
specific T cells, but fail to deliver adequate costimulation for effector T cell proliferation 
(Morelli, 2007) These combined studies suggest that peptides in hydrolysates may 
contribute to preventing allergy by inducing a more tolerogenic response in dendritic cells
Maturation o f DCs by LPS is initiated by binding to Toll-like receptor 4 (TLR4) 
Differences in immunomodulatory effects o f hydrolysates might be explained by differences 
in TLR receptor activating properties, since some studies suggested an interaction between 
TLRs, mamly TLR2 and 4, and varying hydrolysates (Iskander et al 2013, Ndiaye et al 
2012) The interaction of peptides with TLRs can induce immune effects, since these 
receptors are known to sample many dietary molecules in the intestine in order to regulate 
immune effects (Kiewiet et al 2017) Limited findings suggest that TLR activation not only 
induces tolerogenic dendritic cells, but activation of TLRs on antigen -presenting cells also 
prevents a Th2 driven allergic response by skewing a more Thl response (Gangloff et al 
2004) This raises questions surrounding the observed effects on DCs described above The 
effects mediated by hydrolysates on DC maturation could also be induced via TLRs 
expressed on dendritic cells While this was not investigated here this is an area which calls 
for future investigation to show the direct interaction of hydrolysate peptides and TLRs on 
dendritic cells
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Ideally we wanted a hydrolysate that reduced Th2, enhanced or maintained Foxp3 and 
produced IL-10 and reduced DC maturation Whey hydrolysates 42 and its regenerate 79 and 
casein hydrolysates 34, and its regenerates 84,132 and casein hydrolysate 47 all reduced Th2 
and DC maturation As 47 reduced IL-10 production from in a Foxp3 Treg polarisation assay 
it was excluded from further analysis Hydrolysates 79, 42, 34, 84, and 132 did not expand or 
reduce Treg expression but instead maintained Foxp3 expression Having identified 
hydrolysates which promoted an anti- inflammatory /anti-allergy T cell and DC phenotype, 
there was no clear choice o f hydrolysate to choose for further evaluation in a humanised 
mouse model Then based on the results o f other screening bio-assays like (Dipeptidyl- 
peptidase IV (DPP-IV ) assay which is a screening assay for glucose metabolism and murine 
T cell polarisation assays withm FHI, hydrolysate 42 was chosen 2 upscaled samples of 
whey hydrolysate 42 (147 3 hr and 147 6 hr) were generated and screened to confirm their 
immunomodulatory role in vitro before they were tested in vivo Firstly the effect o f 
increasing doses (0 5 mg/ml 1 0 mg/ml, 2 0 mg/ml) o f hydrolysates (147 3 hr and 147 6hr) on 
T cell proliferation in a whole PBMC population was examined in vitro Neither hydrolysate 
had any impact on the proliferation o f CD3+ T cells in a CFSE labelled PBMC assay 
However, the data demonstrated that the hydrolysates are not toxic at these high 
concentrations in vitro In hindsight we questioned the value o f using T cell proliferation 
assays to screen hydrolysates given that there was no effect on T cell proliferation at any of 
the doses examined Moving forward, the DC assay would be more useful to screen 
hydrolysates
Utilizing mtra cellular flow cytometry proved to be more effective that ELISA in 
detecting the ability o f hydro lysate 147 (6hrs) to significantly increase the percentage of 
CD4+T-bet+ cells producing IFN-y in Thl polarised cells Utilizing intracellular flow 
cytometry also proved to be instrumental in detecting the ability o f 147 3 hrs, 147 6 hr and
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wpc80 to significantly decrease the percentage o f CD4+ cells producing IL-4 in Th2 polarised 
cells were previously no Th2 cytokine effect was seen Consistent with earlier studies, both 
upscaled samples o f hydrolysate 42 (147 3hr and 6hr) and wpc80 significantly decreased 
Ror-yt transcription factor and IL-17 cytokine expression in a Thl7 polarisation assay In 
addition, there was no change detected in the MFI, percentage or number o f Foxp3+CD4+ T 
cells when upscaled hydrolysates 147 (3 or 6hr) or wpc80 were added in a Treg polarisation 
assay This data showed 147’s ability to alter the Thl/Th2 balance by increased production of 
T-bet and Thl cells producing IFN-y, inhibited production of GATA-3 and Th2 cells 
producing IL-4, inhibited Ror-yt T h l7 polarisation but does not interfere with Treg balance
All of the findings thus far have suggested that hydrolysate 147 has anti-inflammatory/anti- 
allergic properties however the underlying mechamsm to explain the aforementioned effects are 
still unknown Therefore the next approach was to identify a mechanism by which this anti­
inflammatory effect was being achieved in vitro Following a comprehensive review of existing 
literature to identify potential targets, peroxisome prohferator-activated receptor gamma (PPAR-y) 
was identified as an interesting candidate PPAR-y belongs to the nuclear receptor class II 
superfamily, showing pleiotropic effects in inflammatory processes in their capacity as 
ligand-dependent transcription factor (Zmgarelh and Cook, 2005) P-PARy was found to be 
expressed in different cell types, involving B and T lymphocytes (Greene et a l , 2000), 
monocytes/macrophages (Tontonoz et a l , 1998) and DC (Nenciom et a l , 2002) It has been 
shown that P-PARy was active in DCs and it was likely to be a regulator o f many aspects o f 
DC biology (Gosset et al 20001, Nenciom et al 2002) Tissue-resident DCs are exposed to 
various dietary substances raising the question of whether there are natural mediators (like 
milk derived bioactive peptides) that are capable of P-PARy activation Indeed, several 
compounds have been shown to activate P-PARy in DCs, such as lysophosphatidic (LPA) 
which is a G protein receptor antagonist and oxidized low density lipoproteins (oxLDL)
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which are proteins associated with atherosclerosis initiation and progression (Hourton et al 
2001, Smyth et al 2008) However, most o f our current knowledge on P-PARy’s function in 
DCs is derived from synthetic agonist treatment in vitro Data provided by these studies 
suggest that P-PARy activation negatively affects functional maturation o f DCs in response to 
environmental stimuli It has recently been shown that a casein hydrolysate inhibited the pro- 
lnflammatoiy NF-kB pathway through activation of PPAR-y (Fitzgerald et al 2015)
Therefore as P-PARy ligands have been described as negative regulators o f DC 
maturation, it was imperative to investigate if 147 hydrolysate expressed P-PARy n DC LPS 
stimulated human monocyte derived dendritic cells (MDDC) expressed higher levels of P- 
PARy mRNA than immature DC P-PARy mRNA expression was significantly higher in the 
presence o f hydrolysate 147 (less so with wpc80) in LPS matured DC This increase in P- 
PARy mRNA expression likely corresponds to activation o f P-PARy Given that 147 
hydrolysate activates P-PARy we further examined whether the effects were suppressed by 
the specific P-PARy antagonist BADGE Importantly, the inhibitory effects o f 147 
hydrolysate on co-stimulatory molecule and IL-12 cytokine expression were completely 
prevented when DC (matured m the presence LPS) were treated with BADGE Similarly 
BADGE prevented the anti-inflammatory effects of P-PARy agonist troglitazone in LPS 
stimulated DC The inhibitory effect o f P-PARy on DC maturation was mediated in part 
through nuclear factor of activated T cells, nuclear factor kappa-light chain enhancer of 
activated B cells NF-kB A growing number o f studies have highlighted the interaction o f P- 
PARy and NF-kB P-PARy could inhibit activation of NF-kB through several mechanisms 
and then repress NF-icB-mediated transcription of proinflammatory cytokines (Genolet et al 
2004, Kelly et al 2004) It is well established that the transcription factor NF-kB has a key 
role in mediating inflammatory responses including the regulation o f DC development, 
maturation and APC function (Rescigno et al 1998) NF-kB activation controls both the
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expression o f costimulatory molecules and MHC, as well as the production of cytokines like 
IL-12 (Ouaaz et al 2002) In resting conditions, NF-kB is maintained inactive in the cytosol 
o f cells forming a complex with its inhibitor subunit The phosphorylation o f the p65 subunit 
o f NF-kB on serine -536 is an important step in the activation o f the NF-kB pathway via 
activation o f several kinases including IkB kinases (IKKs)
Therefore the effects of whey hydrolysate and troglitazone on the phosphorylation of 
p65 subunit were examined as an index o f NF-kB pathway activation Our results showed 
that the PPAR-y ligand troglitazone suppressed the activation o f NF-kB by LPS in DC, 
decreasing the phosphorylation of p65 147 hydrolysate and wpc80 induced similar
responses Moreover, BADGE suppressed the effects o f  both troglitazone and the hydrolysate 
suggesting a role for P-PARy in the NF-kB pathway modulation by 147 hydrolysate (Figure 
6 1) Given that NF-kB plays a key role in regulating the expression o f co-stimulatory 
molecules in DC our data on the suppression o f NF-kB suggests that whey hydrolysate 147 
may exert its anti-inflammatory effects on cytokine production and co-stimulatory expression 
through NF-kB Similar findings were found with a casein hydrolysate that exerted anti­
inflammatory effects on human endothelial cells by suppressing NF-kB pathway activation 
through P-PARy dependent mechanisms (Fitzgerald et al 2015) It has been reported that 
endogenous ligands o f PPAR-y such as cyclopentenone prostaglandins, a metabolite o f 
prostaglandin D2 might also exert anti-inflammatory effects through suppression o f NF-kB 
activation in a P-PARy independent manner via direct inhibition o f other signaling 
components of the NF-kB pathway, such as IkB kinase (Rossi et al 2000) There are also 
studies that reported that P-PARy ligands may have anti-inflammatory effects in a P-PARy 
and NF-kB independent manner interfering with other pathways such as activation o f ERK 
(Wilmer et al 2001) or inhibition o f AP-1 pathways (Perez-Sala et al 2003)
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As the hydrolysate used in this study is a complex mixture o f peptides, we cannot 
exclude the possibility that together with the direct effect on NF-kB through P-PARy, the 
hydrolysate might exert its anti-inflammatory effect by acting at other levels o f NF-kB 
activation or even by modulating other pathways However, further study is required to 
specifically identify the functional components (peptides) o f hydrolysate 147 Many o f the 
known bioactive peptides are multifunctional and can exhibit different bioactivities, such as 
immunomodulation or antimicrobial, antioxidant, antithrombotic, and antihypertensive 
properties (Hartmann et al 2007, Meisel 2004) Interestingly, a recent study showed potential 
anti-inflammatory property o f casein hydrolysates mediated by the modulation o f NF-kB 
(Fitzgerald et al 2014) In addition, in the present study, we reported an anti-inflammatory 
bioactivity o f the whey hydrolysate, and we demonstrated that the hydrolysate acts by 
inhibiting transcription factors (NF-kB and PPAR-y) that are involved in the regulation of 
several inflammatory pathways, which in turn, are common to many diseases Therefore, our 
results may offer a useful basis to understand the molecular mechanisms which may regulate 
many bioactivities attributed to milk derived bioactive peptides
Chapter 3 extensively investigated the anti-inflammatory effects o f whey and casein 
hydrolysates in vitro and provided comprehensive findings on the anti-allergic/anti- 
lnflammatory ability o f whey hydrolysate 147 While many have reported on the 
immunomodulatory effects of hydrolysates there have been few reports or m-depth studies 
providing a mechanism to support such interactions Notably this chapter has defined the 
direct effects o f hydrolysates on the key cells involved in allergy and proposed an anti­
inflammatory mechanism o f action by which hydrolysates can modulate their effects These 
findings enhance our knowledge o f the bioactive properties o f hydrolysates in vitro and 
provide a basis from which these investigations can be expanded upon in vivo
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Figure 6.1.Whey hydrolysate 147 exerts its anti-inflammatory effects by suppressing 
NFkB pathway activation through PPARy dependent mechanism (A) Inactive NFkB 
dimers are sequestered in the cytoplasm by interaction with the IKB alpha (IKB).Upon 
stimulation with LPS the IKB proteins are phosphorylated by one or a number o f IKB kinases 
(IKK), ubiquitinylated and degraded thereby allowing the NFkB complex to translocate into 
the nucleus. The active NFkB complex translocates into the nucleus where it mediates gene 
transcriptions and leads to the inflammatory response. (B)147 hydrolysate and PPARy+ 
agonist (Troglitazone) suppressed the activation o f NFkB by LPS in DC by inhibiting the 
phosphorylation o f p65 and translocation to the nucleus. (C) PPARy -  antagonist (BADGE) 
suppressed the effects of both 147 hydrolysate and PPARy+ and allowed the NFkB complex 
to translocate to the nucleus and exert an inflammatory response.
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Chapter 3 identified in vitro evidence that hydrolysate 147 contains specific 
immunomodulating peptides which increase Thl cytokines and decrease Th2 cytokines and 
impair TH17 cells and contribute to preventing allergy by inducing a more tolerogenic 
response in dendritic cells This suggested that hydro lysate 147 could act therapeutically to 
prevent allergic or inflammatory conditions where the induction o f a more balanced immune 
system could be beneficial Therefore a model system to examine the potential o f hydrolysate 
147 to be used therapeutically as a anti-allergy/anti-inflammatory functional food m infant 
formula needed to be developed Although it may seem obvious, the goal for using mouse 
models is to gain insight into the value o f specific agents (147 hydrolysate) for use against 
food allergy As a result of this, the starting point for choosing a mouse model has to be how 
it relates to the human disease Mouse models, despite their individual limitations, have been 
useful tools for the study o f allergic diseases in vivo (Helm et al 2002, Hogan et al 
2001) They have been instrumental in advancing our understanding o f the underlying 
pathophysiologic mechanisms, assessing the allergemcity o f  food products, and evaluating 
new therapeutic strategies (Niggleman et al 2001, Kmppels et al 2002) Mouse models offer 
the ability to study sensitization, studies that are not possible in humans for obvious ethical 
reasons Mouse models vary in terms o f sensitization protocols (type o f food allergen, dose, 
route o f administration, use o f adjuvants), and the methods used to assay the allergic response 
after antigen challenge (measurement o f inflammatory mediators, functional assays o f gut 
function, morphologic studies) It is also important to consider the genetic background o f the 
animal in eliciting an immune response
For example, Balb/c mice are good IgE responders, whereas other mouse strains such 
as C3H/HeJ mice vary in IgE production although they have been used in establishing good 
models o f food allergy (Li et al 1999, Li et al 2000) This may be related to the recent
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observation that this mouse strain has a point mutation in Toll-like receptors preventing 
lipopolysaccharide responses by peritoneal macrophages that might be necessary to elicit a 
full IgE response (Helm et al 2002) Smaller laboratory animals also offer the potential for 
genetic manipulation in which specific effector cells of inflammation (mast cells, eosinophils) 
or mechanisms o f antigen recognition (IgE, antigen-specific T-cell receptors) are 
manipulated Examples include mast cell-deficient mice (Wershil et al 2000) and ovalbumin- 
specific T-cell receptor transgenic mice (Shida et al 2002) As discussed in chapter 1, despite 
the benefits o f mouse models for food allergy, there are limitations which make the prospect 
o f using humanised mouse models more attractive To date, there is no animal model that can 
identify known food allergens, predict the allergic potential o f novel food proteins, or mimic 
the human food-allergic sensitization and allergic responses (Helm et al 2002) However, 
humanised mice with components o f the human immune system can bridge this gap as they 
have been used successfully for studying the human immune system in vivo and for 
predicting the allergic potential of food proteins (Burton et al 2016) Severely 
immunodeficient mouse strains, such as NOD/Shi-scid IL2ry nul1, NOD/LtSz-scid IL2ry nul1 
(NSG) and BALB/c Rag2 nuli IL2ry nul1 enabled long-term engraftment o f human tissues 
because o f the total lack o f the endogenous mouse immune system, enormously improving 
the generation o f humanised mice (Ito et al 2002,Yahata et al 2002, Shultz et al 
2005,Traggiai et al 2004) These strains are highly immunodeficient, lacking B, T, and NK 
cells, and their genetic background is permissive for human hematopoietic engraftment and 
differentiation Upon human CD34+ hematopoietic stem and progenitor cell transplantation, 
most human hematopoietic populations (including B cells, T cells, monocytes, dendritic cells, 
erythrocytes, and platelets) can develop and are detectable m these models (Shultz et al 2007, 
Legrand et al 2006, Ito et al 2002, Traggiai et al 2004, Ishikawa et al 2005) However the 
differentiation o f human myeloid lineage cells, especially granulocytes and mast cells, in
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conventional human HSC NOG mice had been inefficient (Shultz et al 2012) until several 
groups endeavoured to improve the efficiency of human granulopoiesis m humanised mice by 
engineering mice to express human genes encoding these cytokines Mice that express the 
human myeloid cytokines IL-3 and GM-CSF showed increased support of myeloid 
differentiation (Ito et al 2013, Wilhnger et al 2011)
In particular the NOG IL-3/GM-CSF transgenic mouse strain established by Ito 
resulted in the stable presence o f mast cells and basophils and these cells were functional as 
mice developed PCA reactions when exposed to serum from patients with cedar pollinosis 
(Ito et al 2013) The development o f such strains o f mice that mimic human allergic 
responses allow for the study o f novel therapeutics for food allergy for e g a milk protein 
hydrolysate with anti-inflammatory properties to help combat inflammatory disease 
Therefore it was important to identify which strain o f mouse would provide the best host for 
the engraftment o f human immune cells involved in the allergic response (T, B, myeloid, 
eosinophils, mast cells, basophils) As the NOG IL-3/GM-CSF was not commercially 
available the next option was to use commercially available strains o f NOD/Shi-scid-IL-2Ry 
nul1 mice that express human cytokines to support the differentiation of human granulocytes 
and mast cells The first mouse strain chosen was a triple transgenic mouse model expressing 
human stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), 
and mterleukin-3 (IL-3) NOD/Shi-scid-IL-2Ry nul1 mice termed NSG-SGM3 These mice 
were chosen as previously transplantation o f CD34+ HSCs into NSG-SGM3 mice lead to 1) 
robust human hematopoietic engraftment o f immune cells in blood, spleen, bone marrow and 
liver 2) slightly enhanced development o f CD33+ myeloid cells and CD15+ granulocytes 3) 
elevated myeloid dendritic cell (mDCs) frequencies in the bone marrow o f humanised NSG- 
SGM3 mice and 4) elevated human CD4+ Foxp3+ Treg cell populations m the bone marrow,
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spleen , liver and blood o f humanised NSG-SGM3 mice compared with nontransgemc NSG 
mice (Billerbeck et al 2011)
The second strain chosen was a single transgenic mouse model that expressed 
membrane-bound human stem cell factor termed NSG-SCF mice Previously Takagi et al 
2012 demonstrated that after transplantation of CD34+ FISCs into NSG-SCF mice human 
granulocytes accounted for the majority o f engrafted human cells in the bone marrow of these 
mice and c-kit+ human mast cells differentiated efficiently in the bone marrow, spleen and 
mucosal tissues thereby supporting human myeloid development in these mice In addition, 
NSG-SCF mice were chosen as transgenic expression o f human mSCF enabled heightened 
levels o f hematopoietic cell chimensm in the absence o f irradiation thereby eliminating the 
complications associated with irradiation (Brehm et al 2012) To date there is no study that 
compares these two strains of mice for the development of mast cells and so this comparison 
may prove to be useful in future investigations o f  human mast cells
As most studies compare the engraftment o f humanised mice to a non-transgemc strain, 
NSG were included in this comparison study Haematopoietic engraftment m the spleen, 
bone marrow, liver, peripheral blood and thymus was evaluated by flow cytometry 20 weeks 
after CD34+ cells were transplanted into all three strains o f NSG mice Comparable levels of 
human leucocyte (CD45+) engraftment were observed in the spleen, bone marrow and liver 
across all three strains o f mice whereas lower levels o f leucocytes were found in the 
peripheral blood and thymus When comparing myeloid levels m the tissues of NSG, NSG- 
SCF and NSG-SGM3 engrafted humanised mice, we observed a significant increase in 
myelopoiesis in the spleen o f NSG-SCF mice, an increase which was comparable to the 
increase seen by Takagi et al 2012 with myeloid cells B cells engrafted at higher rates in the 
spleen and bone marrow o f NSG-SCF compared to smaller proportions m NSG and NSG- 
SGM3 Little is known about human immune cell reconstitution in the livers o f humanized
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mice Upon further examination o f the immune subset composition o f the human CD45+ 
population, we found that there were significant CD3+ T-cell and CD20+ B-cells populations 
residing in the livers o f NSG-SCF humanized mice which is similar to the findings of 
Dykstra et al (2016) Similar T cell increases were found in the livers o f NSG-SGM3 
Current understanding concerning the education o f developing T cells holds that selection 
occurs in the thymus on MHC molecules expressed by stromal cells o f non-hematopoietic 
origin (Bix et al 1992) Although human hematopoietic cells bearing human MHC molecules 
might enter the mouse thymus m NSG mice, some published studies have predicted that these 
cells cannot effectively select developing human T cells (Shultz et al 2012, Bix et al 1992) 
Although we see low levels o f CD3+ T cells engraftment m the spleen and bone marrow 
moderate levels (~ 12 to 17%), of engraftment were observed in the livers o f NSG-SCF and 
NSG-SGM3 mice We cannot presume that human MHC restricted T cell development may 
be functional in these mice as no functional assay was performed
The mam aim o f this study was to find the most appropriate host for the engraftment of 
mast cells and basophils (in addition to T and B cells) so our focus next turned to analysing 
the populations of effector cells in these mice No mast cells or basophils could be detected in 
the tissues o f NSG mice, however there was an increase in the total number o f mast cells and 
basophils recovered in the spleen, bone marrow and liver o f NSG-SCF mice in comparison to 
those found in tissues o f NSG-SGM3 but the difference was not significant Overall there 
was higher engraftment o f immune cells in the tissues o f non-irradiated mice however this 
statement comes with one caveat Three week old NSG and NSG-SGM3 mice engrafted 
poorly as a result o f the radiation dose (2 4Gy) given to these mice and was not a result of 
the HSC donor As already discussed in Chapter 4, radiation damage in NSG and NSG- 
SGM3 mice resulted in significant damage to the thymus o f these mice Thus, the ability of 
transplanted human HSC to repopulate following radiation injury was significantly reduced
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in these mice NSG mice have been previously shown to survive up to 125 days with this 
sub-lethal dose o f irradiation (> 10 weeks old) (Brehm et al 2012) however as these mice 
were irradiated at weaning age (3 weeks old) they were much more sensitive to the dose of 
radiation All subsequent experiments with the NSG-SGM3 mice were earned out with a 
dose 1 OGy
Using the lower dose of irradiation, the engraftment kinetics o f immune cells was assessed 
at 12, 16 and 20 weeks post transfer o f flow sorted CD34+ HSC (Lonza) into irradiated NSG- 
SGM3 and non-irradiated NSG-SCF mice At the time o f harvest, no observation o f any gross 
macroscopic abnormalities were visible in these mice Flow cytometry was performed to 
evaluate the engraftment levels o f human CD45+ cells The engraftment levels o f leucocytes 
was higher in the peripheral blood (PB) o f NSG-SCF compared to the PB o f NSG-SCF at 6 
weeks post HSC transfer However by 12 weeks, comparable levels o f leucocytes had 
engrafted in the PB of NSG-SGM3 and NSG-SCF mice By 20 weeks similar levels of 
leucocytes had engrafted in PB in both strains o f mice Engraftment in the thymus mirrored 
that was seen m the PB Significantly more leucocytes had engrafted in the spleens o f NSG- 
SGM3 at 12 weeks but by 16 and 20 weeks similar levels o f CD45+ had engrafted in the 
spleens o f both strains o f mice At 16 and 20 weeks engraftment levels o f CD45+ cells in the 
bone marrow were slightly higher in NSG-SCF mice compared to NSG-SGM3 mice but by 
far the highest levels o f leucocytes were found in the livers m both strains of mice and they 
remained high over the course of the experiment Spleens were markedly enlarged in both 
transgenic strains
Consistent with this finding, high levels o f myeloid cells had engrafted in the spleen 
and livers o f NSG-SCF and NSG-SGM3 mice Moderate levels o f B cells were found in the 
spleen, bone marrow, liver and PB at 12 and 16 weeks but levels decreased between 16 and 
20 weeks in both strains o f mice Notably, the only difference between the two strains of
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mice was seen in the engraftment o f T cells There were significantly more T cells in the bone 
marrow o f NSG-SCF than NSG-SGM3 at 16 and 20 weeks and significantly more T cells in 
the circulation of NSG-SGM3 mice than NSG-SCF at the end o f the study The increase in 
the CD3+ cell engraftment in the PB of NSG-SGM3 is in agreement with the Billerbeck study 
that found an overall reduction in B cells was paralleled by a proportional increase in CD3+ T 
cell frequencies (Billerbeck et al 2012) This increase was further confirmed on examination 
o f the CD4+ to CD8+ T-cell ratios in the tissues o f the mice Fligher CD4+ to CD8+ T-cell 
ratios were found in the spleen, bone marrow and livers in NSG-SCF and NSG-SGM3 mice 
This data suggests that the transgenic expression o f SCF, GM-CSF and IL-3 promotes the 
expansion o f human CD4+ T cells in these humanised mice
In this study the development o f mast cells and basophils in humanised mice was 
compared in order to find which strain o f mouse was the better host for the engraftment o f the 
effector cells o f allergy Recently, Takagi et al (2012) demonstrated that the development of 
human mast cells was significantly improved in their hSCF transgenic NSG strain compared 
with normal NSG mice However the expression o f the high affinity IgE receptor (hFCeRl) 
on mast cells was not evaluated In this study, we examined whether human cells expressing 
hFCsRI or CD203c, (phenotypic markers) were present There was a clear subpopulation of 
hFCsRl+ CD203c+ cells present in the spleen, bone marrow and liver from NSG-SCF and 
NSG-SGM3 mice There were no measurable differences in the frequencies and numbers of 
hFCaRH CD203c+ in the spleen and bone-marrow of these mice however there were 
significantly more mast cells detected in the livers of NSG-SGM3 mice in comparison to 
NSG-SCF When these cells were further distinguished by assessing their human c-kit 
expression there were more mast cells that were c-kit+ in spleen, bone marrow and livers of 
NSG-SCF mice while more basophils (c-kit ) were present in the spleen, bone marrow and 
liver o f NSG-SGM3 mice Notably significantly more basophils (-60%) developed m the
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livers o f NSG-SGM3 than in NSG-SCF mice This suggests that mast cells and basophils 
may have been differentially distributed in vanous tissues One other immunodeficient mouse 
strain carrying the human IL-3 and GM-CSF genes have been generated IL-3/GM-CSF-Tg 
(transgenic) (Ito et al 2013) It is noteworthy that there were similarities m phenotypes 
between our study and the Ito study For example, there was high engraftment o f HSCs in IL- 
3/GM-CSF, with an increase in the CD3+ T cell population at 12 week post HSC 
transplantation and FCsRTCD203c+ mast cells and basophils were significantly higher in 
NOG IL-3/GM-CSF than m non-Tg mice and were differentially distributed -  70 and 50% of 
FCsRI+CD203c+ cells o f the whole CD45+ population in the spleen and bone marrow were 
mast cells (Ito et al 2013) The overall objective o f this study was to identify which strain of 
mouse provided the best host for engraftment o f human immune cells involved m the allergic 
response The data suggested that both strains would be useful for engraftment o f and study 
o f immune cells involved in allergy NSG-SCF mice had the highest potential from the point 
of view o f HSC mamtenance and myeloid and mast cell engraftment from the first study but 
there was no real difference between the two strains in terms o f engraftment o f human 
immune cells in the second stud Ideally more HSC donors and studies comparing the two 
strains would have re-affirmed these findings but due to limited time and budget no further 
studies were completed comparing the two strains Based on these findings and to avoid the 
complications o f irradiation, NSG-SCF mice were chosen as the best host for the humanised 
mouse model o f food allergy
After choosing the best host, conditions such as fresh versus frozen CD34+ HSC, male 
versus female mice and dose o f CD34+ were optimised to facilitate the optimal development 
o f this humanised mouse model An equally important component, after identification o f the 
best host in the development o f humanised mice, is the choice o f engrafting cells CD34+ 
cells can be isolated from adult bone marrow, fetal liver, UCB and G-CSF-mobilised
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peripheral blood cells (Alexandre et al 2016) Although human PBMC have been used to 
study IgE-mediated allergic responses (Weigmann et al 2012) several investigators have used 
UCB to study IgE-mediated allergic responses (Takagi et al 2012, Ito et al 2013, Burton et al 
2016) For this reason and since UCB have multi-potency and self-renewal capabilities 
higher than adult bone marrow (Metcalf 2007) UCB was chosen as the optimal type o f HSC 
3 sources of UCB were tested for the humanisation o f mice Fresh UCB from the cord blood 
bank Anthony Nolan Trust, Nottingham, UK, fresh UCB donated from consented women 
undergoing planned CS at NMH, Dublin and frozen cord blood derived flow sorted CD34+ 
cells purchased from Lonza In our experience, the frozen purified CD34+ cells from Lonza, 
were the most reliable source for the generation o f humanised mice as they allowed for 
greater flexibility in terms o f planning experiments and they contained sufficient numbers of 
CD34+ cells to perform experiments Flowever their high cost must be taken into 
consideration when planning experiments
The dynamic interplay between donor hematopoietic stem cells (HSCs) and the recipient 
microenvironment governs the survival and proliferation o f HSCs m a transplantation setting 
(Notta et al 2010) A complex network o f cells within the microenvironment regulates HSC 
function via direct interaction or secretion of cytokines that act in an autocrine or paracrine 
manner (Scadden 2006) Dunng the course of our functional analyses of HSCs using NSG- 
SCF mice, we observed that the recipient gender played a critical role in the engraftment and 
proliferation o f human HSCs Specifically, female NSG mice were far superior to their male 
counterparts in facilitating the engraftment o f human HSCs When 1 x 105 HSCs were 
transplanted into male and female NSG-SCF mice, striking differences m engraftment were 
observed Absolute numbers o f human CD45+ cells in the spleen and liver were 6 fold and 2 
fold higher than male mice, myeloid cells in the spleen were 10 fold higher, T cells in the 
spleen and liver were 11 fold and 15 fold higher and B cells in the spleen increased 6 fold
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compared with male NSG-SCF mice Engraftment levels with a lower dose o f HSCs (5 x 104) 
also resulted in differences in engraftment between male and female mice In the PB the 
percentage o f CD3+ T cells at 12 and 20 weeks increased 4 fold and 2 fold higher than male 
mice, T cells in the bone marrow and liver were 5 fold and 3 fold higher and B cells in the 
liver increased 3 fold compared to their male equivalent Lastly there was a 3 fold increase in 
the absolute number of mast cells in the spleens o f female mice compared to male mice 
These findings are in agreement with Notta et al who reported that female NSG mice 
transplanted with limiting numbers o f human CD34+ cord blood HSCs showed better 
engraftment o f human CD45+ cells than males (Notta et al 2010) They proposed 2 reasons 
for the existence o f this gender difference (1) female NSG mice might be more 
immunodeficient than males, or (2) gender- associated factors, such as steroid hormones, can 
positively or negatively regulate human HSCs Although further experiments are required to 
identify gender-specific mechanisms o f HSC engraftment, our study revealed their key role 
and supported the concept o f recipient gender as a critical variable in the context o f stem cell 
transplantation studies
Food allergy is an important public health issue in industrial countries due to the 
increasing prevalence and the potential life-threatening consequence, effecting up to 8% of 
children and 4 % o f adults (Platts-Mills 2015, Ashley et al 2015) Often patients experience a 
reduction m physical and psychologic well-being and suffer from a decreased quality o f life 
due to disease activity The continuous nse in the number o f people affected by an allergic 
condition indicates an urgent need for better diagnosis and more efficient 
treatment/prevention options Food allergies are often observed m early childhood The 
finding that children can mount allergic responses to food which they have never been 
exposed to before, raised the question whether certain allergens might be transferred by 
breast-milk feeding Indeed, it has been demonstrated that major food allergens are present in
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breastmilk (Pastor-Vargas et al 2015) However, it is still a matter o f debate whether these 
allergens may induce tolerance or if they might promote sensitisation in children (Bion et al 
2016) Although breastmilk is the optimal feed for infants, it is important that research 
continues to improve the composition o f formula available to infants for whom breastmilk is 
not an option In collaboration with FHI, we embarked on innovative research to find specific 
hydrolysed cow’s milk peptides that were anti-inflammatory/anti-allergic that could help to 
induce tolerance in allergy prone infants, thereby reducing the risk o f allergies and associated 
atopic conditions later in life In chapter 3, the ability o f milk protein hydrolysate 147 to 
suppress immune responses in vitro and the associated mechanism through which this occurs 
were identified In chapter 4, the transgenic NSG-SCF mouse was identified as the best host 
for the engraftment o f immune cells involved in the allergic response
Therefore the next step in Chapter 5 was to develop an experimental humanised mouse model 
o f ovalbumin induced allergy and inflammation that mimic the mam clinical characteristics 
of human disease as well to examine the anti-inflammatory/ tolerogenic properties o f a novel 
milk protein hydrolysate in this model The advancement o f humanised models to study food 
allergy and inflammation has provided a clinically relevant setting by which the 
pathophysiology o f the disease can be studied What makes them more advantageous over 
mouse models o f food allergy is that they are designed to facilitate the engraftment o f adult 
human immune cells within the mouse Thus the cells driving the allergic disease are human 
and are capable o f mounting an immune response to sensitised and challenged antigen thus 
making this model clinically relevant and useful for assessing novel therapeutic interventions 
including milk piotein whey hydrolysates While there are a limited number o f humanised 
mouse models available to study food allergy we and others have found the NSG-SCF mouse 
strain to be superior m terms of myeloid engraftment compared to other models (Takagi et al 
2012, Coughlan et al 2016) While this humanised mouse model was originally developed by
277
Takagi et a l , several experiments were earned out (Chapter 4) to find the best host for the 
engraftment o f human immune cells involved in the allergic response and NSG-SCF was 
found to be the more appropnate host Many approaches were undertaken to enhance this 
model, in particular the use o f flow sorted CD34+ HSCs, instead o f freshly isolated 
CD34+HSCs, female mice instead o f male mice and lower dose o f HSC Both sexes are 
afflicted with food allergies in humans, although there are relative differences based on age, 
among adults, most afflicted are males, among children are females (DunnGavin et al 2006) 
Most mouse models have used female mice as females tend to exhibit more robust IgE 
antibody responses in general (Venugopal et al 1995, Melgert et al 2005) A recent study 
using hazelnut allergy mouse model, reported that female mice exhibit higher IgE responses 
compared to males (Parvatanem et al 2009) Thus the findings in Chapter 4, facilitated the 
performance o f a larger scale in vivo study with 4 HSC donors CD34+ flow sorted cells 
purchased from Lonza, combined with the lower dose o f HSC required, allowed the inclusion 
o f more mice per study On this basis, and building on the findings in Chapter 3, this 
humanised mouse model of ovalbumin induced allergy and inflammation was used as a 
platform to test a novel functional compound, hydrolysate 147 against food allergy
To address how hydrolysate 147 affects the severity o f allergic responses in vivo, a 
modified protocol of a well characterised food antigen ovalbumin was used (Dearman et al 
2007) This model consisted o f sensitisation, treatment and challenge phases o f experimental 
food allergy that used Th2-type sensitisation with OVA/alum ip  injections followed by 
repeated gavages o f the treatment (147) and challenge o f the OVA antigen to mimic 
physiological allergen exposure The question may be asked why ovalbumin antigen which 
is the main protein found in egg white was used instead o f whey or casein which are the main 
proteins found in milk The choice of OVA as a model allergen was also driven by the 
clinical observation that allergy to egg in early life is one of the strongest predictors of
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progression o f the allergic march, the process by which children gradually develop severe 
allergic diseases like atopic dermatitis, rhinitis and asthma (Lambrecht 2017) In order to 
assess the relative allergemcity o f novel proteins, it is essential to use known allergens in 
humans as reference proteins OVA is a T cell-dependent antigen commonly used as a model 
protein for studying antigen-specific immune responses in mice The munne immune 
response to OVA has been well characterized, to the extent that the immunodominant 
peptides for eliciting T cell responses have been identified (Weaver et al 2008) Anti-OVA 
antibodies are detectable 8-10 days after immunization using enzyme-linked immunosorbent 
assay so it was foreseeable that these responses would also be elicited m a humanised mouse 
model Normally allergen ingestion by humans or mice results in tolerance so consequently 
adjuvants such as aluminium hydroxide (alum) are used to overcome oral tolerance It is not 
well understood to what extent adjuvants are needed to promote an allergic response, but 
adjuvant signals appear crucial at least in a range o f animal studies Adjuvants influence both 
the activation and subsequent migration o f dendritic cells (DCs) to a draining lymph node, 
which reside m the vicinity o f the first exposure site to potential allergens In several animal 
models o f food allergy, sensitization by the l p route with the use o f aluminium hydroxide 
have been used successfully to decipher the inherent allergenic potential o f proteins and the 
clinical utility o f alum m humans has been approved (Lambrecht et al 2009) Therefore alum 
was used with OVA in our model to stimulate an IL-4-dnven Th2 response
Previously, we used an in vitro platform to screen immunomodulatory effects of a range 
o f whey and casein hydrolysates in a systematic way Our data showed that a specific whey 
hydrolysate induced a greater anti-inflammatory profile than intact wpc80 Since higher 
levels o f anti-inflammatory cytokines have a regulatory function in allergy (Chung et al 2004, 
Akdis et al 2006) it was hypothesised that this whey protein hydrolysate may also have in 
vivo immunomodulatory effects in a OVA allergy setting Therefore, we investigated the
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immunomodulatory capacity o f the hydrolysate 147 m a humanised mouse model of 
ovalbumin induced allergy and inflammation
The first step in the development o f the model was to ensure that the mice were 
sufficiently humanised 1 e that human immune cells involved in the allergic response had 
engrafted Engraftment levels o f lymphoid (CD45+), myeloid (CD33+), T (CD3+) and B 
(CD19+) cells as well as the effector cells o f allergy (mast cells and basophils) were 
monitored in the spleen, bone marrow, liver, PB and thymus after 12 weeks before an 
immunisation regimen began Sufficiently high levels o f all immune cells including mast 
cells and basophils engrafted after 12 weeks post transplantation with HSCs which was 
important for the success of the model going forward
Most animal studies showing beneficial effects o f hydrolysates in allergy mainly focus 
on immunoglobulin levels as a measure for sensitisation (Von Esh et al 2011, Fntsche et al 
1997, Adel-Patient et al 2012, Peng et al 2004) while only a few studies investigated effects 
o f whey hydrolysates on immune populations involved in the allergic response (Van Esh et al 
2011, Adel-Patient et al 2011) A wide range of in vivo and ex vivo readouts were performed 
to assess or support the anti-allergic capacity o f whey hydrolysate 147 The first common 
readout to assess the clinical symptoms o f allergy was adopted from Li et al (2001) Mice 
were sensitised, treated with 147 and wpc80 and challenged with OVA and anaphylaxis 
symptoms were monitored 30 mins after mtragastnc challenge A high anaphylactic score 
was recorded for the OVA mice and no score for the PBS, with reduced symptom scores 
recorded for the 147 and wpc80 treatment mice In a humanised mouse model of peanut 
allergy, peanut anaphylaxis was blocked by treatment with ant-IgE antibody In this study 
they went one step further to test whether human mast cells were responsible for the 
response By using Balb IgE deficient mice, which are immunocompetent and have an intact 
mast cell compartment, they elegantly demonstrated that no anaphylaxis occurred in mice
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that received human IgE This confirmed that human IgE cannot elicit responses by murine 
mast cells and these findings strongly implicated that engraftment by human mast cells 
triggered by human IgE antibodies, produced by engrafted B cells were the sole inducers of 
anaphylactic responses to peanut exhibited by the humanised mice (Burton et al 2016) In a 
similar murine model o f OVA allergy, a novel immunomodulatory protein isolated from the 
edible mushroom Flammulina veluties was tested for its anti-inflammatory properties, mice 
sensitised to OVA in the presence o f the mushroom protein (V\P-fve) were protected from 
systemic anaphylaxis after oral challenge with OVA (Hiesh et al 2003)
The GI tract is central to the pathophysiology o f food allergy It was hypothesised that 
feeding hydrolysates would alter the inflammatory status o f the GI and this proved to be the 
case 147 and intact protein wpc80 displayed a similar protective profile in the jejunum of 
OVA mice compared to OVA mice OVA mice had all the hallmarks o f allergic 
inflammation which included lymphocyte infiltration, villi destruction and blunting, which 
were mostly absent m 147 and wpc80 treated mice 147 and its mtact control wpc80 were 
significantly efficacious m protecting the target organ from allergic inflammation No other 
humanised mouse model has examined the inflammatory status o f the GI tract However, in 
the mouse model study, Hiesh et al (2003) also examined the histological changes of intestine 
(jejunum) after oral challenge with OVA and found in the PIP-fve treatment group, the 
intestine was nearly normal except for very mild mucosal oedema
In the intestinal tract, mast cells are mainly located m the lamina propria and they 
contribute both to tolerance for food as well as to sustain the immune response against 
pathogens (Mekon et al 2015) In allergic individuals, ingestions o f harmless food proteins 
leads to the stimulation of allergen-specific T-helper 2 cells and the production of cytokines 
which are responsible for the production o f allergen specific IgE IgE binds to the high- 
affimty receptor for IgE ( F c e R I )  on mast cells Allergen crosslinkmg of cell-surface-bound
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IgE leads to mast cell degranulation resulting in allergic symptoms therefore it was important 
to investigate the presence o f mast cells in the GI tract No mast cells were identified m the 
jejunum of PBS, 147 or wpc80 by toluidine blue staining but limited numbers were found in 
the connective tissue in OVA mice 18 hours after the mtragsatric challenge These mast cells 
appeared to be intact and revealed no features o f de-granulation It is important to note that 
our experimental regimen only included one intragastric challenge Previously Brandt et al 
(2003) demonstrated that elevated levels of mast cell numbers following OVA challenge only 
increased between challenge 3 and 5 in a mouse model o f OVA induced intestinal 
inflammation Thus, we propose that more mtragastic challenges may have enhanced the 
mast cell numbers m the GI tract of these mice which was recently demonstrated by Burton et 
al (2016) where a significant mast cell expansion was evident in the jejunum and spleen of 
peanut fed mice after intragastric feeding once a week for 8 weeks
A humanised mouse model o f food allergy represents an important tool for studying 
the mechanisms o f induction and repression o f an allergic reaction, as well as for the 
development o f an immunotherapy to prevent or minimize such an adverse reaction Total 
IgE and IgGl (Th2 response) and OVA specific IgGl are good markers for the induction of 
an allergic response in mice Therefore it was important to explore whether oral treatment 
with whey hydrolysate 147 could decrease these markers One week after the final 
sensitisation low levels o f total IgE antibody were detected in the serum of PBS mice 
whereas there was a significant increase in IgE antibody produced in the serum of OVA 
sensitised mice However at the end o f the study, levels o f IgE antibody were similar across 
all groups (PBS, OVA, 147, wpc80) Unfortunately, OVA specific IgE could not be detected 
in our ELISA screening system In the recent humanised mouse model study o f peanut 
allergy, Burton et al (2016) observed variable effects on the production of peanut-specific 
IgE with an anti-IgE (omalizumab) treatment and they concluded that the reductions in
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detection might be related to interference with the anti-IgE capture antibody m their peanut 
specific IgE ELISA , which may have been the case in our assay Both total IgGl and OVA 
specific IgGl antibody levels were significantly reduced with 147 hydrolysate and not with 
intact protein wpc80 These results may point to the possibility that the production o f the so 
called blocking IgG may be involved m the immunodulatory mechanism induced by 147 
hydrolysate Only peanut specific IgGl was significantly reduced with omalizumab treatment 
but total IgGl remained high in the humanised mouse model o f peanut allergy (Burton et al 
2016) OVA sensitised mice showed increased levels o f total and OVA specific IgGl 
compared to the non-sensitised PBS control group, whereas in peanut sensitised mice 
increased levels o f peanut specific IgGl and lower levels o f total IgGl were found in the 
serum of NSG-SCF mice In a mouse model o f OVA allergy mice receiving oral FIP-/ve had 
an impaired OVA-specific IgE response while the IgG2a response was markedly elevated 
indicating a Thl enhanced response (Hsieh et al 2003) Inclusion of IgG2a and IgG4 which is 
associated with the development of tolerance in children in future studies would add further 
weight to the anti-inflammatory/pro-telorogenic evidence o f 147 hydrolysate To study the 
immunomodulatory effects o f whey hydrolysates, we measured the ex vivo cytokine 
production by mesenteric lymph nodes (MLN) During sensitization and challenge, the 
intestinal immune cells are the first to encounter the administered antigen In this challenge 
model, antigens will first encounter the MLN, which may affect the peripheral immune 
response Peyer's patches and the MLN play important roles in allergic responses to food 
allergens as removal of these lymphoid organs results in a decrease m allergic responses 
(Nakajima-Adachi et al 2014) The role of the MLN in oral tolerance and regulating the 
allergic reaction has been studied most The results showed that IL-4 local production by 
MLN from the mice that were treated with 147 hydrolysate and wpc80 were significantly 
reduced in comparison to MLN from OVA sensitised mice In a similar mouse model of
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OVA allergy where treatment with heated OVA was compared with native OVA, the levels 
o f the Th2 cytokines (IL-4, IL-5 and IL-13) were higher in culture media obtained from MLN 
exposed to native OVA in comparison to low or non-detectable levels with the heated OVA 
Golias et al 2013)
Given the capacity of hydrolysates to alter the Thl/Th2/Thl7 balance or enhance Treg 
function, it was important to explore whether hydrolysate 147 anti-inflammatory/anti-allergic 
activity would impact the systemic and GI organs o f OVA sensitised mice Our humanised 
mouse model was used to examine the effect o f 147 hydrolysate on the production of these 
cytokines (IL-4, IL-13, IL-6, IL-17, IL-12, IFN-y and IL-10) Notably 147 hydrolysate 
provided greater protection in both systemic and GI tissues over and above that provided by 
it’s parent control (wpc80) This was exemplified by the overall reduction in the Th2 
cytokines and pro-inflammatory cytokines and increase in the anti-inflammatory cytokine IL- 
10 in these tissues Importantly, 147 and not wpc80 decreased the levels o f IL-13, IL-6 and 
IL-17 and increased IL-10 in the small intestine, similar difference was seen in the spleen 
where 147 and not wpc80 decreased the levels of IL-13, IL-6 and IL-17 and 147 and not 
wpc80 increased the level of the anti-inflammatory IL-10 in the liver
Both Treg deficiency and Treg dysfunction have been found to be associated with the 
development o f allergic diseases However only a limited number o f studies have assessed 
the role of Tregs in IgE food allergy The generation of Treg is a key component of oral 
tolerance and to date few studies have shown an effect o f hydrolysates on Treg formation in 
vivo Our study found no difference between the Treg frequencies in the spleens o f OVA, 
147 and wpc80 mice however the levels were significantly reduced in comparison to the PBS 
control group This reduced Treg expression m splenocytes o f OVA, 147 and wpc80 may 
point to a suppressive state or it may suggest that Tregs may be elsewhere for example in the 
small intestine Assessing the balance o f Treg to activated T cells may provide a more
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sensitive measure of Treg expression than enumeration o f Treg populations Healthy subjects 
showed a clear and robust increase in this ratio following allergen exposure (Akis et al 2004) 
which fits with the convincing argument that the dominant response in healthy subjects is a 
Treg response compared to a transient increased ratio for sensitised infants and delayed 
response in allergic infants In the recent humanised peanut allergy study (Burton et al 2016) 
there was a higher percentage o f Foxp3CD127 low CD25+’ cells m the spleens of unsensitised 
mice than that seen in our model which again may be due to the differences in sensitisation 
regimens but the authors failed to show the effect that the anti-IgE treatment had on 
development o f Treg response
Many researchers regard allergy as a Th2 weighted imbalance, and immunologists 
have been investigating ways to redirect allergic Th2 responses in favour of Thl responses to 
try to reduce the incidence o f atopy Some groups have been looking at using high dose 
exposure to allergen to drive up the Thl response in established disease and other groups 
have been studying the use o f mycobacterial vaccines m an attempt to drive a stronger Thl 
response in early life Few studies have addressed the issue o f T-cell differentiation skewed 
by hydrolysates in vivo Here, we demonstrated that there was an increased Thl/Th2 (IFN- 
y/IL-4) ratio in splenocytes o f 147 treated mice but not in mice treated with intact wpc80 
Significantly there was a lower Thl/Th2 ratio in OVA mice compared with PBS control 
Babies tend to be bom with a Th2 biased immune responses over Thl response These can 
be switched off rapidly postnatally under the influence o f microbiological exposure or can be 
enhanced by early exposure to allergens or potentially by exposure to immune balancing 
infant formula This data demonstrates further that 147 has immunomodulatory capacity to 
skew the T cell differentiation from a Th2 subtype toward Thl which would be highly 
beneficial in infant formula
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The use o f animals transgenic for the obligatory mast cell human growth factor SCF 
in this model ensured the differentiation and localisation o f human mast cells in the tissues of 
the humanised mice engrafted with human CD34+ cells NSG that were not injected with 
HSC had no tissue mast cells, whereas engrafted animals had mast cells in the bone marrow, 
spleen and liver As mast cells had engrafted sufficiently at 12 weeks the next step was to 
investigate if  sensitisation, treatment and challenge would alter the effector cells of allergy in 
bone marrow o f PBS, OVA, 147 treated and wpc80 treated mice Percentage and number of 
mast cells were significantly reduced in the bone marrow o f 147 and wpc80 control mice 
Mast cell numbers in 147 and wpc80 mice were more equivalent to that seen in the bone 
marrow o f the PBS control group OVA sensitised mice had increased percentages (-24%) 
and number of mast cells m the bone marrow which was likely a result o f their activation by 
antigen specific IgE antibodies as lower mast cell percentages o f -15  % were observed before 
sensitisation occurred at 12 weeks post transfer o f HSC cells In a recent NSG-SCF peanut 
mouse model study a significant percentage and number o f mast cell engrafted in spleen, and 
small intestine, 6 months after transplantation with CD34+ HSCs (Burton et al 2016) but 
again no data was presented on the development o f mast cells post treatment with anti-IgE 
therapy
Dendritic cells (DCs) are the most important antigen presenting cells to activate naive 
T cells, and they are therefore the central players o f the immune system crossing the bridge 
between innate and adaptive immunity To play such an important role and keep the balance 
between health and disease, they have a unique set o f features that enables them to operate at 
the interface o f host defense and tolerance One such feature involves the process o f DC 
maturation following encounter with antigen The upregulation o f co-stimulatory molecules 
such as CD86 usually results in development o f a functional immune response and in the 
context o f allergen an allergic reaction Alternatively, differential kinetics o f co-stimulatory
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molecule expression may favour immune regulation Addition o f milk hydrolysates to 
activated dendritic cells in vitro in Chapter 3 resulted in a significant decrease in CD86 co- 
stimulatory molecule expression In this humanised mouse model there was significant 
reduction in absolute number and percentage o f CD86+C D llc+ DC in the bone marrow of 
147 treated mice and wpc80 mice in comparison to OVA mice which points again to a more 
tolerogenic DC population Analysis o f human dendritic cell populations in spleens of peanut 
sensitised NSG-SCF mice after IgE treatment revealed a reduction in the MFI o f C D llc+ 
HLA-DR+ cells in the spleens o f treated mice in comparison to peanut sensitised mice Thus 
treatment did have an effect o f the activation o f dendritic cells in this model
The majority o f myeloid cells in the bone marrow were CD33+HLA-DR' granulocytes 
However treatment with 147 hydro lysate and its intact control wpc80 significantly reduced 
the percentage and number o f granulocytes in the bone marrow o f NSG-SCF mice Probing 
this further resulted m unveiling the most striking result with hydrolysate 147 Investigation 
of the proportions o f lymphocytes, monocytes and granulocytes (through basic lymphocyte 
gating on FSC and SSC) m the bone marrow revealed a remarkable finding Treatment with 
147 and not wpc80 selectively blocked granulocytes accumulation in the bone marrow o f 147 
treated mice with a corresponding increase in the lymphocyte populations Closer phenotypic 
analysis using cell number data however revealed a significant reduction in CD45+cells, T 
helper cells, cytotoxic T cells, B cells and myeloid cells in the bone marrow of these mice 
This somewhat contradictory finding may be explained in the following manner, 147 
promoted the accumulation o f another cell type (for e g NK, iNKT, ILCs, none o f which 
were analysed here) which may explain the increased percentage o f cells in the lymphocyte 
gate and that this unidentified lymphocyte population resulted in the suppression o f the 
granulocyte population Natural killer cells are a subset of lymphocytes that principally 
participate in innate immunity but may also have important roles in determining the outcome
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of the adaptive immune responses Recent developments in the discovery of NK cell subsets 
have supported their potential role in allergic diseases via their contribution to allergen- 
specific immune suppression, allergen-specific TH1 cell generation and IgE production 
Little is known about the contribution o f the invariant natural killer T (iNKT) cells in the 
onset o f food allergy However they have been shown to have a role in CMPA INKT cells 
suppressed cow's milk allergic symptoms m mice and differentially regulated oral 
sensitization when mice were sensitised with casein and whey (Schoutenet et al 2012) This 
dramatic reduction in the granulocyte population remains unexplained but warrants further 
investigation
In Chapter 5, we evaluated the immunomodulatory capacity o f the 147 hydrolysate, 
demonstrating the anti-inflammatory and tolerogenic potential o f 147, using a humanised 
mouse model o f OVA allergy However it is important to highlight the similarities and 
differences between the two treatments Results revealed that both hydrolysate 147 and 
wpc80 offered preventive and therapeutic protection against allergy to OVA in the GI tract, 
by reduced anaphylaxis score in GI o f treated mice, both inhibited the local ex vivo 
production o f IL-4 by MLNs In the small intestine, both 147 and wpc80 decreased IL-4 and 
increased IL-10, both reduced the production o f the Th2 cytokine IL-4 and pro-inflammatory 
cytokine IL-12 in the spleen and they both reduced the cytokine production o f the Th2 
cytokine IL-13 and o f IL-12 in the liver Both 147 and wpc80 decreased the mast cell load in 
the bone marrow and both decreased the percentage o f CD8+T lymphocytes and reduced the 
co-stimulatory molecule expression m the bone marrow Importantly 147 alone exerted a 
marked reduction m humoral IgGl antibody response, decreased the Th2 response while 
promoting anti-inflammatory and balancing Thl/Th2 response in the spleen 147 alone 
reduced the production o f pro-inflammatory cytokines IL-6, IL-12 and IL-17 in the small 
intestine, decreased IL-6 and IL-17 and increased production of anti-inflammatory IL-10 in
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the spleen Treating OVA mice with 147 hydrolysate resulted in an overall suppression o f 
the granulocyte populations in the bone marrow and livers o f 147 treated mice which was 
accompanied by reduction of CD3+CD4+T lymphocytes and B cells in the bone marrow 
This hydrolysate was more effective than intact wpc80 in desensitising mice by virtue of its 
lower allergemcity and its immunomodulating capacity
Future studies using this humanised model should include dose-sensitization data 
Ideally, an appropriate animal model should be (a) validated by dose-response curves with 
different sensitizations and (b) be sensitive for distinguishing a threshold beyond which 
significant sensitization would be predicted Thus, one can conclude that both forms o f this 
protein possess sensitizing capacity and the doses relevant for human exposure should be 
taken into consideration when qualifying the potential risks for humans Also to enhance its 
clinical relevance more gastric challenges need to be performed to generate a more clinically 
relevant model The contribution made from host munne mast cells was not explored in this 
model To completely rule out the possibility that murine mast cells might be mediating the 
human IgE effect, examination o f murine mast cell protease 1 in these mice would be 
required Measuring the contribution that TSLP, IL-25 and IL-33, along with ILC2s, may 
have in the intestine during food allergy sensitization may provide additional predictive 
markers o f sensitizing capabilities Measuring NK activity in the bone marrow during food 
allergy may provide a regulatory role for these important innate cells Another interesting 
concept is to explore the role o f hydrolysates and the microbiome in food allergy prevention 
in these mice The altered dysbiosis m the GI tract has a huge effect on the development o f 
food allergy This presents an interesting concept whereby the interplay between immune 
cells of allergy and the microbiome can be explored
This thesis showed that DC maturation was the best screening assay for the 
identification o f potential anti-inflammatory hydrolysates Thl/Th2/Thl7/Treg polarisation
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assays were also useful in screening hydrolysates Importantly in chapter 3 we identified the 
capacity for 147 to inhibit DC maturation in a PPAR-y NFkB dependent pathway In chapter 
4, the best strain o f mouse was identified for the engrafiment o f immune cells involved m 
allergy In Chapter 5 a novel humanised mouse model o f OVA induced allergy and 
inflammation was developed which verified the in vitro findings in chapter 3 that 147 
reduced Th2 and promoted Thl/Th2 balance in the spleen Also the reduction in DC 
maturation in the bone marrow confirmed the earlier findings in vitro with monocyte derived 
dendritic cells Importantly this thesis provides the proof o f concept that a whey protein 
hydrolysate is anti-allergic/anti-inflammatory in a humanised mouse model o f OVA allergy 
This was demonstrated by presenting the capacity for 147 to increase the IgGl response, 
promote a Thl/Th2 ratio in the spleen, increase the systemic production of the anti­
inflammatory IL-10 while reducing the pro-inflammatory cytokines (IL-12JL-6, IL-17) in 
small intestine and (IL-6, IL-17) spleen, by altering the ratio o f granulocyte and lymphocyte 
populations while reducing T and B cell populations in the bone marrow, effects which 
outnumbered wpc80 effects This thesis has furthered our knowledge o f humanised mouse 
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